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Abstract
One of the major fascinations with protein biochemistry is the way that proteins can 
discriminate between similar substrates to perform specific reactions. This specificity is 
very evident in the cell where communication relies on these interactions. Even more 
incredible, however, is the ability of bacteria to evolve toxins which are also highly 
specific for particular eukaryotic cellular targets, in order to elicit particular cell responses. 
The C3 exoenzymes specifically ADP-ribosylate the Rho GTPases RhoA-C, and 
sometimes RhoE/Rnd3, but do not ADP-ribosylate the 55% identical GTPases Rac and 
Cdc42. The botulinum neurotoxins are delivered specifically to the neuromuscular 
junctions via their cell binding domains rather than to the inhibitory neurones of the spinal 
cord as for the homologous tetanus neurotoxin. In addition, there is great medical interest 
in engineering toxins such as these for therapeutics. This thesis presents research to 
forward the understanding of these molecules and their specificity and to aid further 
interest in engineering them for therapeutic use.
As this thesis contains structural data from X-ray crystallography, chapter 1 
outlines its general principles and gives an overview of the practice of this technique. 
Chapter 2 provides a general structural background to ADP-ribosylating toxins and Rho 
GTPases, a structural and mechanistic overview of the botulinum neurotoxins as well as an 
in depth literature review of the C3 exoenzyme from Clostridium botulinum. The particular 
context of each piece of work is presented in the individual chapter introductions. Chapter 
3 presents the purification, crystallisation and structure determination of C3 (C3botl) from 
Clostridium botulinum in a previously undetermined crystal form. Chapter 4 presents the 
expression, purification, crystallisation and structure determination of C3stau2 from S. 
aureus and its complex with NAD. It compares NAD binding between the C3-like and 
binary toxins and comments on the difference in protein target specificity between C3botl 
and C3stau2. Chapter 5 presents a basic functional characterisation of C3botl and C3stau2 
as well as preliminary experiments to investigate C3-Rho binding. Chapter 6 describes the 
attempts to crystallise the He domain of botulinum neurotoxins A and F. A brief final 
section comments on the status of, and future for, research in these areas.
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Chapter 1 Protein Crystallography
1.1 Introduction
The technique of x-ray crystallography is one of many techniques which can be 
used to study the structures of biological macromolecules in order to understand how they 
function. Amongst these techniques, however, crystallography is unique in its ability to 
provide a detailed, high resolution picture of molecular structures. In essence, x-rays are 
used to take a ‘photo’ of the molecule. The need for x-rays is due to the details of 
molecular structure being smaller than the wavelength of visible light which is between 
400-700nm. Covalently bonded atoms therefore require x-ray radiation with its wavelength 
between 0.1-lnm  to resolve them. The use of x-rays to visualise molecules adds the 
complication that x-rays diffracted from an object cannot be focused back onto a screen. 
Therefore, the unfocussed information must be collected and converted back to an image 
using a computational process. A further complication is that single molecules do not 
diffract x-rays strongly, most x-rays will pass straight through. To overcome this obstacle, 
crystals containing repeating arrays of the molecule are grown to produce a larger signal. 
This chapter will discuss the steps involved in protein crystallography from producing 
protein crystals through to structure determination in order to study protein function.
1.2 Crystals and Diffraction
Crystals comprise a lattice of a regularly repeated unit known as the unit cell. The 
unit cell is defined as the smallest building block for a crystal which can be built into the 
entire crystal using only translation functions. Unit cells are defined by the length of their 
three axis, a, b and c, and the angles between them, a , p, and y. There are seven crystal 
systems for describing unit cells based on their shape. Each of the unit cells can be built up 
in one of 14 Bravais lattices to produce the crystal. Because the unit cell is chosen as the 
smallest unit that does not require rotation, the contents of the unit cell often display 
rotational symmetry. The rotational symmetry within the unit cell can restrict its shape so 
that only certain point group symmetry elements are associated with each of the 14 Bravais 
lattices (Figure 1.1). The smallest unit which possesses no crystallographic symmetry is 
known as the asymmetric unit. In addition to rotational symmetry, crystals can also possess 
screw axes, where the asymmetric unit is not only rotated around the symmetry axis, but 
also translated a fraction of the unit cell length. Screw axes are denoted as subscript 
numbers related to the fraction translation of the unit cell e.g. 2i is a two-fold rotation axis 
with a screw corresponding to half the unit cell length. The combination of Bravais lattices,
2
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symmetry point groups and screw axes combine to give a possible 65 space group for non- 
centrosymmetric molecules such as proteins. The details of the symmetry and equivalent 
positions for these space groups, as well as other possible space groups for 
centrosymmetric objects, are found in Volume A of the International Tables for 







triclinic P a ± b ± c a^ p ^ Y 1
monoclinic P C a ± b ± c a  = y = 90, p > 90 2
hexagonal P a = b ± c a  = p = 90, y = 120 6, 622
trigonal PR IIII<3 a  = p = y i190 3, 322
cubic P IF a =b = c o
OsIIIICO.IIS 23,432
tetragonal P I a = b p c P II TO II II SO © 4,422
orthorhombic P I C F a ± b ± c oOsIIIICO.IIS 222
Figure 1.1: The table shows the unit cell dimensions that correspond to diagram A for 
the 7 crystals systems and the lattice types they can create. The types of lattices are P, 
primitive, /, body-centred, F, face-centred, C, base-centred and R, rhombohedral. The 
point groups denote the type and number of symmetry axes possible for these crystal 
systems.
When x-rays are shone at a crystal, the resulting diffraction pattern comprises many 
reflections, each arising from a plane of lattice points in the crystal. These planes include 
the faces of the unit cell but also other sets of parallel planes which are defined by where
3
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they intersect the unit cell axes. The planes are given a notation (hid), where each of these 
denotes into how many parts this set of planes splits each axis of the unit cell. Although 
there are many sets of planes though the crystal, for any one orientation of the crystal 
coherent diffraction can only occur from sets of planes whose spacing conforms to Bragg’s 
Law. Bragg’s law (Figure 2.1) shows that for any angle of incident radiation which hits the 
crystal, coherent diffraction only occurs from those sets of planes whose spacing allows a 
difference in path length between the waves to equal to an integral number of wavelengths 
(Blundell and Johnson 1976). This keeps the resulting diffracted rays in phase and 
therefore produces a coherent signal. Bragg’s law is expressed mathematically as
2d sin0 =  nk  ,
where d is the inter-planar distance, 0 is the angle of the incident beam, n is the number of 
wavelengths and X is the wavelength.
Figure 1.2: A schematic to represent Bragg’s law. The extra distance travelled by 
the second wave, between A and B, must equal a whole number of wavelengths to 
produce coherent diffraction. 0 is the angle of incident radiation and d the inter- 
planar spacing.
Because waves are only diffracted coherently from sets of planes in the crystal, the 
diffraction pattern observed for a single crystal is a coherent pattern of dots whose 
properties are related to the dimensions of the crystal. The diffraction pattern is the inverse 
of the crystal structure. The waves which are diffracted from planes in the real lattice of the
4
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crystal, form dots, or reflections, in the reciprocal lattice of the diffraction pattern. The 
reciprocal nature of the diffraction pattern can be comprehended with reference to Bragg’s 
law. Those sets of planes which are closer together will only give coherent diffraction at 
narrow angles of incidence, leading to more disperse spots on the diffraction pattern, 
whereas those planes which are further apart will give coherent diffraction at wider angles 
of incidence resulting in spots closer to the centre of the diffraction pattern. From this it 
follows that information about the overall structure of the unit cell contents will be more 
concentrated in the low resolution reflections at the centre of the diffraction pattern, as 
these originate at the wider spaced planes in the crystal. The details will be more 
concentrated in the high resolution reflections further out in the diffraction pattern, which 




Figure 1.3 -  The Ewald sphere construction for a set of planes that obey Bragg’s 
law. A is the crystal centre, and O, which represents the point of exit for the non­
diffracted beam, the origin of reciprocal space. The radius of the circle is MX. 
When the reciprocal lattice is rotated about O, the origin, point B in the reciprocal 
lattice intersects with the circle resulting in a reflection. This is because the 
magnitude of the vector OB, the distance between the origin of reciprocal space 
and the diffracted beam, equals M&hki where d is the lattice spacing. OC, which is 
M 2dhkh is equivalent to MX sinG. Therefore, Mldhki =1/A sin0 which is equivalent 
to sin0 2dhki= X , is Bragg’s law if n=l.
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As discussed previously, for any one angle of incident radiation, coherent 
diffraction will only occur from some sets of planes in the crystal the conform to Bragg’s 
law. This implies that diffraction patterns from many angles of incident radiation must be 
recorded to obtain all the information about the crystal. This can be easily achieved by 
rotating the crystal. This idea can also be described in reciprocal space by a sphere of 
reflection. The construction in Figure 1.3, shows that in reciprocal space there is a sphere 
of possible reflections waiting to happen when the crystal, and therefore the reciprocal 
lattice, rotates to bring them into view (Blundell and Johnson 1976). The radius of this 
sphere is the inverse of the real space wavelength. From this it follows that the shorter the 
wavelength of the incident radiation, the larger the sphere of reflection, allowing more of 
the potential reflections to be measured. Alternatively, there is more information in the 
diffraction pattern which is gained by access to the more closely spaced planes within the 
crystal.
The reflections that are recorded on the diffraction pattern actually represent a sum 
of waves diffracted from the atoms on the planes and are known as structure factors. All 
waves can be described as a sum of simple sine and cosine waves of the form
f(x) = FcoslnQvc + a)  ,
where f(x) is the vertical height of the wave, F  is the amplitude, h the frequency and a  the 
phase. Alternatively, waves can be described as a combination of sine and cosine terms 
expressed as a complex number of the form
f(x) = Fh [coslnhx + ism2n(hx) ] ,
or
f(x )= F he2M(hx).
In this form, the phase is implicit in the combination of sine and cosine terms. The 
structure factor can therefore be described as a sum of three dimensional waves as
f(x,y,z) = Y.Fhkle2M(kc + kl+t).
The contribution of individual atoms to the diffracted wave can also be written in this form 
and is known as the atomic structure factor. It is written as
6
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= j -  e 2m(hxj + kyj +lzj)
where fj is the scattering factor of the atom j, and depends on the size of the atom and xjy yj 
and Zj are the coordinates of the atom. The structure factor can therefore also be described
as a sum of these atomic structure factors
77 _  v  r  2m(hxj + kyj +lzj)
fhki ~ Z'Jj e
The intensity of the measured reflection is equal to the squared structure factor 
amplitude, but contains information about the atoms contributing to the diffraction. The 
diffraction pattern in reciprocal space, which can be described as a sum of three 
dimensional waves, and the molecular structure in real space, which can also be described 
as a sum of three dimensional waves, are therefore related by a Fourier transform. Fourier 
transforms are functions which link functions of one variable with functions of another 
variable. The structure factors can therefore be described in terms of the volume of 
electron density at any point in the unit cell by the Fourier transform
Fhkl= \ 9(x,y,z)e1’ti(hx+ky+b>,
V
where p represents the electron density at point x,y,z for a volume, F, of the unit cell. 
Alternatively, the function of electron density can be described as a Fourier transform of 
the structure factors as
p(x,y,z) = 1/FEES Fhkl e'2”ffe+^ +/z;.
h k I
These two equations are therefore essential to retrieving information about the molecular 
structure from the measured intensities, but also for checking the correctness of the 
experimental model against the observed data.
1.3 Protein expression and purification
The technique of protein crystallography (Figure 1.4) is often regarded as starting 
at the point of expression and purification of protein for crystallisation. Good data requires 
good crystals and good crystals require a good supply of highly pure (>95%), soluble, 
homogeneous protein. The use of recombinant expression systems have been a valuable 
tool in the production of large amounts of proteins which are relatively scarce in nature. 
This has lead to standard procedures where proteins from many different organisms are 
cloned into vectors for expression in Escherichia coli (E. coli). These vectors are designed
7




Data collection and processing
Phase determination
Electron density map calculation
Model building and refinement
V 7
Structure validation and analysis
Figure 1.4: A flow chart showing the steps in structure determination by protein 
crystallography.
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with high expression promoters, which are often inducible. They allow levels of protein 
expression much greater than the native level that are clearly visible by SDS-PAGE. 
Unfortunately, bacterial recombinant expression systems often result in improperly 
processed proteins, in the case of animal and plant proteins, or insoluble protein. Incorrect 
processing of proteins can be circumvented by alternative expression systems such as yeast 
cultures, insect cells, mammalian cells, or even plants, although these systems often cannot 
produce the same quantities of protein as bacteria. For some cases, E. coli can be 
engineered to express the tRNAs it lacks to increase expression and solubility of the 
recombinant protein. The use of E. coli proteins as expression tags such as glutathione S- 
transferase (GST) (Smith 2000) and maltose binding protein (MBP) (Sachdev and 
Chirgwin 2000) can also lead to greater solubility of the protein. These tags also aid 
purification by the use of glutathione and amylose affinity columns respectively. Another 
affinity tag used for purification is the His tag (Bomhorst and Falke 2000), comprising a 
short chain of histidine residues, which is purified with divalent metal ion columns. This 
tag does not help the solubility of the protein but is useful in studies where cleavage of the 
tag is inconvenient. Alternatively, insoluble proteins can also be refolded from inclusion 
bodies using a denaturant followed by dialysis or drop-wise addition into a suitable buffer. 
If optimised, this protocol often acts as a good purification step, removing the soluble 
protein.
1.4 Crystallisation
Once suitable protein has been produced, it is then persuaded to crystallise by 
mixing with various precipitants. There are two commonly used methods for 
crystallisation. The first is the direct mixing of protein and precipitant under oil. This does 
not allow for evaporation of the precipitant and gives a quick assessment of the proteins 
solubility in the various precipitants tried. This technique is becoming more common with 
large scale crystallisation trials where robots can set up many very small drops with ease, 
conserving protein. The more traditional method, still widely used by those who set up 
their crystallisations by hand, is the vapour diffusion technique. In this technique, a small 
volume of protein and precipitant are mixed together and suspended over a reservoir of the 
precipitant in an air tight system. Water vapour can then diffuse from the drop into the 
reservoir, concentrating the protein and allowing crystallisation. Despite much research 
into crystallisation and characterisation of the crystallisation process, most crystallisation
9








Figure 1.5: Diagram showing the change in protein saturation for increasing 
precipitant and protein concentrations. Below the solubility curve the protein is 
undersaturated and cannot crystallise. The metastable zone is where the protein 
saturation is not high enough to nucleate crystals but will allow growth of seeds. 
Above the supersolubility curve, there is too much protein to stay in solution and the 
excess protein will either nucleate crystals or precipitate. The ideal protein 
concentration is just high enough to nucleate crystals which will then grow in the 
metastable zone due to the decrease in soluble protein concentration during crystal 
growth.
attempts are characterised by a trial and error method. In some cases previous knowledge 
of the solubility of the protein in different salts or buffers may be used to design a 
crystallisation trial, but more often a commercial screen of widely used precipitants is used 
as a starting point. If no preliminary crystals are produced, however, the protein solubility 
in various precipitants must be used to design further screens.
The solubility of a protein depends on several factors of which the main ones are its 
concentration, the pH of the solution, the concentration of any precipitants and the 
temperature (McPherson 1985). For crystals to grow, these factors need to conspire to
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supersaturate the protein in the solution without precipitating it (McPherson 1990). The 
effect of protein and precipitant concentration on the solubility can be demonstrated 
schematically by a simple graph as shown in Figure 1.5. Therefore, the aim of the 
crystallisation trial is to optimise all these factors to give good quality crystals.
Although there is some guess-work in determining the type and concentration of 
precipitant to use, it is well known that there are two stages to crystal growth, nucleation 
and growth. However, the conditions required for nucleating crystals are not always the 
same as those which encourage growth of a large crystal from the nucleus. This has lead to 
the development of a technique known as seeding, where small crystals nucleated in one 
condition, are transferred to a slightly different condition to be allowed to grow further. 
This technique can also be used when a condition that nucleates well, cannot grow the 
crystals due to protein depletion following too much nucleation. There are three main ways 
of seeding: macroseeding, microseeding and streak seeding. Macroseeding involves the 
transfer of one small crystal, or ‘seed’, into a new drop, sometimes after a ‘wash step’ to 
get rid of any impurities that may be preventing growth on the surface (Thaller et al. 1985). 
Microseeding avoids that problem by transferring small fragments of crystals which have 
been crushed and diluted with the crystallisation solution. The dilution step allows control 
of how many ‘seeds’ are added to the drop (Fitzgerald and Madsen 1986). Streak seeding 
involves transferring seeds into a new drop by touching an existing crystal, or crystalline 
precipitate, with a cat’s whisker, or similar, and then running it through the new drop 
(Stura and Wilson 1991). It can be harder to control the number of seeds in this method but 
works well for some crystals.
1.5 Crystal manipulation
The mounting of a crystal for data collection depends on whether the crystal is 
going to be frozen. For data collection at room temperature, the crystal must be sucked 
from the crystallisation drop into a thin glass capillary, with some of the crystallisation 
solution, or ‘mother liquor’. A drop of mother liquor in the capillary with the crystal is 
essential to stop the crystal drying out, due to the high water content of protein crystals 
(Blundell and Johnson 1976). This capillary is then sealed at both ends with wax, ready for 
mounting on the goniometer head. It is becoming more common, however, to freeze 
crystals at 100K for diffraction as this can reduce the amount of radiation damage the
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crystal receives, allowing more data to be collected from a single crystal. This is 
particularly useful for anomalous dispersion techniques if several wavelength data sets can 
be collected from one crystal to avoid non-isomorphism. However, not all crystals can be 
successfully frozen without disruption to the crystal lattice. Crystals that are frozen often 
need to be soaked in a cryoprotectant first. This reduces the amount of water picked up 
with the crystal and also prevents icing of the solvent in the crystal on freezing. Both 
excess water and ice diffract x-rays to produce noise in the diffraction pattern. 
Cryoprotectants are usually viscous liquids such as glycerol, oils, or high concentrations of 
polyethylene glycol (PEG). The crystal, held by a nylon loop, is soaked briefly in the 
cryoprotectant before being mounted on the goniometer head where it is flash-frozen in the 
cold nitrogen stream used during data collection.
1.6 X-ray sources
The X-rays used for protein crystallography usually come from one of two sources. 
Crystallography laboratories often have rotating copper anode tube as a ‘home’ source. 
Electrons from a cathode are accelerated towards a rotating, water-cooled, copper anode, 
resulting in emission of Cu-Ka radiation at a fixed wavelength of 1.54A. Home sources 
are ideal for characterising crystals and collecting data for crystals that diffract well. 
Synchrotron sources, however, have many advantages of shorter wavelength radiation, 
tuneable wavelength radiation, greater brilliance and greater flux (Helliwell 1997). 
Synchrotron radiation is produced when electrons are accelerated near the speed of light by 
a magnetic field. The forced curving of the electron path as they are accelerated around the 
large storage ring, causes a loss of energy resulting in the emission of electromagnetic 
waves. This electromagnetic radiation, emitted at a tangent to the ring, is then guided and 
focussed for use in experiments. Because of the complete range of electromagnetic 
radiation produced, the experimental stations can be designed to offer a range of X-ray 
wavelengths for diffraction experiments. This not only allows very high resolution 
experiments, but also the ability to choose wavelengths close to the absorption edge of 
heavy metals for anomalous scattering experiments.
1.7 Data collection
There are many factors to be considered in data collection to achieve the highest 
possible resolution data set for the crystal. The diffraction limit depends on the order of the
12
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crystal and the wavelength of the x-radiation being used. The increasing use of synchrotron 
radiation at shorter wavelengths under lA  has lead to more high resolution structures. 
However, the intensity of synchrotron radiation which allows a better signal to noise ratio, 
also brings problems of radiation damage. Radiation damage can be reduced by freezing of 
the crystal, as mentioned above, but has also led to an improvement in detector systems. 
The quicker the data can be recorded for each orientation of the crystal, the less time the 
crystal is exposed in the beam. A commonly used detector at synchrotrons is the charge- 
coupled device, or CCD, detector. CCDs accumulate charge on the pixels of the detector 
where the radiation hits. These charges are systematically passed via fibres to an amplifier 
before reading. The CCD detector has the advantage of accurate recording of the position 
and magnitude of the reflections, which are continuously read, making data collection fast 
and accurate.
The advances in ciyo data collection and fast detectors combined with automation 
of the data processing and scaling software allow highly redundant, mostly complete data 
sets to be collected with ease for most good crystals. HKL2000 (Otwinowski and Minor 
1997) can process the data simultaneously with data collection. This provides immediate 
assessment of the quality of the data as well as the completeness of the data set, allowing 
alterations to be made to the data collection strategy if necessary. Rapid deterioration of a 
crystal can be spotted allowing the crystal to be changed. Also, completeness of data sets 
for very mosaic crystals can be monitored. Mosaicity, or disorder, in the crystal can cause 
each Bragg reflection to be recorded in more than one position, making the data harder to 
process. In the case of high mosaicity, high redundancy in the data is required to be able to 
scale a complete data set.
Although the data collection can be monitored, several important factors should be 
considered before starting a data collection run. Initial images of the crystal should be used 
to optimise the exposure time, depending on the strength of diffraction, the crystal to 
detector distance, depending on the diffraction limit of the crystal, the probable number of 
images to be collected, depending on the symmetry of the space group, and the angle 
through which the crystal is rotated, depending on the size of the unit cell (Dauter 1997). 
For example, most reflections for the space group P222 can be collected with a 90° rotation 
of the crystal, although more images should be collected to get good redundancy to reduce 
errors.
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1.8 Data processing and scaling
The choice the unit cell within the crystal lattice can be arbitrary, but is usually 
chosen as the smallest volume unit cell that displays obvious rotational symmetry and 
retains perpendicular lattice translations. The crystal lattice spacings are calculated as the 
inverse of the reciprocal lattice of the diffraction pattern by software which then 
statistically ranks possible lattices and unit cells. It is practice to choose the best ranked 
highest symmetry lattice to process the data in. The space group is chosen during scaling 
based on systematic absences. The procedure of processing the data involves the indexing 
all of the reflections from planes in the chosen unit cell. Following indexing, the data is 
scaled so that the backgrounds from different diffraction images match (Leslie 2001). 
Scaling can also combine data sets from more than one crystal, as long as the crystals are 
isomorphous, i.e., have the same unit cell dimensions.
The output from the programs that scale the data display important statistical 
information about the quality of the data. The first of these is the data completeness. For a 
given space group, at a particular resolution, the number of possible reflections from 
planes in the crystal can be calculated. This is then compared to the number of unique 
reflections recorded in the data collection and the completeness calculated as a percentage. 
A complete data set, which is usually easily achievable with modem x-ray sources and fast 
detection systems, is ideal, and can make the structure solution more straight forward. It is 
particularly necessary for anomalous scattering phasing methods to ensure the anomalous 
signal is as clear as possible. For less than ideal situations, e.g. where the crystals are very 
mosaic, a lower level of completeness can still allow a more careful structure solution.
Another measure of the quality of the data is Rsym. Rsym measures the ratio of the 
mean difference between symmetry related intensities that should be the same and the 
mean magnitude of the intensities. This value depends on the order of the crystal but may 
also reflect inaccurate detecting of the reflections. As many of the reflections are measured 
more than once in data collection, another value often quoted is Rmerge, which averages the 
intensities and differences of the other equivalent reflections as well. A low percentage 
value of Rmerge indicates accurately recorded data, but it is important not to ignore less 
accurate reflections at the expense of the completeness. A value of 5% for Rmerge is very
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good. For higher resolution structures, or more redundant data, values of up to 15% may be 
acceptable, as Rmerge increases with redundancy.
The resolution to which a data set can be considered reliable, depends on the 
completeness, Rmerge» and also the signal to noise ratio, known as I/ct(I) (Dauter 1997). This 
is the ratio of the mean reflection intensity to the standard deviation of the intensities. All 
of these statistics are calculated for resolution bins as well as the entire data set and in the 
case of I/a(I), the figure for the highest resolution bin will show whether spots for that 
resolution can actually be seen. The Wilson B factor for the data is also linked with 
resolution. The Wilson B factor, or temperature factor, gives an indication of the disorder 
of the crystal by the comparison of the decrease in the intensity of reflections with 
increasing resolution. To take into account the decrease in the contribution of any 
particular atom at higher resolution, the mean intensity for a given resolution is divided by 
the mean intensity for the average protein. A graph of the log (I/f2) against (sin0/X)2, where 
I is the mean intensity, f  is the mean protein and X is the wavelength, gives a straight line 
with a gradient equalling -B  in A 2. It is practise to set the initial atomic B factors for your 
model to this value.
When data are being assessed, all these statistics should be considered as the 
relationship between them often allows one to be improved at the expense of the others. 
For example, the completeness of the data can usually be improved by limiting the 
resolution, with loss of the higher resolution reflections. The scaling of the data therefore 
needs to combine these factors sensibly to produce the highest resolution, best quality data 
set.
1.9 Phasing methods
The necessity of collecting unfocussed x-rays as a diffraction pattern causes the 
loss of phase information and has been termed ‘the phase problem’. In order to calculate 
the molecular transform from the diffraction pattern the phases need to be estimated. 
Currently, there are three techniques in use and crystallographers choose one or a 
combination depending on the appropriateness for the problem. Two of these methods 
provide ‘novel’ phases, for molecules for which no structural information is known 
whereas the third requires the use of a homologous model.
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1.9.1 Novel phasing methods
Multiple Isomorphous Replacement- Multiple Isomorphous replacement (MIR) is 
the classical method for solving new structures which utilises phase information from the 
comparison of structure factors from native and derivative crystals, soaked in heavy metals 
(Green et al. 1954). Because atoms contribute most strongly to structure factors from 
planes which intersect their positions, the uniform addition of heavy atoms, with larger 
scattering factors, at certain points in the unit cell gives rise to an increase in the amplitude 
of those structure factors. If the native and the derivative crystals are isomorphous the 
resulting intensities can be compared with the native intensities to retrieve phase 
information for these atoms. This phase information can then be used to position these 
heavy atoms in the unit cell to provide a rough framework for the model to be built into. 
To determine the phases as accurately as possible, several derivatives are often necessary, 
requiring the careful production of many isomorphous derivative crystals.
Anomalous Scattering- The other technique for novel phase estimation uses the 
absorption of x-radiation by heavy atoms to derive information about phases (Hendrickson 
et al. 1985). All diffraction patterns are centrosymmetric as diffraction from each plane 
gives 2 reflections, hid and -h-k-l which are equal in intensity. This is known as Friedel’s 
law. All atoms absorb radiation at specific wavelengths which correspond to the required 
energy for electron excitation. For certain heavy atoms, these wavelengths correspond to 
X-radiation wavelengths suitable for crystallography. If the x-rays used for the experiment 
are tuned to this absorption edge, the absorption of the radiation results in an observable 
breakdown in Friedel’s law known as anomalous scattering, which can be used to retrieve 
phase information for these atoms. This technique can combat the problem of non- 
isomorphism of heavy atom soaks as the same frozen crystal may last long enough to 
record native (at a low-absorbing wavelength) and anomalous data sets. Another advantage 
of this method is the option of using seleno-methionine, with an absorption edge at 0.98A, 
which can be incorporated during expression of the protein. Bacterial cultures grown in 
seleno-methionine media can be used to produce recombinant proteins where methionine is 
uniformly replaced with seleno-methionine, which circumvents the need for crystal 
soaking. However, anomalous scatterers can be added by crystal soaking which requires 
optimisation by trial and error, as for MIR, to produce good diffracting, isomorphous,
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derivative crystals. This technique is also particularly useful for metal containing proteins 
such as metalloproteases.
The use of a combination of both these methods to estimate phases is also 
increasingly common. Phase information from the increased scattering factor and the 
anomalous scattering of heavy atoms can be combined in a technique referred to as Single 
Isomorphous Replacement with Anomalous Scattering, or SIRAS. In practise, there are 
now a good range of phasing and density modification programs that with the use of 
excellent data collection technique and careful refinement, structures can be solved with 
very minimal phase information.
1.9.2 Molecular replacement
If the structure to be solved has over 30% sequence identity with another protein, 
this usually indicates that they share a common fold. Molecular replacement takes 
advantage of the reversible nature of Fourier transforms to calculate phases from a known 
model to use as an estimate for the structure to be solved. The proposed model is unlikely 
to share the same space group or orientation as the unknown structure so the molecular 
replacement program is required to find a rotation matrix and translation vectors which 
relate the known model to the unknown structure. This is achieved by moving the known 
model through a random unit cell with the unknown structure in. In practice, however, to 
find the six variables is a computationally demanding task and so the search is split into 
finding the orientation first and then the translation.
This is commonly done using Patterson functions. Whereas the Fourier transform 
relates the intensities and phases of the reflections to the model structure, the Patterson 
function relates the squared intensities of the data to a set of vectors between the atoms. 
Therefore, a Patterson function can be accurately calculated for both the known model and 
the unknown structure.
The Patterson function can be written as
P(u) = E I Fh 12 exp -2nU,u,
which is the same form as the electron density equation but using squared amplitudes 
rather than a phase term in the exponential. As the Patterson function describes the relation 
of the atoms within the structure to themselves, if the known model and the unknown
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structure are indeed similar in shape, they should produce similar Patterson maps which 
can then be rotated until they match (Rossmann and Blow 1962). For whole proteins, 
however, the Patterson map is very complicated and the parameters of the search often 
need careful planning.
In order to find a good match where the two structures only share low sequence 
identity it is often necessary to perform the rotation search at low resolution This prevents 
the details of the two structures, which are likely to be different, confusing the matching of 
the overall fold. The model used is also an important factor and it is often helpful to delete 
flexible termini or different sized loops which enhance the differences between the two 
structures. Additionally, the sphere radius over which the functions are compared can 
affect the success of a match. The Patterson map from the unknown crystal structure will 
also contain vectors which relate symmetry related molecules in the unit cell, known as 
cross-vectors. The sphere radius therefore needs to be large enough to include enough 
intra-molecular vectors so a good match can be found, but not too large, that the match is 
overwhelmed by the noise of the intermolecular vectors. The translation function also uses 
Patterson functions and works in a similar way. In this case, the intermolecular vectors of 
the unknown structures are overlapped with generated intermolecular vectors, of the same 
symmetry, for the model.
The hardest part of finding a molecular replacement solution is actually working 
out at which coordinates the known model superimposes on the unknown structure. The 
problem of identifying a correct solution for molecular replacement occurs due to the way 
the matches are ranked statistically. The program AMORE (Navaza 1994) ranks possible 
rotations by correlation coefficient and R factor. The correlation coefficient compares the 
position of the peaks in the Patterson functions and their signs within a volume of the 
model and scales the results to -1 to 1. The R factor is the ratio of the difference between 
the observed and calculated amplitudes to the size of the observed amplitudes and can be 
expressed mathematically as
2  I |F obs| -  \Fcalcl I •
R = ----------------------
2  F o b sl
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However, the solution with the best statistical scores is not always the correct one, and 
solutions need to be checked to be able to generate proper, non-clashing, symmetry related 
molecules on the graphics computer. The program Molrep (Vagin and Teplyakov 1997) 
checks the symmetry clashes as well so is therefore more likely to offer the correct 
solution.
If there is more than one molecule in the asymmetric unit, molecular replacement 
will have to be repeated for each of the other molecules. The knowledge of the number of 
molecules in the unit cell comes from the Matthews coefficient (Matthews 1968) which, 
from the size of the protein and the unit cell, estimates the solvent content o f the crystal for 
different numbers of molecules in the unit cell. These solvent contents are then compared 
to the average solvent content of protein crystals to determine how many molecules per 
asymmetric unit there are.
1.10 Electron Density Maps, density modification and model 
building
Once the rotation and translation operations, or the heavy atom positions, have been 
found the model phases can be combined with the observed amplitudes from the 
diffraction pattern. These structure factors can then be refined against the model structure. 
If the MR solution or the heavy atom positions are correct, the R-factor, which is the ratio 
of the difference between the computed amplitudes for the model and the observed 
amplitudes, to the observed amplitudes, should go down. These structure factors can then 
be used to generate an initial map, which if the phase information is good enough, should 
be interpretable. There then follows many round of model building and refinement to 
generate a model which represents the observed data as closely as possible.
One of the skills required by crystallographers is map interpretation (Jones and 
Kjeldgaard 1997). The electron density equation generates values for electron density for 
each point, p(x,y,z,), in the unit cell, from the structure factors. These figures are then 
displayed as three dimensional contour maps on a graphics computer using a program such 
as O (Jones et al. 1991). In order not to bias the map to the model structure-factor 
amplitudes, these are normally subtracted from a multiple of the observed amplitudes e.g. a 
2F0-FC map is the sum of twice the observed structure factor amplitudes, minus the
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calculated amplitudes, multiplied by the phase term. This map is used to represent the 
positive, continuous electron density of the model. F0-Fc maps are also generated and these 
provide both positive peaks, where there is something in the data which is lacking in the 
model, and negative peaks, where there is something in the model which is not in the data. 
This map, along with the amino acid sequence of the protein, is essential in improving the 
model so that the calculated model amplitudes more closely resemble the observed 
amplitudes. Both the 2F0-FC map and the F0-Fc maps are contoured to a set level for 
viewing in the graphics, but local adjustment of these levels is often useful to see where the 
peaks are strongest to help interpret the map. Also, for parts of the model which are 
uncertain, the use of omit maps can be very useful. These maps omit all the structure 
factors for the uncertain bit of the model out of the map calculation to produce a map 
without model bias for that area.
For structures solved by molecular replacement, the initial model is usually 
reasonably good and gives a map which is interpretable in most places. Initial maps for 
structures solved by multiple isomorphous replacement or anomalous scattering, however, 
are not always as easy to interpret. For these maps in particular, the technique of density 
modification is very useful. Density modification takes general knowledge about protein 
structures and electron density maps not found in the structure factors to improve the maps 
(Zhang et al. 1997). The first of these is solvent flattening. Protein crystals often contain 
50% or more solvent which is disordered in the crystal and therefore does not produce 
strong peaks in the map, unlike the protein. Solvent flattening attempts to define the 
boundary between the protein and the solvent mass and then assign the solvent to a fixed 
level. This electron density distribution can then be used to calculate new structure factors, 
the phases of which can be combined with the previous phases to produce a better estimate, 
and therefore a better map. This effectively makes the protein part of the map stand out 
more from the bulk solvent. Histogram matching is another technique that improves the 
protein part of the electron density to improve the phases. The electron density can be 
represented as a histogram with peaks where protein regions lie. From knowledge of 
previously refined structures, it is known that these histograms have a usual shape for 
protein structures at particular resolutions. In this technique, the histograms are fitted to 
this expected shape, improving the electron density and therefore the phases. Another 
essential density modification technique is the use of non-crystallographic symmetry. 
Where there is more than one molecule in the asymmetric unit, providing the symmetry
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axes which relate these molecules are known, the electron density peaks for these 
equivalent regions can be averaged to cancel out noise from the solvent and poor phases. 
This technique has been particularly powerful for structures with multiple copies (e.g. virus 
structure solution).
Model building itself is often carried out with the program O (Jones et al. 1991) on 
the graphics computer. This program allows the electron density to be displayed as a 
contour map and a stick representation of the model coordinates to be manipulated to fit 
the map better. The new coordinates from the manipulated stick representation can then be 
output for refinement.
1.11 Refinement
Between rounds of model building in real space, reciprocal space refinement is also 
used to improve the model. Refinement is the optimisation of a function, to find the global 
minimum, by changing the parameters of the model. The function to be optimised in 
crystallography is the agreement between the observed structure factor amplitudes and the 
calculated model amplitudes. The model parameters include the position, occupancy and B 
factors of the atoms. The function used for this refinement, as well as the method of 
optimisation, varies between refinement programs. The traditional function used as 
implemented by SHELX (Sheldrick and Gould 1995; Sheldrick and Schneider 1997) is the 
Least Squares (LS) function which is the sum of the weighted differences between two sets 
of observations (the observed and calculated amplitudes). The limitation of least squares is 
that it assumes the errors in the model are independent and normally distributed and so 
mainly works best on models where the phase information is already good. An alternative 
to Least Squares is the Maximum Likelihood (ML) function implemented in Refinac 
(Murshudov et al. 1997) and CNS (Briinger et al. 1998). The ML function finds the set of 
parameters which are the most probable to produce the experimental results seen. The 
advantage of ML is that, although it still assumes that all errors are independent, it models 
the errors better and does not assume they are normally distributed. The third option is 
energy minimisation, also implemented in CNS, for which the target is the model with the 
lowest calculated energy.
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As well as differing in the target function, programs also differ in their method of 
optimisation, which often involves derivitising the function. An example of optimisation 
using no function derivative is simulated annealing, implemented by CNS (Briinger and 
Rice 1997). This technique optimises to the lowest energy model. It has a large radius of 
convergence and the advantage of overcoming local minima by simulated slow cooling of 
the model from a high temperature. Derivative function methods include conjugate 
gradient method, also used in CNS and full matrix minimisation implemented by SHELX. 
Derivative optimisation allows a faster rate of convergence of the function, but often at the 
expense of a smaller radiance of convergence, making entrapment in local minima more 
likely.
To avoid model bias and entrapment in local minima, it is often helpful to start 
refinement at a lower resolution and increase this resolution in one or more steps. This 
ensures the gross features of the model are correct first and that wrongly assigned details 
do not bias the model. Using restraints and constraints in refinement is also important, 
especially at low resolution. Model parameters can only be optimised if there is enough 
data that the refinement is over determined. Adding restraints increases the observation to 
parameter ratio. Therefore, a good technique is to restrain the geometry of the protein 
tightly until the phases are more accurate as distortions in local geometry cannot be 
assigned without good phases. Restraining non-crystallographic symmetry partners 
together is also particularly useful and can average out noise in the phases. Initial 
refinement is usually rigid body refinement where the protein is refined as a whole 
followed by optimisation of atom positions. If the data is of a high enough resolution, 
water molecule positions and protein B factors can also be refined.
The refinement process is usually monitored by two parameters, Rcryst and Rfree- The 
Rcryst (also just known as R) is calculated as the sum of the differences between the 
modulus of the observed and calculated structure-factor amplitudes divided by the sum of 
the observed structure-factor amplitudes as discussed previously. This is a measure of how 
well the model fits the data. The Rfree is calculated as the Rcryst but for a randomly selected 
percentage of reflections known as the test set which are not used in the refinement 
(Briinger 1992). This acts as a cross validation tool to check that the refinement is not 
biasing the model away from the data. As cycles of real space modelling and reciprocal 
space refinement proceed, both R factors should decrease as the model structure converges
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with the observed data. Towards the end of refinement structured solvent molecules can be 
modelled and these reduce the R factors further. The quality of the model should not just 
be judged by the R factors though and it is important that the structural geometry is good, 
and that the map appears to be interpreted as far as possible.
1.12 Structural validation
Although R factors give an indication of the quality of the model, it is important to 
use additional measures to validate the model (Kleywegt and Jones 1997). The most 
common of these is the Ramachandran plot (Ramachandran et al. 1963) which displays the 
peptide phi and psi angles for all residues in the model. It is important that over 90%, and 
preferably, 100% of the residues are in the ‘allowable’ regions. This plot gives a good 
estimate of the geometric accuracy of the model. Root mean square deviations from 
ideality can also be calculated for bond angles and lengths. It is important that models 
adhere to these geometric restraints unless they are of a high enough resolution (>lA) that 
there is sufficient data to refine them. Another important factor when analysing structures 
is the B factor as although a low B factor does not always mean a good model, or a well 
placed side chain, a high B factor can indicate a problem with the model or high mobility 
which cannot be modelled. Often density is missing for regions with high B factors. It is 
important when analysing structures to consider all these indicators as none of them are 
sufficient in isolation. The program PROCHECK (Laskowski et al. 1993) is useful for 
these types of validation. Once a correct model is achieved, it can then be analysed for its 
biological relevance and the coordinates deposited in the Protein Data Bank (PDB).
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The results in this thesis cover the C3-like exoenzymes (ADP-ribosylating toxins), 
their interactions with Rho GTPases and also the botulinum neurotoxins. Therefore, this 
introduction starts with a brief structural overview of the other ADP-ribosylating toxins as 
well as the Rho GTPases. Crystal structures of Rho GTPase complexes are also described 
as a background to how they interact with other proteins. These brief overviews are 
followed by a more in depth literature review of the best characterised C3-like exoenzyme, 
C3 from Clostridium botulinum. Finally, a brief introduction to botulinum neurotoxin 
structure and function is given. Brief introductions to later chapters will build on this 
background information to present the context of the work described as relates to the 
current literature.
2.2 ADP-ribosylating toxins
ADP-ribosylation is a common mechanism for many bacterial toxins. These toxins 
catalyse the cleavage of NAD with transfer of ADP-ribose to the target protein and release 
of nicotinamide (Figure 2.1). Bacterial ADP-ribosylating toxins (ADPRTs) are grouped 
into several structural and functional classes. All structures of ADPRTs solved so far reveal 










Figure 2.1: Schematic picture of NAD showing the cleavage site during ADP- 
ribosyltransfer.
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A
Figure 2.2: The cell binding (pink) and catalytic (blue/green) domains of the 
ADP-ribosylating toxins. A, Diphtheria toxin (PDB code 1SGK) (Bell and 
Eisenberg 1997), B, Catalytic component of the Iota toxin (PDB=1GIQ) (Tsuge et 
al. 2003), C, C3 exoenzyme (PDB=1G24) (Han e t a l. 2001) and D, Cholera toxin 
(PDB=1XTC) (Zhang e t a l  1995).
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see (Passador and Iglewski 1994; Krueger and Barbieri 1995) (Figure 2.2). The first 
structural group, which is characterised by Diphtheria toxin (DT) and Pseudomonas 
aeruginosa Exotoxin A (ETA), are synthesised and released as a single polypeptide but are 
later cleaved to form two domains linked by a disulphide bridge. These two domains 
comprise an A, or ADP-ribosylating domain and a B, or cell binding domain (Figure 2.2). 
Both toxins ADP-ribosylate elongation factor 2 (EF-2), inhibiting protein synthesis. 
Cholera toxin (CT) and Escherichia coli heat-labile enterotoxins (LT) characterise a second 
group of ADPRTs which ADP-ribosylate the small heterotrimeric G-proteins. These toxins 
also have A and B subunits but with the stoichiometry A:Bs. The binary toxins, which 
ADP-ribosylate actin, are characterised by Clostridium botulinum C2 toxin, Clostridium 
perfringens Iota toxin and Vegetative Insecticidal Protein (VIP) from Bacillus cereus. 
These toxins are synthesised as two separate ADP-ribosyltransferase and cell binding 
proteins which are not linked. Finally, the C3-like exoenzymes, characterised by C3 from 
Clostridium botulinum, ADP-ribosylate Rho GTPases and comprise a single enzymatic 
subunit with no cell binding domain. The groups of toxins can also be split into two 
families based on their catalytic residues. All ADP-ribosyltransferases utilise a conserved 
glutamate for catalysis. However, the CT-like, binary and C3-like toxins also require a 
glutamate/glutamine adjacent but one of the N-terminal side (Han and Tainer 2002) (Figure
2.3). This residue is associated with substrate recognition as it is a glutamine amongst the 
asparagine-ribosylating C3 exoenzymes (Figure 2.3) but a glutamate amongst the arginine- 
ribosylating binary and CT-like toxins. The DT-like toxins, like the eukaryotic poly ADP- 
ribosyltransferases (PARPs) lack this residue.
Figure 2.3: Sequence alignment of the C3-like and binary toxins. Residue numbers are 
from the first residue of the mature protein except for C3botl and 2 where they are labelled 
as the crystal structure. Residues conserved in all toxins are shown in red, those just 
conserved in C3-like exoenzymes in pink and those in the four binary toxins shown, in 
blue. The YXSTX motif is highlighted blue, the phosphate-nicotinamide (PN) loop, in grey 
and the ADP-ribosylating toxin turn turn (ARTT) loop in yellow. The arginines conserved 
in C3-like toxins are labelled above, 1-4. 2 and 3 are conserved in the binary toxins. Y246 
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4 1 ---------- a y s n t y q e f t n i -d q a k a w g n a q y k k y --g l s k s e k e a i v s y t k s a -s e i n g k l r q n k g v i n g f p s n l i k q v e l l d k s f n k --m k t p e n i m i .f r
4 1 ---------- SYADTFTEFTNV-EEAKKWGNAQYKKY— GLSKPEQEAIKFYTRDA-SKINGPLRANQGNENGLPADILQKVKLIDQSFSK— MKMPQNIILFR
1 ---------- PYADSFKEFTNI-DEARAWGDKQFAKY— KLSSSEKNALTIYTRNA-ARINGPLRANQGNTNGLPADIRKEVEQIDKSFTK— MQTPENIILFR
1 GNIPTKPKDCNNVDKYKLCTNK-EEADAWGKKQFNKW SKEEKSAIRDYTKNA-RPYNEFLRMHAGKLDS-DPTMKKKIESLDKALNRKEAKVNDNIKVYR
I -------------- ADVKNFTDL-DEATKWGNKLIKQA— KYSSDDKIALYEYTKDS-SKINGPLRLAGGDINKLDSTTQDKVRRLDSSISK— STTPESVYVYR
1 -------------- AETKNFTDL-VEATKWGNSLIKSA--KYSSKDKMAIYNYTKNS-SPINTPLRSANGDVNKLSENIQEQVRQLDSTISK— SVTPDSVYVYR
1 -------------- DDVKNFTDL-TEATNWGNKLIKQA--NYSSKDKEAIYNYTKYS-SPINTPLRSSQGDISNFSADLQEKILRLDRLISK--SSTSDSVYVYR
266 -------------- KSLDFKNDINAEAHSWGMKNYEEWAKDLTDSQREALDGYARQDYKEINNYLRNQ-GGSGNE— KLDAQIKNISDALGK— KPIPENITVYR
2 1 4 ---------- SLSQELDFYNKG SEAWGAENYGDYISKLSHEQLGALEGYLHSDYKAINSYLRNN-RVPNND— ELNKKIELISSALSV— KPIPQTLIAYR
2 1 1 -----------------LDFKDDV-SKGDLWGKENYSDWSNKLTPNELADVNDYMRGGYTAINNYLISN-GPLNNPNPELDSKVNNIENALKL— TPIPSNLIVYR
257 ---------------- LDFKDDV-SKGDSWGKANYSDWSNKLSSDELAGVNDYMRGRYTAINNYLIAN-GPTNNPNAELDAKINNIENALKR— EPIPANLWYR
3 4
129 GDDPAYLGT------- EFQ-NTLLNSNGTINKTAFEKAKAKFLNKDRLEYGl
12 9 GDDPAYLGP------- EFQ-DKILNKDGTINKTVFEQVKAKFLKKDRTEYG
8 9 GDDPGYLGP--------DFE-NTILNRDGTINKAVFEQVKLRFKGKDRKEYG
98 GDDAWIFGK--------EYD-NSII-KNGKVDREKFKEIQKKFQGKTTTEFG
8 6 LLNLDYLTSIVGFTNEDLY-KLQQTNNGQYDENLVRKLNNVMNSRIYREDG 
86 LLNLDYLSSITGFTREDLH-MLQQTNNGQYNEALVSKLNNLMNSRIYRENG 
8 6 LLNLDYLSSVKGFSSEDLE-LLYKTENGKYNEELVKKLNNIMNSKIYTEYQ
339 WCGMPEFGYQISDP-------- L---------- PSLKDFEEQFLNTIKEDKG
300 RVDGIPFDLP -S— DFSFDKKENGEIIADKQKLNEFIDKWTGKEIENLS
2 96 RSGPQEFGLTLTSP--EYDFNKI--------- ENIDAFKEKWEGKVITYPN
341 RSGPQEFGLTLSSP— EYDFNKV--------- ENIDAFKEKWEGQTLS YPN
220 HSTYHIDDMRLSS-----DG---- KQIIITATMMGTAINPK 251
219 NNSYYISDMQISP-----NN---- RQIMITAMIFK-------- 244
180 SSTYTISDMQIAP-----NN---- KQIIITALLKR-------- 205
191 NTVYKIEKIYIAI---- DNNTQKEQIKVEATIK--------- 219
186 GTEYAVGSVELSN-----DK---- KKIIITAIVFKK 212
18 6 GTEYAVGSVKLSD-----NK---- RKI11TAWFKK 212
186 GTDYTINTVKLSD-----DH---- KRILIEGIVFKK 212
433 DSKYHIDKVTEVI---- IKGVK— RYWDATLLTN 4 61
395 NSTFKIFRITPITSIINRVTKMT— QVVIDAEGIQNKEI—  431
385 GSKFKINKVDSYK---- DGTVT— KLILDATLIN-------- 413
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The first ADPRT structures solved, ETA and DT, revealed the ADP-ribosylating 
domain comprised two perpendicular p-sheets surrounded by a-helices (Figure 2.4). The 
active site resides in a cleft at the junction of the two p-sheets between one of the P-sheets 
and helix 3 (Choe e t a l. 1992). It is not similar to the Rossman fold binding cleft of 
dehydrogenases where NAD/NADH are used as cofactors (Allured e t a l. 1986). The 
structure of DT with NAD (Bell and Eisenberg 1996), demonstrated that NAD binds DT, in 
a manner different to that observed for dehydrogenases, with a conformation which was 
presumed to aid cleavage of the N-glycosidic bond on catalysis. Additionally, DT 
undergoes structural change upon NAD binding, resulting in a loop near the active site 
(now termed the active site loop) becoming disordered (Bell and Eisenberg 1996) (Figure
2.4). The loop, which is stabilised by a hydrogen bond network in the NAD free structure, 
was proposed to be disrupted by NAD interference with its bulky hydrophobic residues. 
This disruption was speculated to be an important step prior to protein substrate binding 
(Bell and Eisenberg 1997).
active site loop
Figure 2.4: A, Diphtheria toxin (PDB=1SGK) (Bell and Eisenberg 1997) with 
a-helices in turquoise, p-strands in blue and the active site loop in orange. B, 
Diphtheria toxin in complex with NAD in pink (PDB=lTOX) (Bell and 
Eisenberg 1996) and the active site loop missing.
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By comparison, the binary toxins have not been as well studied as the A:B toxins 
and the most well characterised are C2 from Clostridium botulinum, the Iota toxin from 
Clostridium perfringens and the vegetative insecticidal protein (VIP) from Bacillus cereus. 
The first extensive analysis of the residues involved in catalysis for a binary toxin, C2, 
confirmed that both the conserved catalytic glutamate and the second conserved glutamate 
in the binary toxins were both essential for ADP-ribosyltransferase activity. Also, the first 
serine of the conserved STX (also known as STS for binary toxins) motif and the conserved 
arginine in the binary and C3-like toxins (labelled 2 in Figure 2.3) were essential for this 
activity (Barth et al. 1998).
In the presence of NAD, but absence of protein substrate, all ADP- 
ribosyltransferases will undergo a slow NAD hydrolysis activity, effectively transferring 
the ADP-ribose group to water. Assays of this activity can be used in site directed 
mutagenesis studies to categorise residues as important for NAD binding/hydrolysis rather 
than protein substrate binding/transferase activity in vitro. Interestingly, mutation of the 
second conserved glutamate abolished ADP-ribosyltransferase activity but had very little 
effect on NAD hydrolysis suggesting that this residue is only important for the former 
(Barth et al. 1998). Mutation of the threonine of the STX motif was found to reduce the 
glycohydrolase activity suggesting a possible role in binding or hydrolysing NAD.
The first crystal structure of a binary toxin, VIP2 (2 denoting the enzymatic 
component rather than the cell binding component), and its complex with NAD, showed it 
to be a modular protein with a catalytic C-terminal domain and a homologous N-terminal 
domain which is required for interacting with the cell binding component (as shown for the 
Iota toxin in Figure 2.2) (Han et al. 1999). Both domains share a similar overall fold to the 
catalytic domains of DT and CT. They consist of a core comprising a five-stranded mixed 
p-sheet packed against a three-stranded antiparallel p-sheet flanked by five a-helices. 
However, they lack an active site loop equivalent to that in DT (Han et al. 1999). NAD 
bound in the cleft between the five-stranded p-sheet and the third a-helix (a8) (Figure 2.5). 
The flexibility of the toxin was revealed by the four independent molecules of VIP2 in the 
unit cell being of two distinct conformations, depending on a 6° rotation of the sub-domain 
including a8 towards the active site. By contrast, the NAD complex was in an intermediate 
conformation with a 3° rotation (Han et al. 1999) (Figure 2.5).
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Figure 2.5: Vegetative insecticidal protein 2 (VIP2) from B. cereus.
(PDB=1QS2) (Han e t al. 1999). Native structure in blue and NAD complex in 
grey, NAD in pink. The N and C termini are labelled, along with helix a 8 .
Subsequently, the structural and extensive mutational analysis experiments have 
also been carried out for the enzymatic component of the Iota toxin (la). The Iota toxin 
shares an identical topology to VIP2 with the exception of an extra helix in the N-terminal 
domain (Tsuge e t al. 2003). Complex structures with NADH and NADPH showed these 
substrate analogues to bind in a similar way to NAD with VIP2 (Tsuge e t a l. 2003). 
Mutational and kinetic analyses showed that similar residues to those identified for C2 are 
important for NAD binding and ADP-ribosyltransferase activity (Tsuge e t a l. 2003). 
Additionally, Y246, conserved in the binary and C3-like toxins (Figure 2.3), was also 
shown to be kinetically important for binding the protein substrate, actin. Another 
interesting finding was that and an asparagine on the third helix (a 8 ), was shown to be 
important for protein substrate specificity (Sakurai e t a l. 2003).
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2.3 Rho-GTPases structure and regulation
C3 from Clostridium botulinum has been widely used as a tool to study the Rho 
GTPases due to its specificity for RhoA, B and C and not other Rho GTPases such as Rac 
and Cdc42. RhoA-C have 83% sequence identity whereas the Rho GTPase family, 
including Rac and Cdc42, only share 55% sequence identity as shown by the sequence 
alignment in Figure 2.6. The Rho GTPases are part of a larger family of Ras-related 
GTPases which have 30% sequence identity between them. The Ras and Rho families of 
GTPases play a central role in many cell signalling pathways and are regulated through the 
binding and hydrolysis of GTP. There are many members of the Rho GTPase family and 
these include RhoA-E, RhoG, RhoH, Rac 1-3, Cdc42, TC10, TTF and Rndl-3. Of these, 
RhoA, Racl and Cdc42 are the best characterised and have been widely studied for their 
roles in organisation of the actin cytoskeleton.
The Rho GTPases cycle between the GTP bound active form and the GDP bound 
inactive form of the enzyme as shown in Figure 2.7. GDP is exchanged for GTP through 
the action of guanosine nucleotide exchange factors, or GEFs, leading to a change in 
conformation allowing interactions with downstream effector molecules. Rho activation 
occurs at the membrane, where it is anchored via one or two famesyl or geranylgeranyl 
groups attached to a C-terminal cysteine containing motif. The signal is terminated by 
GTPase activating proteins, or GAPs, which enhance the low intrinsic rate of GTPase 
hydrolysis leaving the GTPase bound to GDP. The system is further regulated by GDP 
dissociation inhibitors, or GDIs, which bind the inactive GTPase-GDP complex, 
preventing association with GTP which is more abundant in the cell. The GDIs bind the 
membrane anchor and thereby relocalise the GTPase in the cytosol away from its effector 
proteins.
The structures of Rho and the related Ras GTPases have been extensively studied 
(for recent review see (Paduch et al. 2001)) and have revealed two switch regions which 
alter shape depending on whether GDP or GTP are bound (Figure 2.8). Interactions of the 
GTPase with signalling effector molecules therefore depends of the conformation of the 
switch regions. Binding of GDP requires coordination by Mg which binds the p- 
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Figure 2.6: Sequence alignment of some Rho family proteins and RalA. Conserved residues for all seven proteins are shown in >
red. The two switch regions are highlighted in yellow and the phosphate-binding loop in blue. Residues shown to be involved in
H
binding C3botl in RhoA are highlighted in grey where conserved. Rac 133 and RhoA T37 (red) and their equivalents are shown in
u>u>


















Figure 2.7: Flow diagram of GTPase activation. Rho is activated at the 
membrane via exchange of GDP for GTP by guanine exchange factors (GEFs).
Rho can then signal to effectors at the membrane. Rho is inactivated via hydrolysis 
of GTP, aided by GTPase activating proteins (GAPs). Rho can then be further 
down-regulated by translocation to the cytosol via binding of GDP dissociation 
inhibitors (GDIs).
water molecules and the carbonyl oxygen of Thr 37 in switch I. The interaction of GEFs 
with switch I was hypothesised to dislodge the Mg2+, and therefore GDP, through 
movement of Thr 37 (Wei e t al. 1997). This was confirmed by the structure of RhoA-GDP 
without Mg2+ which shows a large movement of switch I away from the GDP binding site 
leaving it in an open conformation (Shimizu e t a l. 2000). The binding of GTP also requires 
Mg2+ but in the structure of RhoA with the non-hydrolysable GTP analogue, GTPyS, the 
magnesium was shown to be shifted 1A from its position in the GDP structure. Also, it is 
coordinated, similar to as seen in the Ras-GTPyS structure, between the p and y phosphates 
with hydrogen bonds from Thr 19, Thr 37 and two waters (Ihara e t a l. 1998) (This is 
illustrated later in Figure 2.9). The GTPyS structure also showed the expected large 
rearrangements in the switch regions compared to the GDP bound form (Figure 2.8).
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Hydrophobic residues in switch I flip out to shield the GTP from hydrolysis, but also help 





Figure 2.8: A, RhoA in complex with a GTP analogue (A) (PDB=1 A2B)
(Ihara e t a l  1998) and GDP(B) (PDB=1FTN) (Wei e t a l. 1997) in blue, 
highlighting the switch regions and magnesium in green.
The structures of GAPs and GEFs and their complexes with Rho GTPases, as well 
as the use of transition state analogues, have also helped clarify the mechanism of 
regulation. GDP and AIF4 ' /AIF3 combinations have been very important as transition state 
mimics for the GTPase reaction and have been used in various Rho structures (Rittinger e t 
al. 1997b; Nassar e t al. 1998). GTP hydrolysis proceeds via an in-line nucleophilic attack 
on the y phosphate by a water molecule. The transition state of the y phosphate is planar 
leading to an inversion of conformation after the addition of the water. Both aluminium 
fluoride structures mimic the planar y phosphate but AIF3 mimics the trigonal arrangement 
of the intermediate phosphate better, whereas the AIF4 ' has the more appropriate charge. 
Recently, a structure has been solved using MgF3‘ which fulfils both of these requirements 
(Figure 2.9) (Graham e t a l. 2002).
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RhoGAPs inactivate Rho by enhancing its natural GTPase activity to hydrolyse 
GTP to GDP. Consequently, there are many rhoGAPs and the GAP domain is often part of 
a larger protein with several domains for interacting with other effectors. Although there 
are not many conserved residues amongst this diverse range of GAPs, the few there are 
allowed the Rho-interface domain to be identified in the first GAP structure -p50rhoGAP 
(rhoGAP), and Arg 85, termed the arginine finger, hypothesised as involved in enhancing 
GTPase activity (Barret e t a l. 1992). The identity of the arginine finger as a transition state 
stabiliser was apparent from the Rho-related Cdc42Hs -p50rhoGAP -GMPPNP complex
RhoGAP
R85
Figure 2.9: Active site of the RhoArrhoGAP complex with a transition state 
analogue of GDP with MgF3* (PDB=10W3) (Graham e t a l. 2002). RhoA residues are 
labelled in pink and rhoGAP residues in blue. Bonding interactions are shown as grey 
lines. The planar, trigonal MgF3' mimics the third phosphate of GTP which is cleaved. 
Residues and waters coordinating to the Mg2+ and MgF3‘ ions are shown. The 
interactions of rhoGAP R85, the arginine finger, are also shown.
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structure (Rittinger e t a l. 1997a). The high resolution structure of RhoA -rhoGAP- 
GDP.AIF4 ' confirmed the role for the arginine finger, showing that it contributed directly 
to the Rho active site in a position to stabilise the transition state (Rittinger e t a l. 1997b) 
(Figure 2.9). Additionally, recent molecular dynamics simulations of the related Ras 
GTPase suggest that the arginine finger may help activate the water molecule for 
nucleophilic attack aiding the well established catalytic Gin 61 in that role (Resat e t al. 
2001).
The arginine finger is not the only required feature for GAP activity as mutation of 
this residue to lysine, decreases but does not abolish the catalysis (Rittinger e t a l. 1997a). 
These results emphasised that the stabilisation of the two switch regions by a pocket on 
rhoGAP, between the B and F helices, is also important for catalysis (Figure 2.10) 
(Rittinger e t a l. 1997a). This was later confirmed by the structure of an alanine mutant of 
the arginine finger of rhoGAP in complex with Cdc42 and GDP. AIF3 (Nassar e t a l. 1998). 
In this case, the arginine deficient rhoGAP was still able to stabilise the transition state. It 
was thought that the ordering of the two switch regions, which are highly mobile before
RhoGAPRhoA
Switch I
Figure 2.10: RhoA (pink) in complex with rhoGAP (blue) with GDP (blue) and 
MgF3  (pink) (PDB=10W3) (Graham e t a l. 2002). The switch regions and the Mg2+ are 
shown in green and R85, the arginine finger from rhoGAP, in pink. RhoGAP helices B 
and F are labelled.
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rhoGAP binding, is key. Indeed, mutational analyses have identified two asparagines, and 
to a lesser extent, a second arginine as essential for stabilising switches I and II 
respectively (Fidyk and Cerione 2002). The triple mutant is virtually inactive with a 500- 
fold decrease in activity, indicating that these residues are the most critical in catalysis.
iSwitch n
Sw itch I
Figure 2.11: Racl (pink) in complex with the Dbl and PH domains (blue) of 
Tiaml (PDB=1LB1) (Snyder e t a l. 2002). The switch domains are shown in green.
Like GAPs, the GEF domain is diverse and is often part of a larger protein with 
other modules for different signalling pathways. The most common type of GEFs for Rho 
GTPases are the Dbl-homology, or DH, domains. These domains are always found in 
partnership with pleckstrin-homology, or PH domains, which are thought to possibly play a 
role in the localisation or regulation of DH. Three structures of Rho proteins with DH-PH 
domains have been solved, Racl with Tiaml (Worthylake e t a l. 2000), and Cdc42 and 
RhoA with Dbs (Snyder e t a l. 2002).
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The structure of Racl-Tiaml (Figure 2.11) showed that binding of DH to Racl 
caused a rearrangement of switch I of which the two major consequences are movement of 
Thr 35 and lie 33. Thr 35 (equivalent to RhoA Thr 37) was moved away from the Mg2+ 
binding site, preventing it coordinating the ion, whereas lie 33 (equivalent to Val 35 in 
RhoA -Figure 2.6) is moved towards the ribose binding site, sterically hindering the 
binding of the GDP. Switch H also shows conformational change moving Ala 59 towards
^ L
the Mg binding site preventing magnesium binding. This positioning of the alanine is 
supported by a GEF lysine which is highly conserved amongst GEFs. Interestingly, the 
complex of Racl with the bacterial toxin SopE, which acts as a GEF, shows that SopE 
holds Racl in the same conformation as Tiaml despite a very different structure 
(Buchwald et al. 2002). It appears to act with the same mechanism, but using different 
amino acids.
The Rac-Tiaml complex showed no interaction of the PH domain with Racl 
suggesting that its role in ensuring full GEF activity is stabilisation of the DH domain 
(Worthylake et al. 2000). However, in the complex of Cdc42 with Dbs, the PH has a more 
direct role in stabilising DH residues involved in Cdc42 binding and actually interacts with 
Cdc42 itself (Rossman et al. 2002). Surprisingly, mutation of the PH-binding Cdc42 
residues shows no decrease in the activity in vitro (Rossman et al. 2002).
Unlike the GAPs and the GEFs, there is a lot less diversity amongst the GDIs. 
There are two groups which have no significant sequence homology: the rabGDI’s and the 
rhoGDI’s, although the members within these two families are similar. RhoGDI’s are 
about 200 residues in length and regulate all Rho family proteins. The NMR structure of 
rhoGDI revealed that there are two domains. The N terminal domain is unstructured in 
solution and comprises the first third of the protein, whereas the C-terminal domain which 
has an immunoglobulin-like fold, comprises the last two thirds of the protein (Keep et al. 
1997). The crystal structure of the C-terminal domain (Keep et al. 1997) identified a 
hydrophobic cavity which was hypothesised as the binding site for the Rho GTPase 
geranylgeranyl membrane anchor. This was confirmed by NMR experiments, showing that 
isoprenyl groups interact with the structured domain in solution, and the crystal structure of 
Racl-rhoGDI, where the binding of its geranylgeranyl group was observed (Grizot et al. 
2001). The crystal structures of the Rac2-rhoGDI (Scheffzek et al. 2000) and RhoA-
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rhoGDI (Longenecker e t al. 1999) complexes showed that the N-terminal domain of the 
rhoGDI does become ordered on binding Rho GTPases (Figure 2.12). The core of the N- 
terminal domain forms a helical hairpin which stacks against and stabilises the switch II. 
RhoGDI also contacts switch I and appears to prevent GDP dissociation by stabilisation of 
the Mg2+ without actually blocking the nucleotide binding site (Scheffzek e t a l. 2000). The 
interaction with the switch regions also inhibits the binding of GAPs or GEFs.
LyGDI
Figure 2.12: Rac2 (pink) in complex with LyGDI (blue) (PDB=1CC0) (Scheffzek 
e t a l. 2000). The switch regions and Mg2+ are shown in green and GDP in blue. The 
N-terminal domain of GDI (LyN) becomes ordered on binding.
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2.4 The history of C3 from Clostridium botulinum and C3 
exoenzymes
The C3 exoenzyme from Clostridium botulinum was initially discovered during 
studies of the botulinum neurotoxins. It was noted that preparations of neurotoxins C and 
D also appeared to have ADP-ribosyltransferase activity associated with them (Ohashi and 
Narumiya 1987; Didsbury et al. 1989). However, it was later shown that this was due to 
contamination with C3 (Aktories and Frevert 1987a; Rosener et al. 1987; Adam-Vizi et al. 
1988). The confusion was probably due to the expression of C3 concurrently with the 
neurotoxin Cl on the same phage (Rubin et al. 1988). Therefore, the C3 exoenzyme from 
C. botulinum was originally named as it was the third toxin to be found in strain C of C. 
botulinum after the neurotoxin (Cl) and the ADP-ribosyltransferase binary toxin C2. C3 
was first identified in 1987 as being distinct from C2 as it is half the size, at about 24kDa, 
and has a cellular protein target with a mass of around 20kDa, instead of actin (Aktories et 
al. 1987b). The nature of the substrate for C3 was only known by its size, 20-22kDa, the 
same substrate that was incorrectly reported for botulinum neurotoxin D (Ohashi and 
Narumiya 1987). Following research showed it to be a GTP-binding protein, as its 
ribosylation was inhibited by GTP[S] (Aktories and Frevert 1987a). Also, it was thought to 
be related to the ras family of G-proteins as when injected into cells it produced similar, 
but not identical, morphological changes. This research later pioneered the way for 
studying Rho GTPase signalling. It showed that when introduced into cells by osmotic 
shock, C3 produces distinctive cell rounding in NIH 3T3 fibroblasts or growth of neurites 
in neuronal PC 12 cells (Rubin et al. 1988; Morii and Narumiya 1995).
Surprisingly, the first observation of the C3 ribosylation target as the small G- 
protein Rho, was incorrectly attributed to the enzymatic activity of botulinum neurotoxin 
Cl (Kikuchi et al. 1988). The paper also noted that the enzyme ribosylated three very 
similar substrates, one of which was identified as ‘Rho’, and that the ribosylation was 
dependent on Mg . The ribosylation reaction was characterised in more detail and 
confirmed as attributable to C3 after more thorough purification of the enzymatic agent 
(Aktories et al. 1988). Amino acid sequencing of the purified substrate confirmed it to be 
Rho (Narumiya et al. 1988; Braun et al. 1989). Further experiments showed that 
recombinant RhoA (Aktories et al. 1989) and RhoC (Chardin et al. 1989), the product of
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two of the three Rho genes known of at that time, were substrates for C3 in vitro. 
Experiments with RhoC also demonstrated that the reversible morphological changes 
observed in Vero cells, on addition of C3, were due to dissolution of actin filaments as 
shown by fluorescent staining of F-actin (Chardin et al. 1989). These experiments 
suggested a probable role for Rho in actin filament regulation.
A more detailed study of the effect of a constitutively active Rho, Vall4Rho, and 
C3 ribosylated Rho in Swiss 3T3 cells (Paterson et al. 1990) agreed with this role for Rho 
in actin filament organisation. Injection of ribosylated Rho caused cells to round up with 
the same morphology as C3 treated cells, even though endogenous Rho was present, 
whereas ribosylated Vall4Rho had no effect on cells. This suggested that ribosylated 
normal Rho in its GDP-bound form competes with the endogenous Rho for GEFs, but 
could not function normally due to the ribosylation (Sehr et al. 1998). Also, the 
ribosylated, constitutively active Vall4Rho in its GTP-bound form would not be able to 
bind GEFs and so not interfere with the endogenous Rho. During the meanwhile*, a more 
detailed amino acid analysis of the ribosylated Rho identified an asparagine residue, later 
known as Asn 41, as the target residue (Sekine et al. 1989). It was also shown that 
injection of the constitutively active, ribosylation resistant Vall4/Ile41Rho prevented the 
C3 induced rounding up of cells (Paterson et al. 1990). However, injection of ribosylation 
resistant normal Rho could not rescue the C3 induced phenotype.
These experiments give some insight into the complexity of Rho signalling and it is 
now known that the three C3 targets, Rho types A-C (Aktories et al. 1989; Chardin et al. 
1989; Williamson et al. 1990) (Figure 2.6), vary in their functions which may have 
contributed to this confusion. Also, much research has shown that the localisation of 
signalling molecules, such as Rho, in the cell can be of primary importance to their 
function. In normal cell signalling in human fibroblasts, activation of RhoA leads to 
recruitment to specific areas of the plasma membrane enriched with actin, where it binds 
its effectors. Treatment with C3 has been suggested to cause mislocalisation to other 
membrane areas via interference with the localisation signal, preventing the signalling 
(Michaely et al. 1999). Also, scrape loading of C3 into rat fibroblasts has been shown to 
actually lead to degradation of RhoA (Malcom et al. 1996). Alternatively, viral expression
* Alternative to meanwhile or during the meantime from Monty Python’s Flying Circus
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of C3 in human adenocarcinoma cells showed that not all the RhoA in the cells was 
accessible to C3, probably depending on location (Meacci et al. 1999). Recently, it has 
been suggested that ribosylation of RhoA causes it to be trapped in the GDI complex 
(Genth et al. 2003).
The cloning of two C3 genes from Clostridium botulinum in 1991 allowed easier 
study of the enzyme circumventing the necessity to work with lethal bacteria and 
botulinum neurotoxins. The latter, however, could be precipitated out of solution heating 
the impure protein to 100°C for five minutes, taking advantage of C3s thermostability 
(Aktories et al. 1988). The C3 clones from type C strain 468 and type D strain 1873 are 
identical (Popoff et al. 1991) and were later classified (Wilde and Aktories 2001) as 
C3botl. The clone from type C strain 003-9 (Nemoto et al. 1991) was later known as 
C3bot2. Both C3bots are synthesised with a 40 residue propeptide which is cleaved to 
produce the mature enzyme with a molecular mass of 23KDa (Morii and Narumiya 1995), 
and a calculated pi of approximately 9.8 (Nemoto et al. 1991).
Further studies added insight into the details of the ADP-ribosylation reaction. It 
was confirmed that GDP-bound Rho was a better substrate for C3bot than Rho-GTP and 
that confusions over this is the past were probably due to the different affinities of Rho for 
GDP and GTP (Habermann et al. 1991). EDTA therefore inhibits ribosylation as it 
sequesters the Mg ions essential for Rho nucleotide binding (Habermann et al. 1991). It 
was also noted that although the forward ribosylation reaction had a pH optimum of 7.5, 
the reverse reaction, creating NAD from nicotinamide and ADP-ribose could be observed 
optimally at pH 5.5 (Habermann et al. 1991).
Fortunately, information about the C3 active site residues proved to be more 
conclusive than the mechanism of Rho inhibition. Site directed mutagenesis cleared up the 
confusion from two reports. The first was used [32P]nicotinamide-2-azidoadenine 
dinucleotide as a photoaffinity probe in C3bot to identify residue 9-19, in particular Trp 18, 
as part of the binding site (Chavan et al. 1992). The second used [carbonyl-14C] NAD with 
UV irradiation of the homologous C3 from Clostridium limosum, which shares 63% 
sequence identity with C3bot (Just et al. 1992), to identify Glu 174 as the catalytic residue 
(Jung et al. 1993). It was shown that mutants with substitutions of Trp 18 remained fully 
active whilst any mutation of Glu 174 caused a large decrease in activity, indicating the
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central role of Glu 174 (also known as Glu 214 if not numbered from the start of the 
mature protein) in catalysis (Saito et al. 1995).
Despite the ever increasing characterisation of C3, any evidence as to a possible 
role for C3 in Clostridium botulinum pathology was missing. The lack of binding or 
translocation domain, only allowing cell entry by pinocytosis, and the high toxicity of the 
botulinum neurotoxins with which C3 is secreted (Rubin et al. 1988) does not suggest an 
obvious role. However, this has not prevented C3 from becoming a widely used tool in 
Rho research, due to its specificity for RhoA-C and not for the related proteins Rac and 
Cdc42 (Aktories et al. 1989; Chardin et al. 1989; Just et al. 1992). This specificity was 
investigated through protein engineering of the Rho and Rac proteins (Wilde et al. 2000). 
Different domains of RhoA were substituted for the equivalent domain in Rac to identify 
the first ninety residues as necessary for ribosylation to occur. Secondly, site directed 
mutagenesis of Rac with RhoA residues identified six amino acids, Arg 5, Lys 6, Glu 40, 
Val 43, Glu 47 and Glu 54 (Figure 2.6) as important for the formation of the C3-RhoA 
complex.
C3 has also been shown to interact with the ras related RalA GTPase. Interestingly, 
RalA is not ribosylated by C3 but appears to be an inhibitor of ribosylation (Wilde et al. 
2002a). Of the Ras-related GTPases, RalA is most similar to RasH, N and K with 48% 
sequence identity (Chardin and Tavitian 1986) and is thought to be involved in numerous 
signalling cascades including regulation of the cytoskeleton (Ohta et al. 1999), vesicle 
trafficking and endocytosis (Nakashima et al. 1999; Jullien-Flores et al. 2000; Moskalenko 
et al. 2002; Sugihara et al. 2002). The affinity of RalA for the homologous C3 from C. 
limosum, is very high with a Kd of 12nM (Wilde et al. 2002a). Also, RalA does not appear 
to bind to C3 at the same site as RhoA, but appears to increase the NAD-glycohydrolase 
activity of C3. This suggests that it binds C3 in a way that optimises the glycohydrolase 
activity but blocks the binding of RhoA. Although in some cases, this additional activity of 
C3 may have had a complex effect on experiments designed to characterise RhoA, this is 
likely to be quite small as the interaction is not enzymatic.
The ability of C3 to stimulate neurite outgrowth in PC 12 cells (Rubin et al. 1988) 
has led to further research showing that C3, through inactivation of Rho, can also stimulate 
axon regeneration in vitro and overcome growth inhibition in vivo (Lehmann et al. 1999).
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It has been proposed that C3 has potential as a therapeutic for stimulating differentiation of 
neurones (Watanabe et al. 2000). As a development of this C3 has been engineered for 
easier cell entry. In one report, several short peptides, the most effective of which was a 
short proline rich peptide, were added to its carboxyl-terminus to increase the uptake of C3 
into neuronal cells, whilst maintaining its activity (Winton et al. 2002). C3 has also been 
engineered to include a fragment of the N-terminal domain of the Clostridium perfringens 
Iota toxin la. This allows the translocation of la into the cell, with the help for the cell 
binding component, lb, by receptor mediated endocytosis. It was found that a 129 residue 
stretch of la was sufficient to transfer active C3 into Vero cells in an lb dependent manner 
(Marvaud et al. 2002).
The structure of C3botl from C. botulinum was solved in 2001 showing it to 
consist of a mixed a/p fold with a p-sandwich core (Han et al. 2001) (Figure 2.13). A three 
stranded anti-parallel p-sheet flanked by the first four helices is stacked against a five 
stranded mixed p-sheet flanked by helix five. The topology was identical to the catalytic 
domain of the binary toxin, VIP2 from Bacillus cereus (Han et al. 1999), which suggested 
a similar NAD binding site positioned between the p-sheet core and helix a3. The related 
DT-like toxins have an active site loop in the position of a3 of C3botl, but comparison 
with VIP2 suggested a unique active site for the C3-like and binary toxins. This 
corresponds to residues 207-214 in C3botl, of which Glu 214 (also known as Glu 174) is 
the conserved catalytic glutamate, named the ADP-ribosylating toxin tum-tum (ARTT) 
motif. It was hypothesised that that Gin 212, the conserved asparagine in C3-like 
exoenzymes, could have a role in binding the target residue of Rho, Asn 41. However, it 
has since been shown by site-directed mutagenesis that it is not involved in NAD or Rho 
binding, but is essential for stabilising the C3botl-NAD-Rho complex for ribosylation 
(Menetrey et al. 2002). Phe 209, which also resides in this loop, is thought to be involved 
in binding to a hydrophobic patch on the Rho surface near Asn 41 (Han et al. 2001).
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Figure 2.13: C 3 b o tl from  C. b o tu l in u m  (PDB=1G24) (Han et al. 2001). The 
ARTT loop is shown in pink and the PN loop in green. Helices and strands are 
labelled.
The crystal structure of C3botl in complex with NAD gave further insight into the 
residues involved in catalysis (Menetrey et al. 2002). C3botl undergoes conformational 
changes upon binding NAD including the ARTT loop and the NAD binding loop (between 
strands P3-P4), termed the phosphate-nicotinamide (PN) loop. It also undergoes a ‘crab- 
claw’ movement of a large sub-domain, comprising p2, p7, p8 and a5, which closes the 
active site around the NAD, similar to that seen for VIP2. This report also confirmed by 
site-directed mutagenesis that the conserved ‘STS’ motif, which had been speculated to be 
important for active site stability as it is in the binary toxins (Han et al. 2001), was not 
essential for NAD binding or ribosylation.
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The family of C3-like exoenzymes is rapidly growing as more proteins with 
sequence similarity to C3botl are identified. The other C3-like exoenzymes characterised 
so far, apart from C3botl and C3bot2, include C31im from Clostridium limosum, C3cer 
from Bacillus cereus, and three enzymes from Staphylococcus aureus known as EDIN A 
(C3staul), C3stau2 (EDIN B) and C3stau3 (EDIN C). Early characterisation of C31im 
included the calculation of the Km for NAD to be 0.3pM and the specific ADP- 
ribosyltransferase activity to be 3.1 nmol/mg platelet membrane protein/min (Just et al. 
1992). Photolabelling of C31im with [carbonyl-u  C] NAD also highlighted the catalytic site 
to be within the sequence equivalent to 211-219 in C3botl (Jung et al. 1993), suggesting 
that the conserved glutamate (Glu 214) was also important for catalysis in C31im.
C3cer has recently been cloned and analysed by site directed mutagenesis based on 
previous structures and analyses and shown to have the same functional residues as C3botl 
and C3stau2 (Wilde et al. 2003). Additionally, mutation of a threonine, the first residue in 
the ARTT loop (serine in C3botl), caused a large decrease in the transferase activity with 
little effect on the NAD glycohydrolase activity (Wilde et al. 2003). However, the precise 
role of this residue in catalysis is unclear at present. Interestingly, it was noted that its 
specific activity for RhoB was lower than for RhoA and even less for RhoC. This pattern 
also appeared to be mirrored by other C3 exoenzymes including C31im, C3botl and 
C3stau2. Of the C3 exoenzymes from S. aureus, C3stau2 is the best characterised an the 
only one to have its structure solved (Evans et al. 2003). These enzymes will be discussed 
more fully in chapter four.
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2.5 Botulinum neurotoxin structure and mechanism
The Botulinum neurotoxins (BoNTs) are produced by Clostridium botulinum in 
seven distinct serotypes, BoNT A-G, and are responsible for the deadly food poisoning 
known as botulism. Botulism is characterised by flaccid muscle paralysis due to the 
inhibition of acetylcholine release from neuromuscular junctions. The deadly tetanus toxin 
from Clostridium tetani is also part of the same family of neurotoxins. Its mode of action is 
to cause spastic paralysis, however, by inhibition of neurotransmitters such as glycine and 
GAB A from inhibitory neurones in the spinal cord. These neurotoxins all share over 30% 
sequence identity with each other, and in particular, the catalytic domains of tetanus toxin 
and BoNT/B share 51.6% sequence identity. Both the botulinum and the tetanus toxins are 
synthesised as a 150kDa polypeptide which is post-translationally cleaved to yield a 50kDa 
light chain and a lOOkDa heavy chain. The light chain, which holds the toxin enzymatic
Figure 2.14: Botulinum neurotoxin A, (PDB=3BTA) (Lacy et al. 1998) showing the 
binding domain in green, the translocation domain in pink and the endopeptidase 
domain in blue with the catalytic zinc ion in grey.
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activity, cleaves intracellular proteins to block transmitter release. The heavy chain 
consists of both the translocation domain at its N-terminus, and the receptor binding 
domain at its C-terminus. The two chains remain connected by a disulphide bond which is 
essential for cell entry but which must be cleaved for release of the light chain into the 
cytosol for toxic activity.
The crystal structures of both BoNT/A (Lacy et al. 1998), and B (Hanson and 
Stevens 2000; Swaminathan and Eswaramoorthy 2000) share the same topology and have 
a clear domain structure (Figure 2.14). The binding domain consists of two equivalent 
sized p-strand sub-domains connected by an a-helix. The N-terminal sub-domain 
comprises a jelly roll motif whereas the C-terminal one forms a modified p-trefoil fold. 
The binding domain tilts away from the translocation domain leaving all surfaces open for 
binding. The central part of the translocation domain consists of two long, anti-parallel, 
amphipathic, kinked helices wrapped around each other, two helical bundles and a 
disordered area that was previously suggested to be a putative membrane spanning helix by 
the program TMAP (Persson and Argos 1996). The catalytic domain is globular and 
contains the zinc binding motif HEXXH, comprising the endopeptidase active site. The 
other main feature of the toxin is the belt region of the translocation domain which 
surrounds the catalytic domain and partly blocks the active site.
Intoxication by botulinum neurotoxins usually results from toxin contaminated 
food, or occasionally by a food derived infection of Clostridium botulinum in the gut in 
young children (Simpson 2000). The neurotoxins are carried by the blood to their target 
cells at the neuromuscular junction where they are taken up via receptor mediated 
endocytosis (Dolly et al. 1984). The binding mechanism is thought to involve two 
receptors; a low affinity receptor comprising a ganglioside which then facilitates binding to 
a high affinity protein receptor which allows toxin internalisation (Montecucco 1986). 
Antibodies against these gangliosides have shown that they are essential to BoNT binding 
(Kozaki et al. 1998). The evidence for the identity of the protein receptors varies, but the 
best characterised is for N-terminal region of synaptotagmin as the receptor for BoNT/B, to 
which it bound in the presence of gangliosides GTlb and GTla (Nishiki et al. 1994; 
Nishiki et al. 1996; Kozaki et al. 1998) (Figure 2.15).
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Figure 2.15: Schematic diagram of ganglioside G Tlb. Gangliosides comprise a 
sialic acid containing oligosaccharide attached to ceramide. BoNTs require 
gangliosides with two sialic acid groups attached to the internal galactose for 
binding. Glu is glucose, Gal, galactose, GalN, galactosamine and Sia, sialic acid.
Although the necessity for ganglioside binding has been well established, the 
details of the binding site and the mechanism of the binding are not well understood. The 
ganglioside binding site has been best characterised for tetanus toxin, where the binding 
domain (He) has been crystallised with an analogue of GTlb, minus the ceramide 
(Fontinou et al. 2001) (Figure 2.16). Interestingly, this structure indicated binding sites on 
the toxin for both the galactose/galactosamine moiety and the internal double sialic acid 
moiety (Figure 2.15), causing the adjacent domains in the crystal to be cross-linked 
(Fontinou et al. 2001). This suggested that cross-linking of several toxins may be a 
possible mechanism in vivo. More recent toxin-ganglioside binding studies show that this 
is not the case but speculate that the sialic acid binding site may play a part in the 
difference in specificity between tetanus toxin and the BoNTs (Rummel et al. 2003). The 
only BoNT structure with a ganglioside mimic is the BoNT/B-sialyllactose complex 
(Swaminathan and Eswaramoorthy 2000), where the sialic acid is observed binding at a 
similar site to that seen for the galactose/galactosamine moiety in tetanus toxin (Figure 
2.16).
Once the toxin has been internalised through receptor-mediated endocytosis, the 
catalytic light chain needs to be released for activity. For the catalytic light chain to reach 
the cytosol, it must translocate through the vesicle membrane for which it requires the low 
pH of the endosome (Simpson et al. 1994). The translocation domain forms cation 
channels in the membrane at low pH (Hoch et al. 1985; Blaustein et al. 1987; Shone et al. 
1987) and has recently been shown to act as a channel to translocate the light chain across
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NMA
Figure 2.16: Binding of sugars to tetanus toxin and BoNT/B. A: The P-trefoil domain of 
tetanus toxin (PDB=1FV3) (Fontinou e t a l. 2001) and BoNT/B (PDB=1F31) (Swaminathan 
and Eswaramoorthy 2000) in complex with a GTlb analogue and sialyllactose respectively. 
BoNT/B is shown in blue and tetanus toxin in pink. B: Close up of the sialyllactose binding 
of BoNT/B. Monomers of the sialyllactose are labelled showing that the sialic acid is 
located in the binding cleft. C: Close up part of the GTlb analogue binding to tetanus toxin. 
Monomers of the GTlb analogue are labelled. The galactose moiety is centrally located in 
the cleft, equivalent to the position of sialic acid for BoNT/B.
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the membrane (Koriazova and Montal 2002). Using circular dichroism, with channel 
currents and the light chain protease activity as assays, it was shown that at pH 5, the light 
chain partially unfolds and blocks the HC channel under non-reducing conditions. 
However, under reducing conditions, the light chain was translocated across the membrane 
and retrieves its catalytic activity (Koriazova and Montal 2002). The proposed mechanism 
for translocation is that the HC undergoes structural change and inserts in the membrane at 
the low endosome pH and the light chain partially unfolds. The light chain is then 
translocated through the channel formed by the HC, refolds, possibly through a chaperone­
like activity of the HC, and dissociates from the HC in the reducing conditions of the 
cytosol.
Once inside the cell, the neurotoxins all perform the same zinc dependent 
endopeptidase reaction. The target of the protease action is the SNARE family which 
facilitate exocytosis of the neurotransmitter. Three SNARE proteins are required for 
correct exocytosis and the different neurotoxins cleave one of the three. BoNT/B, BoNT/D, 
BoNT/F and BoNT/G all cleave synaptobrevin/VAMP, whereas BoNT/A and BoNT/E 
cleave SNAP25 and BoNT/C cleaves syntaxin (for recent review see (Turton et al. 2002)). 
The fact that between them, the botulinum toxins cleave all three proteins involved in 
membrane docking, has allowed them to be used as a tool to study the roles of these 
proteins in transmitter release.
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3.1 Introduction
At the outset, the aim of this project was to crystallise and determine the structure 
of C3botl in order to characterise C3 exoenzymes and to help elucidate the basis for their 
protein substrate specificity. Whilst purification of C3botl was still underway, the 
structure was solved elsewhere (Han et al. 2001), but this project was continued in order to 
crystallise a complex with one of the substrates. Crystallisation attempts followed the 
published ones for the original structure and soaks were carried out with NAD, 
nicotinamide, ADP-ribose and 3-acetylpyridine adenine dinucleotide, a substrate analogue. 
Whilst these experiments were going on, the structure of C3botl in complex with NAD 
was also solved elsewhere (Menetrey et al. 2002). Unfortunately, none of our structures 
showed any binding of the substrates. However, of the two crystal forms described in the 
original paper (Han et al. 2001), the second one, with which we had the most success, 
could not be refined by the authors. Therefore, this chapter describes the purification, 
crystallisation and structure determination of C3botl in this crystal form and analyses the 
differences in crystal packing.
3.2 Methods and Results
3.2.1 Purification of C3botl
All protein for purification was provided as E. coli cell paste by Dr. J.M. Sutton at 
the Health Protection Agency (HPA), Porton Down. Although purification of recombinant 
C3botl has been described previously, this purification procedure resulted in a yield of 
only 3mg C3botl/litre cells (Morii and Narumiya 1995). Therefore, C3botl was initially 
expressed as a His-tagged protein in order to aid purification. The addition of a His tag, 
however, resulted in the majority of the recombinant protein being located in the insoluble 
fraction upon lysis by sonication. Refolding of this protein was attempted by solubilisation 
in 7M guanidine HC1 followed by drop wise addition into a variety of buffers, 50mM 
Tris/HCl pH 7.5 or pH 8.5 plus 0.1M NaCl with additives 1% PEG 400, 20% glycerol, 
33mM Chaps or 1M guanidine HC1 or 50mM BisTris pH 6.5, 50mM Sodium phosphate 
and 0.5M arginine. Refolding in these buffers proved unsuccessful. Therefore, an 
alternative approach of purifying the protein in 8 M urea was tried as the binding of the His
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tag to the metal affinity column does not require a correctly folded protein. However, only 
a small percentage of the denatured protein bound to cobalt or nickel affinity columns.
Following the lack of success with the His-tagged protein, a C3botl-MBP construct 
was created by Dr J.M. Sutton at the HPA. MBP tags are often used to improve the 
solubility of proteins but have the disadvantage of large size and the necessity of cleavage 
during purification (Sachdev and Chirgwin 2000). The Apal-HindUl fragment from the 
expression vector pMALc2x (New England Biolabs) was isolated and subcloned into the 
vector pBC SK+ (Stratagene) to generate the vector pBCmalE. The construction of the 
vector was confirmed by restriction digest and sequencing. A EcoKI fragment containing 
the C3botl cloning sequence was subcloned into pBCmalE digested EcoRl and the clone 
verified. The majority of the recombinantly expressed C3botl-MBP was soluble upon cell 
lysis by sonication but only a maximum of 2.5mg fusion protein (a small percentage of that 
expressed as assessed by SDS-PAGE) bound the amylose affinity column (in 20mM Tris 
pH 7.5) from half a litre of cell culture. To improve this yield, an initial step involving 
purification by SP-sepharose column in 20mM Na.Hepes pH7.3 was included. A large 
peak was eluted from the SP-sepharose column by an ascending NaCl gradient. However, 
this only improved the yield after amylose affinity chromatography to 5mgs per half a litre 
of cell culture.
As the yield from the amylose column was so low, this step was omitted and the 
C3botl-MBP purified by SP-sepharose chromatography was cleaved by Factor Xa 
(Novagen) overnight at room temperature as C3botl is stable at high temperatures. The 
enzyme concentration used was optimised to 0.5U Factor Xa (Novagen) per mg fusion 
protein. This concentration was required for complete cleavage as C3botl-MBP was not 
easily purified from C3botl. The C3botl was further purified away from the MBP by SP- 
sepharose chromatography in a buffer of 20mM Na.Hepes pH 7.3, 20mM NaCl. The MBP 
did not bind the column and the C3botl was eluted on an ascending NaCl gradient. If 
further purification was necessary, NAD affinity chromatography was performed with a 
Pharmacia HiTrap Blue Sepharose column (Amersham) (Figure 3.1). A final purification 
step by gel filtration was added which also allowed buffer exchange into 20mM Hepes 
pH7.3, 20mM NaCl, 2mM MgCl2 , ImM EDTA. The purified C3botl proved to be very 
soluble and was easily concentrated to 39mg/ml for storage at -70°C. The yield from this 
purification was approximately lOmg per litre cells. The final protocol is outlined below.
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Figure 3.1: 12% SDS-PAGE gel of the C3botl purification. Lanel, Low molecular 
weight marker (Amersham); lane2, cell extract; lane 3, soluble extract; lane 4, 
insoluble cell extract; lane 5, peak from 1st SP-Sepharose column; lane 6, cleaved 
protein; lane 7, peak from 2nd SP-Sepharose column; lane 8, peak from the HiTrap 
Blue Sepharose column (Amersham). C3botl-MBP, MBP and C3botl have 
molecular weights of 67KDa, 43KDa and 24KDa respectively.
For expression the clone TB1 pBCmalE C3botl was grown overnight at 30°C in 
Terrific Broth supplemented with 35 pg/ml chloramphenicol and 0.5% (w/v) glucose. The 
overnight culture was diluted 1:5 in fresh media and grown for 4 hours. The culture was 
induced with IPTG at a final concentration of 500pM and grown for a further 2 hours at 
25°C before harvest. The cells were collected by centrifugation and stored at -20°C. Cells, 
from 1 litre of culture, resuspended in 30mls lysis buffer (20mM Hepes pH 7.3, 20mM 
NaCl, ImM EDTA, ImM PMSF), were lysed with 30pl 1 mg/ml lysozyme on ice for an 
hour. The cells were lysed further by sonication, 5 bursts of 40s at 26microns (Soniprep 
150), resting on ice between bursts and the cell debris were collected by centrifugation. 
The C3botl-MBP was purified from the supernatant by SP-sepharose chromatography in 
20mM Hepes pH 7.3 and eluted on a 0-1M NaCl gradient in two batches. Fractions
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containing C3botl-MBP were pooled and cleaved overnight at room temperature by 
incubation with factor Xa (Novagen), 0.5U/mg fusion protein. C3botl was diluted and 
purified further by either SP-Sepharose or Pharmacia HiTrap Blue Sepharose (Amersham) 
chromatography in 20mM Hepes pH 7.3 or both. The purest fractions were concentrated in 
a centrifugal 15KDa cut off concentrator (Amicon) and finally purified in batches of 300pl 
on a Superdex-200 HR 10/30 (Amersham) gel filtration column run at 0.75ml/min in 
20mM Hepes pH 7.3, 20mM NaCl, 5mM MgCh and ImM EDTA. The pure protein was 
concentrated to 39mg/ml, aliquoted and stored at -70°C.
3.2.2 Crystallisation
Crystallisation was performed using the hanging drop vapour diffusion technique 
with precipitants based on the published conditions (Han e t a l. 2001). Crystals were grown 
at 19°C in a drop containing 1.5pl 35mg/ml C3botl in 20mM Hepes pH 7.3, 20mM NaCl, 
5mM MgCb and ImM EDTA and 1.5pl well solution. The well solution contained 18% 
PEG 3350, 0.1M Imidazole/malate pH 5.5, 3% saturated sodium orthovanadate solution, 
0.15M NaCl and 20mM Tris pH 7.5. Plate like crystals (Figure 3.2) that diffracted up to
Figure 3.2: Tetragonal crystals of C3botl grew in two days at 19°C using the hanging 
drop technique at a protein concentration of 35mg/ml. 1.5pl C3botl in 20mM Hepes pH 
7.3, 20mM NaCl, 5mM MgCl2 and ImM EDTA was mixed with a 1.5pl well solution 
(18% PEG 3350, 0.1M Imidazole/malate pH 5.5, 3% saturated sodium orthovanadate, 
0.15M NaCl, 20mM Tris pH 7.5).
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1.6A formed within two days but were highly mosaic. Soaking these crystals in 27% PEG 
3350, 0.1M Imidazole/malate pH 5.5, 3% saturated sodium orthovanadate, 0.15M NaCl 
and 20mM Tris pH 7.5 decreased the mosaicity in some cases.
Co-ciystallisations with nicotinamide and 3-aminobenzamide were performed with 
the same precipitant but with either 20mM, 15mM or lOmM of the additive added. These 
crystals were also transferred to the higher precipitant concentration containing the 
corresponding level of additive. Soaks of native crystals with NAD, nicotinamide, ADP- 
ribose and 3-acetyl pyridine adenine dinucleotide were performed at the higher precipitant 
concentration containing lOOmM additive.
Crystals were also grown at the other published conditions by Han et al but these 
were even thinner, more plate-like and grew in mosaics over the whole drop making 
crystal manipulation difficult. Crystallisation with the later conditions published (Menetrey 
et al. 2 0 0 2 ) was also attempted but without success.
3.2.3 Data collection
Crystals were soaked in cryoprotectant containing 27% PEG 3350, 0.1M 
Imidazole/malate pH 5.5, 3% saturated sodium orthovanadate solution, 0.15M NaCl and 
20mM Tris pH 7.5 and 20% glycerol and cryo-cooled to 100K. One native and several 
derivative datasets were collected on stations PX 14.2 and PX 9.6 at the Synchrotron 
Radiation Source at Daresbury, UK, using an ADSC-CCD detector (Table 3.1). The 
highest resolution data set came from native crystals soaked in 27% PEG 3350, 0.1M 
Imidazole/malate pH 5.5, 3% saturated sodium orthovanadate solution, 0.15M NaCl and 
20mM Tris pH 7.5 with lOOmM nicotinamide for 30hrs (Figure 3.3). After refinement, no 
nicotinamide was observed bound so this data set was refined as the highest resolution 
native data set. The data were processed and scaled in the space group 14 in HKL2000 
(Otwinowski and Minor 1997) to 1.89A. The cell dimensions were a=b= 73.29, c=218.23. 
All the crystals were mosaic, and most highly mosaic, but the high symmetry of the space 
group meant that 91.6% completeness was achieved for this highest resolution data set. 
There were two C3botl monomers per asymmetric unit and the crystals contained 59.4% 
solvent.
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Data reduction was carried out using the program TRUNCATE (CCP4 1994). The 
structure was determined by molecular replacement with MOLREP (Vagin and Teplyakov 
1997) using the previously determined C3botl structure (Han et al. 2001). The solution for 
the first monomer had an R-factor of 50.2% and a correlation coefficient of 37.3, which 
improved to 39.7% and 61.2 respectively for both solutions.
















1.89 0.5 1 0 5.7 (58.4) 85.0 (70.4)
lOOmM Nicotinamide, 
30hr soak 1.89 0.5 1 0 9.4 (35.7) 91.6 (91.8)
50mM ADP-ribose, 
95min soak 2.35 0.5 1 2 4.8 (44.0) 8 8 . 6  (87.7)
20mM 3-acetylpyridine 
adenine dinucleotide, 
2 0 min soak
2.84 0.5 1 2 8.5 (47.5) 8 8 . 6  (87.9)
5mM NAD, 30min soak 2.9 0.5 1 2 8.5 (47.5) 94.0 (87.9)
a Rsym = Eh |7(h) -  7,(h)|/ Eh Ei/(h), where 7,(h) and 7(h) are the fth and the mean 
measurements of the intensity of reflection h, respectively.
3.2.4 Refinement
The first round of rigid body and restrained refinement, carried out using Refmac5 
in CCP4i (Murshudov et al. 1997), gave an R-factor of 29.2% and a R-ffee (758 
reflections) of 32.9%. Inspection of initial maps showed that none of the additives were 
bound so the nicotinamide soak was refined as the highest resolution native data set. NCS 
was imposed in the first rounds of refinement and restraints were used to keep the r.m.s. 
bond length deviation low. Water molecules were added in the final stages of refinement 
by the implementation of ARP/wARP (Lamzin and Wilson 1993) in Refmac5. The water 
positions were checked to have heights above 3a in the F0 -Fc map and to have a 
temperature factor less than -50A2. The program O (Jones et al. 1991) was used to rebuild
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Figure 3.3: Diffraction image for C3botl. Collected on station PX 9.6 at the SRS, 
Daresbury, U.K. The rings mark the resolution limits 7.64A, 3.81 A, 2.52A and 1.9A 
proceeding outwards from the centre. The data were processed to 1.89A.
the model and visualise the maps. The F0-Fc map contained two peaks unexplained by the 
protein or solvent structure which were finally modelled as a vanadate and malate ions. 
The vanadate ion was modelled at 0.7 occupancy (B=30.85) to fit the height of the 
difference density peak. The malate ion was modelled with an occupancy of one and 
explained most of the difference density in that area. Its position would ideally be slightly 
further away from its adjacent symmetry related partner, but fits the density. The final 
model contains 3314 protein atoms and 327 water molecules has an Rcryst of 20.9% and an 
Rfree value of 24.7%. Crystallographic statistics are in Table 3.2. At 1.89A the N and C 
termini were clearly visible in the structure. However, the extremities of side chains of 56, 
64, 65, 70, 73, 85, 94, 103, 146, 147, 157,182, 233, 235 for both molecules A and B were
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Table 3.2: Crystallographic statistics for the refined data set
(30hr, lOOmM nicotinamide soak)
Space group 14
Maximum resolution (A) 1.89
Unit cell dimensions (A) a=73.29 b=73.29 c=218.23
Measured reflections 683474
Unique reflections 41904
Completeness (%) (last shell)a 91.6 (91.8)
Mean I/a (last shell) 3 15.3 (4.4)
Rsym (%)b (last shell) 3 9.4 (35.7)
Rcryst (%) 20.9
Rfree (%)“ 24.7
Number of protein atoms 3314
Number of solvent atoms 327
Number of ligand atoms
Vanadate 1 0
Malate 18
R.m.s. deviation in bond lengths (A) 0.009
R.m.s. deviation in bond angles (°) 1.24
Average B factor for protein atoms (A2) 26.9
Average B factor for solvent molecules (A2) 29.9
Average B factor for ligand atoms (A2)
Vanadate 30.85
Malate 44.1
3  Last shell is 1.94-1.89A.
b Rsym = Sh Si |/(h) -  7,{h)|/ Zh Si/(h), where //(h) and /(h) are the rth and the mean 
measurements of the intensity of reflection h, respectively.
° Rcryst=  Sh \Fo - Fc \! I hF„, where F0 and Fc are the observed and calculated structure factor 
amplitudes of reflection h, respectively.
d Rfree is equal to Rsym for a randomly-selected 758 reflections not used in the refinement 
(Briinger 1992).
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modelled with an occupancy of zero due to insufficient density. The extremities of 
residues 106, 150, 153, 159, 165, 181 and 232 in molecule A and 191 in molecule B were 
also modelled with an occupancy of zero due to insufficient density. Figure 3.4 shows 
examples of the good and the poor regions of the map for the final model. The average B 
factor for molecules A and B were 27.0A2 and 26.8A2 respectively. The structure was 
checked with PROCHECK (CCP4 1994). All figure were produced with Molscript 
(Kraulis 1991) and rendered with Povray (www.povray.org) unless otherwise stated.
Figure 3.4: Final map and model for A, part of the N-terminus, and B, part of the 
variable region (residues 143-147). The C3botl model is shown as a stick representation, 
the 2F0-FC map at la  is represented as a 3D blue mesh, the F0-Fc map at 3a as a green 
mesh (B) and as a red mesh (A). This picture was created in O (Jones e t a l. 1991).
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3.2.5 Structure and crystal packing of C3botl
The overall topology of this structure of C3botl (Figure 3.5) at 1.89A in the space 
group 14 is identical to that of the published structures (Han e t al. 2001; Menetrey e t al. 
2002). 94% of the residues were within the most favoured regions of the Ramachandran 
plot (Figure 3.6) and only two (for both A and B) were in the disallowed regions. Apart 
from a slightly raised B factor for molecule A, resulting in more disordered residues, there 
are few differences between the two molecules and they have a Ca r.m.s. deviation of 
0.08A. Even though NCS restraints were removed at the end, most side chain positions are 
conserved between them. The exceptions were Met 125 and Leu 143 which are both 
solvent exposed.
Figure 3.5: Overall structure of C3botl with the vanadate ion (green) and the 
malate ion (pink) shown. Helices are: a l ,  52-66, a2, 69-81, a3, 83-92, a4, 102-114, 
a5, 151-162. Strands are: p i, 124-131, P2, 165-170, P3, 172-176, p4, 187-194, p5, 200- 
203, p6, 213-217, p7 ,221-230, p8, 236-246.
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In general, our C3botl has higher B factors than the published native structures in 
space group C2 (Han e t a l. 2001; Menetrey e t a l. 2002) (Figure 3.7A) which probably 
accounts for the larger number of disordered residues seen. These disordered residues are 
all solvent exposed and do not appear to play a role in catalysis. They are visible in both 
the published structures. We have also modelled less waters for our structure with only
163.5 on average per monomer in the asymmetric unit rather than 217.5 for the published 
structure (Han e t a l. 2001), which is of higher resolution. However, our C3botl has 
identical topology to this structure with a Ca r.m.s. deviation of 0.45A for molecule A 
from both structures (Figure 3.7 B-D). Only residues 184-185, 147-151 and 232-236 have 
a different Ca backbone with Ca r.m.s. deviations of 0.01 A, 0.40A, and 1.55A 
respectively. All three regions are parts of loops which have high B factors (Figure 3.7A). 
Residues 147-151 are part of the region which varies most in sequence between the C3 
exoenzymes (Figure 2.3, Chapter 2), termed the variable region, corresponding to helix a5
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Figure 3.7: A, B factor plot for our C3botl and the published native C3botl 
(1G24) (Han e t a l. 2001). Approximate positions of the PN and ARTT loops, the 
variable region (helix a5 and the loop preceding it) and p7 are shown. B, 
Superposition of our C3botl (purple) and the published native C3botl (orange). 
C, Insert shows closer view of the most divergent region comprising the variable 
region and the loop between p7 and p8. These loops correspond to the regions in (A) 
that have the highest B factors. D, A 90° rotated view of C.
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and the loop preceding it in C3botl. Residues 232-236 are part of the loop between 
strands p7 and p8 which interacts with the variable region. Residues 184-185 are part of 
the phosphate-nicotinamide (PN) loop required for NAD binding.
Our C3botl is not only similar in topology to the published structures but also 
shares a similar packing arrangement in the asymmetric unit. Our structure has two 
monomers in the asymmetric unit rather than four but these two superimpose well on the 
one of the of the two dimers (Figure 3.8).
Figure 3.8: Superposition of our C3botl asymmetric unit with the published native 
structure (pdb=lG24) (Han e t a l. 2001). The published asymmetric unit with four 
molecules (pink) is superimposed on our asymmetric unit in blue.
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Unlike the previous structures, however, two ions were modelled for the structure 
which appear to have been necessary for the crystal packing (Figure 3.5). The first, a 
malate ion, is located adjacent to the crystallographic axis and participates in hydrogen 
bonds with two symmetry related molecules as well as its own symmetry related partner 
(Figure 3.9). The second, a vanadate ion, is located at the intersection of three of the 
symmetry related molecules in the unit cell (Figure 3.10) and participates in the hydrogen 
bonding network.
These crystals were soaked in several substrates and substrate analogues without 
any binding observed. This suggested that the crystal packing may be preventing access to 
the active site. Analysis of the crystal packing showed this to be the case as the N-terminus 
of a symmetry related molecule is observed packing against helix a3 and hydrogen 
bonding with helix a3 and a residue in the ARTT loop (Figure 3.11). Both these regions 
are observed to move on binding NAD (Menetrey e t a l. 2002). It is likely that this packing 
arrangement not only blocks the active site, but may also prevent the conformational 
change required for substrate binding.
Figure 3.9: The malate ion bridges two symmetry related molecules between helices 2
and 3. Hydrogen bonds between the malates and the symmetry related molecules are 
coloured blue and green to match the residues.
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A
Figure 3.10: The vanadate ion is involved in crystal packing. A shows two 
vanadate ions (pink) and four waters (pink and yellow) positioned between three 
adjacent molecules in the unit cell. B shows the involvement of the vanadate ion and 
three water molecules in the hydrogen bonding network in the crystal packing.
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Figure 3.11: A, The N-terminus packs against helix a3 and the active site. The active 
site is marked by the superposition of NAD (blue) from the published crystal structure 
(PDB=1GZF) (Menetrey e t a l. 2002). The ARTT loop is coloured green and the N-terminus, 
brown. B, Residues Q47, E l22 and Q54 hydrogen bond to and electrostatically interact 
with residues K81 (a3) and D204 (ARTT loop) respectively.
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3.3 Discussion
Although the soluble expression and purification of C3botl was not straight 
forward at first, the final protocol utilising a C3botl-MBP fusion protein resulted in a good 
yield for crystallisation. C3botl was also noted to be very soluble, achieving high 
concentrations, and reasonably thermostable as previously reported (Aktories et al. 1988; 
Han et al. 2001). Reproduction of the tetragonal and monoclinic crystal forms from the 
original paper (Han et al. 2001) was easily achieved using the published conditions. 
However, the second set of conditions published (Menetrey et al. 2002) never resulted in 
any crystals.
This data, at 1.89A, is not as high resolution as the original publication at 1.7A 
(Han et al. 2001) and so does not reveal much extra information about the structure, and 
therefore the biology, of the molecule. The lack of very complete and redundant data, 
maybe responsible for the messy and less well defined regions of electron density. The 
backbone was clearly visible throughout, however, and there were only a few side chains 
that were not visible at all. The regions which varied from the original publications were 
loop regions known to be flexible. The slight difference of position of the residues in the 
PN loop is not surprising as this region moves on NAD binding. The most useful 
observation from the structure is the packing arrangement which probably blocks the 
binding site. The lack of NAD binding could also be explained by the crystal pH of 5.5. 
NAD binds C3botl optimally at pH 7.5 (Habermann et al. 1991), although the C3botl- 
NAD complex was solved at pH 3 (Menetrey et al. 2002). However, C3botl binds 
nicotinamide and ADP-ribose optimally at pH 5.5 (Habermann et al. 1991) suggesting that 
our crystals would have been ideal for these complexes, if  access could be gained to the 
active site.
The previous publication of the crystallisation conditions reported diffraction to 
2.15A. This data could not be refined due to the mosaicity of the data (Han et al. 2001). 
However, our data diffracted to 1.89 A, and although not perfect, refined well enough. 
There are several possibilities for these differences. The resolution difference maybe due to 
a shorter wavelength radiation used to collect the data (0.87A). Alternatively our crystal 
quality could be better due to either the purity of the protein, any slight variation in
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crystallisation conditions (e.g. fluctuations in temperature) or the soaking of our crystal in 
a higher precipitant concentration prior to data collection. The difference in protein purity 
is hard to assess, but both purifications used gel filtration as a final step. Soaking crystals 
in a higher precipitant concentration may have been responsible for lowering the mosaicity 
of our crystals to 0.57° which is much less than theirs (>1.5°). However, we found that only 
some of the soaked crystals showed less mosaicity than those that were not. Whatever the 
reason for the difference in resolution, it is possible that refinement of their data against a 
perfect model would be possible. The poor phases from a low homology molecular 
replacement model probably meant that the density was not good enough to build in the 
new features. The poor quality of our maps meant it was difficult to identify the extra 
difference density and position the malate and vanadate ions until the refinement was 
mostly complete. However, although the electron density is not completely interpreted in 
every place, it had been achieved as far as the data quality and noise of the maps would 
allow.
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Chapter 4
The Structure of C3stau2 and its 
Complex with NAD
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Introduction
C3stau2, from S. aureus is classified as part of the C3-like ADP-ribosylating 
exoenzyme family and shares 35% sequence identity with C3botl (Wilde et al. 2001). 
C3stau2, however, is more related to, and shares 78% sequence identity with, another 03- 
like exoenzyme from S. aureus, C3staul, generally know as EDIN, or EDIN A. EDIN was 
first discovered in 1990 as the factor in the cultured supernatant of S. aureus from impetigo 
lesions that inhibits calcium-induced terminal differentiation in cultured mouse 
keratinocytes. Thus it was given the name ‘Epidermal Cell Differentiation Inhibitor’ 
(Sugai et al. 1987). EDIN was characterised as a single polypeptide with a molecular 
weight of 27,000 and a pi >9 (Sugai et al. 1990). The cloning of this protein showed the 
first 35 residues to be a signal sequence, which when cleaved, gave a mature protein of 212 
residues which had 35% sequence identity with C3 from C. botulinum (C3botl) (Inoue et 
al. 1991).
This homology with C3botl resulted in testing EDIN for ADP-ribosyltransferase 
activity. EDIN was found to ADP-ribosylate both RhoA and RhoB and a comparison of 
the kinetics of RhoB ribosylation with C3bot2 showed them to be similar (Sugai et al. 
1992). EDIN and C3bot2 were also compared for their effects on keratinocytes. Although 
both EDIN and C3bot2 both inhibited keratinocyte differentiation in vitro and stimulated 
proliferation of human keratinocytes in vitro and mouse epidermis in vivo, EDIN has more 
potency for these activities (Sugai et al. 1992).
The role of C3s from Clostridia in disease has always been unclear due to no 
known mechanism for cell entry. By contrast, S. aureus has been shown to be an 
intracellular pathogen, offering an obvious mechanism for C3-like exoenzymes to play a 
role in pathogenesis. Both C3botl and EDIN have been shown to ribosylate RhoA-C in 
human umbilical cord vein cells (HUVECs) and inhibit endothelial cell migration and 
wound repair through the inactivation of RhoA (Aepfelbacher et al. 1997). EDIN has also 
been reported as the probable cause of acquired subglottic stenosis (ASGS) in methicillin 
resistant S. aureus (MRSA) infections of the trachea in neonates requiring intubation 
(Yamada et al. 2001). The ASGS was thought to be caused by EDIN mediated delayed 
wound repair of the subglottis. Prevalence of EDIN-producing strains of S. aureus has not
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been widely studied but 12% of the clinical isolates in Japan have been reported to produce 
EDIN (Yamada et al. 2001).
C3stau2 was initially discovered in 2001 from screening clinical isolates of S. 
aureus for C3-like activity (Wilde et al. 2001). It was later found to be encoded on a novel 
pathogenicity island on the chromosome in tandem with exfoliative toxin D, ETD, and a 
serine protease gene (Yamaguchi et al. 2002). A third C3-like exoenzyme from S. aureus 
has also been discovered from sequencing of the exfoliative toxin B (ETB) plasmid and 
named EDIN C or C3stau3 (Yamaguchi et al. 2001). C3stau3 shares ~65% sequence 
identity with EDIN A and C3stau2 (see Figure 2.3, Chapter 2) and has been shown to 
ribosylate RhoA more efficiently than EDIN in vitro (Yamaguchi et al. 2001). So far 
C3stau3 activity and any possible role in disease has not been widely studied, but strains 
having the ETB plasmid are more common than those without indicating that it may have a 
possible role in virulence (Mulligan et al. 1993). One local study of the prevalence of these 
exoenzymes in passive and pathogenic strains of S. aureus showed that strains isolated 
from infection sites had a higher prevalence of EDIN genes than those isolated from nasal 
carriers (Czech et al. 2001). Also, 90% of the EDIN genes found in this study were 
C3stau2 (EDIN B), probably due to its chromosomal location. Although it was reported 
that C3stau3 (EDIN C) is more common in Japan. This data has not been correlated with 
type of infection however.
C3stau2 was highlighted for investigation due to the finding that it not only ADP- 
ribosylates RhoA-C, but also RhoE/Rnd3 on the equivalent residue, Asn 44 (Wilde et al.
2001). RhoE/Rnd3 is 50% identical to RhoA but lacks GTPase activity and is therefore 
constitutively active (Foster et al. 1996) (Nobes et al. 1998). RhoE/Rnd3 modification was 
observed in vitro and in vivo but was noted to be much slower possibly due to its ‘GTP 
bound’ conformation, as RhoA-GTP is a poorer substrate for C3botl than RhoA-GDP 
(Wilde et al. 2000). Mutational analysis of C3stau2 has assessed the importance of key 
residues involved in NAD-binding and ribosyltransferase activity in C3botl (Wilde et al. 
2002c). Mutants were tested for NAD glycohydrolase activity and ADP-ribosyltransferase 
activity to distinguish between these two roles. R48K, R85K and E180L all showed 
decreased glycohydrolase activity as well as decreased transferase activity showing that 
these residues are probably involved in NAD binding. This would be expected for the 
catalytic residue, Glu 180, and the equivalent residues in C3botl to Arg 48 and Arg 85
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appear to be involved in NAD binding in the crystal structure (Menetrey et al. 2002). 
Mutation of the exposed Tyr 175 in the ARTT loop decreased transferase activity but 
actually increased glycohydrolase activity suggesting that it plays a part in RhoA 
recognition, although the increase in glycohydrolase activity is unexplained. Ser 137 is the 
first serine in the conserved ‘STS’ motif, which in C3stau2 is actually STQ. This residue 
was originally speculated to be involved in stabilising the catalytic glutamate in C3botl but 
mutation studies have since shown it to have no role in transferase activity (Menetrey et al. 
2002). Mutation of this residue showed no decrease in transferase activity suggesting that it 
has no role to play in catalysis in C3stau2 either. Finally, Gin 212 in C3botl, which was 
originally speculated to be involved in RhoA recognition from the C3botl structure but has 
now been shown not to be involved in NAD hydrolysis or RhoA binding (Menetrey et al.
2002) is equivalent to Gin 178 in C3stau2. Mutation of this residue causes no decrease in 
NAD hydrolysis or RhoA recognition, as in C3botl, but in both proteins its mutation 
knocks out transferase activity suggesting it is involved in stabilising the C3-Rho-NAD 
complex.
In order to further characterise this protein and to address the question of substrate 
specificity for the C3 exoenzymes we have crystallised and solved the structure of the 
native and the NAD bound forms of C3stau2 to 1.68A and 2.02A respectively. More recent 
results show that EDIN A also ribosylates RhoE/Rnd3 (Wilde et al. 2003) suggesting that 
this structure characterises the new subfamily of C3-like exoenzymes from S. aureus.
4.2 Methods
4.2.1 Cloning and expression
The cloning was carried out by Dr. J. Mark Sutton at the Health Protection Agency, 
Porton Down. A synthetic gene encoding C3stau2 was synthesised using codon bias 
optimised for expression in E. coli. A series of overlapping oligonucleotides was 
synthesised (Sigma-Genosys; UK) as Table 4.1. The numbering indicates the order of the 
oligonucleotides with the forward primers numbered 5’-3’ along the sense strand and the 
reverse primers numbered 5’-3* along the anti-sense strand. In addition to the structural
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oligonucleotides, flanking primers were designed to introduce a 5’and a 3’ BamYR site and 
sequence encoding a Factor Xa cleavage site immediately prior to the initial alanine of the 
mature C3stau2 peptide sequence. The oligonucleotides at a concentration of 25nmol/pl 
for the structural primers and 500nmol/pl for the flanking primers were assembled in a 
single PCR reaction using VENT polymerase (New England Biolabs) in a buffer 
containing lOmM KC1, 20mM Tris-HCl (pH 8 . 8  at 25°C), lOmM (NFL^SO^ 4.5mM 
MgSC>4 , 0.1% Triton X-100, ImM dNTPs. PCR amplification of 30 cycles was carried out 
using the parameters 94°C 1 min, 56°C 1 min, 72°C 1 min followed by 72°C lOmins. The 
PCR product was analysed on a 1.2% agarose gel in TAE electrophoresis buffer and a 
principal band at approximately 750 base pairs was excised from the gel. The band was 
extracted from the gel using Qiaex II gel extraction resin (Qiagen) and subcloned into the 
sequencing vector PCR4.0 TOPO (Invitrogen) according to manufacturer’s instructions. 
The clone was sequenced and showed two point mutations in the regions of primer 
C3sBamXa.for and C3sl0.rev. These were corrected by amplification with these primers, 
followed by extension to give the full-length clone and re-amplification with the flanking 
primers. Cloning and sequence verification were carried out as described above.
For expression of the C3stau2 fragment a modified malE fusion vector was 
generated to ensure that the gene could not be disseminated to other bacteria. The Apal- 
HindlII fragment from the expression vector pMALc2x (New England Biolabs) was 
isolated and subcloned into the vector pBC SK+ (Stratagene) to generate the vector 
pBCmalE. The construction of the vector was confirmed by restriction digest and 
sequencing. A BamYR fragment containing the C3stau2 coding sequence was subcloned 
into pBCmalE digested BamYR and the clone verified. For expression the clone TB1 
pBCmalE C3stau2 was grown overnight at 30°C in Terrific Broth supplemented with 35 
pg/ml chloramphenicol and 0.5% (w/v) glucose. The overnight culture was diluted 1:10 in 
fresh media and grown for 4 hours (OD6 0 0  ~3.9). The culture was induced with IPTG at a 
final concentration of 500 pM and grown for a further 2 hours 30 minutes at 25°C before 
harvest. The cells were collected by centrifugation and resuspended in 20mM MES pH5.8. 
The cells were lysed by sonication (5 burst of 40s at 26microns, resting on ice between 
bursts -Soniprep 150) in batches corresponding to half a litre of culture and the cell lysate 
was collected by centrifugation.
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KDa 1 2 3 4 5 Figure 4.1: 12% SDS-PAGE gel showing 
purification stages of C3stau2. Lane 1 is the 
low molecular weight marker (Amersham), 
lane 2, the soluble extract from the lysed cells, 
lane 3, the first peak purified from the SP 
sepharose column at pH 5.8, lane 4, the 
cleaved fusion protein and lane 5, the C3stau2 
after purification with the SP sepharose 
column at pH 7.3. The molecular weights for 
C3stau2-MBP, MBP and C3stau2 ~66.0KDa, 












Figure 4.2: Final purification of C3stau2. Chromatograph from the final 
purification by gel filtration using a Superdex 200 HR 10/30 (Amersham) column 
run at 0.75ml/min. Fractions corresponding to the main peak were collected and 
concentrated.
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4.2.2 Protein purification
The C3stau2-MBP fusion protein was initially purified by cation exchange 
chromatography. The protein bound to a SP-sepharose column optimally equilibrated with 
20mM MES pH 5.8, and was eluted on an ascending NaCl gradient as a single peak. The 
fractions corresponding to the peak were pooled and 150U Factor Xa were added per half 
litre of cells to cleave the MBP as the cleavage reaction was very inefficient. The initial 
yield of C3stau2-MBP was ~50mg, corresponding to ~17mg C3stau2. During cleavage, the 
protein was dialysed for 24hrs at room temperature against a buffer containing 20mM 
Hepes pH 7.3, 50mM NaCl and 5mM CaCh to improve the cleavage efficiency and to 
raise the pH for further purification. The cleaved C3stau2 bound to the SP-Sepharose 
column equilibrated in 20mM Hepes pH 7.3 and 50mM NaCl and was eluted again, mostly 
pure, on an ascending NaCl gradient (Figure 4.1). Final purification and de-salting was 
achieved by gel filtration. The protein was concentrated in an lOkDa cut off centrifugal 
concentrator (Amicon) and applied to a Superdex 200 gel filtration column (Amersham) 
equilibrated in 20mM Hepes pH7.3, 50mM NaCl (Figure 4.2). The purified protein was 
finally concentrated to 35mg/ml and stored in 20mM Hepes pH 7.3, 50mM NaCl at -70°C. 
The final yield of C3stau2 from half a litre of cells was ~7mg.
4.2.3 Crystallisation
The solubility of C3stau2 was initially characterised using commercial screens by 
the vapour diffusion hanging drop technique. 1 pi of the well solution was mixed with 1 pi 
protein to conserve material. Initial experiments carried out at 22°C and 16°C at varying 
protein concentrations suggested that a protein concentration of 8-10mg/ml was suitable
Figure 4.3: C3stau2 crystals. Orthorhombic 
crystals for C3stau2 grew in two days (after 
seeding) at 22°C using the hanging drop technique 
at a protein concentration of 8.75mg/ml. lpl 
C3stau in 20mM Hepes pH 7.3, 50mM NaCl was 
mixed with lpl well solution (30% PEG 8000, 
0.1M Sodium Cacodylate pH6.5).
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for further screening at 22°C. As commercial screens did not produce preliminary crystals, 
grid screens were designed to test a range of precipitants to find suitable conditions for 
further screens. C3stau2 concentrations of 8.75-10.25mg/ml produced large single 
orthorhombic crystals in 29-30% PEG 8000, 0.1M Sodium cacodylate pH 6.4-6.6 at 22°C 
in three weeks. Not all drops produced large crystals so some drops were streak seeded. 
Seeding produced larger numbers of good sized crystals which grew within 3 days and 
were suitable for cryo-diffraction (Figure 4.3). Co-crystallisation experiments with either 
lOmM nicotinamide or ADP-ribose were also performed. Additionally, crystal soaks were 
performed with NAD, nicotinamide and ADP-ribose. Neither nicotinamide or ADP-ribose 
were observed bound to these crystals, which may be due to the pH of the crystallisation. 
The optimal pH for the forward enzyme reaction, hydrolysing NAD, as assessed for 
C3botl, is pH7.5, whereas it is pH 5.5 for the reverse reaction (Habermann et al. 1991). 
This suggests that nicotinamide and ADP-ribose are probably more likely to bind at this 
pH. Unfortunately, soaking these crystals at pH 5.5 caused them to dissolve.
4.2.4 Data collection and processing for native C3stau2
A room temperature data set from a large crystal was collected first using a ADSC- 
CCD detector on station PX 14.1 at the Synchrotron Radiation Source at Daresbury, UK. 
The data was processed and scaled in HKL2000 (Otwinowski and Minor 1997) to a 
resolution of 2.62k and the symmetry and systematic absences were consistent with the 
space group P2i2i2i. The Matthews coefficient (Matthews 1968) of 2, indicated that there 
was one C3stau2 monomer per asymmetric unit and the crystals contained 40% solvent. 
Data reduction was carried out using the program TRUNCATE (CCP4 1994). Data 
processing statistics for all data sets collected are shown in Table 4.1. From this data set, a 
molecular replacement solution was found with MOLREP (Vagin and Teplyakov 1997) 
using residues 47-246 of the crystal structure of the native C3botl (Han et al. 2001). 
MOLREP was run several times using different resolution limits and the most common 
solution ranked first had an R-factor of 56% and a correlation coefficient of 31.4. 
However, initial refinement, carried out using CNS version 1.0 (Brimger et al. 1998) 
showed it to be correct.
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The large structural differences between C3stau2 and C3botl made it hard to 
discern the position of the extra loops in the density so a further data set under cryo 
conditions was collected. Native crystals, soaked in a cryoprotectant containing 0.1M 
Sodium Cacodylate, pH6.5, 30% PEG 8000 and 20% glycerol and cryo-cooled to 100K, 
diffracted to 1.79A on a ADSC-CCD detector on station PX 14.2 at the Synchrotron 
Radiation Source at Daresbury, UK. Later, crystals co-crystallised with lOmM 
nicotinamide were cryocooled and diffracted to a resolution of 1.68A on a ADSC-CCD
Figure 4.4: Diffraction image for C3stau2 from the data set scaled to 1.68A. The
rings mark the resolution limits 6.71 A, 3.31 A, 2.21 A and 1.65A proceeding outwards 
from the centre. The reflections are clearly defined and lunes are visible on the left hand 
side. The data were collected on station PX 9.6 at the SRS, Daresbury, U.K. The 
wavelength was 0.87A and the exposure time 12 seconds.
81
Chapter 4 The Structure of C3stau2
detector on station PX 9.6 at the Synchrotron Radiation Source at Daresbury, UK. These 
crystals were shown to have no nicotinamide bound and were used as the highest 
resolution native data set. Using this data set all the new residues could be built in. For all 
of the data sets collected, the reflections were well defined and showed a clear, non-mosaic 
pattern (Figure 4.4).
Figure 4.5: Final map and model for the C-terminal end of a l. The C3stau2 
model is shown as a stick representation, the 2F0-FC map at la  level is represented 
as a 3D blue mesh and the F0-Fc map at 3a level as a red mesh. This picture was 
created in O (Jones e t a l. 1991).
4.2.5 Refinement and Model Building for native C3stau2
The refinement was performed in three stages, refinement of the 2.6A data set, 
followed by increasing the resolution to 1.79A, allowing the building of the extra loops of 
C3stau2, not in C3botl, before continuing the refinement with the maximum resolution 
data set at 1.68A. The initial refinement of the 2.6A, 1.79A and 1.68A data sets was carried 
out using the program CNS (Briinger e t a l. 1998). In the later stages of the refinement of 
the 1.68A data set some water molecules were added. Insertion of further water molecules 
and final refinement were performed in SHELX (Sheldrick and Gould 1995) to aid the
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addition of alternate conformations. The water positions were checked to have heights 
above 3cr in the F0-Fc map and to have a temperature factor less than 40A2. The behaviour 
of the Rfree value (872 reflections) was monitored throughout the refinement. Refinement 
statistics are shown in the crystallographic statistics in Table 4.3. The program O (Jones et 
al. 1991) was used to rebuild the model and visualise the maps. The final model contains 
1660 protein atoms and 284 water molecules has a crystallographic RcrySt of 17.0% and an 
Rfree value of 23.7%. At 1.68 A , the density for the loop regions of C3stau2, not seen in 
C3botl, are well defined (Figure 4.5). The N and C termini were clearly visible in the 
structure but residues 197-199 appeared slightly disordered at this resolution. The 
extremities of side chains of 85, 94, 116 and 200 have been modelled with an occupancy of 
zero due to insufficient density. The structure was checked with PROCHECK (CCP4 
1994) and the Ramachandran plot showed that 90% of the residues were in the most 
favourable regions of the plot and only one, which was disordered, was in a disallowed 
region (Figure 4.6).
-L35- SER 197
-L80 ^155 3 5  0  4*5 90 L?5 L80
Phi (degrees)
Figure 4.6: Ramachandran plot for C3stau2.
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Figure 4.7: Initial positioning of NAD in the F0-Fc density at 2a level. Figure was 
created using O (Jones e t a l. 1991). For NAD atoms see Figure 2.1, Chapter 2.
4.2.6 Data collection and processing for C3stau2-NAD complex
Data sets were collected for crystals soaked in nicotinamide and ADP-ribose but 
did not show binding of the substrate. Co-crystallisations with nicotinamide showed none 
bound, and crystals did not grow with ADP-ribose in the crystallisation solution. 
Concentrations of substrates tried and data collection statistics are shown in Table 4.2. 
Soaking native crystals in NAD proved successful however. Native crystals were soaked in 
25mM NAD for 1 hour and llhrs and then in cryoprotectant containing 0.1M Sodium 
Cacodylate, pH 6.5, 30% PEG 8000 and 20% glycerol before cryo-cooling to 100K. The 
crystals diffracted to 2.02A and 2.64A on stations 14.2 and 14.1 respectively at the 
Synchrotron Radiation Source, Daresbury, UK. The data were collected using a ADSC- 
CCD detector. The data were processed and scaled in HKL2000 (Otwinowski and Minor 
1997) and data reduction was done with TRUNCATE (CCP4 1994).
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4.2.7 Refinement and model budding for the C3stau2-NAD complex
As the data were isomorphous with the native data, the phases were taken directly 
from the native model followed by a round of rigid body refinement. As both sets of data 
showed the NAD bound, refinement proceeded with the 2.02A data set. Refinement and 
water picking were performed using CNS (Briinger et al. 1998) and the behaviour of the 
Rfree value (925 reflections) was monitored throughout the refinement. The water positions 
were checked to have heights above 3cr in the F0-Fc map and to have a temperature factor 
less than 50A2. NAD was included in the refinement as clear difference density for NAD 
was observed in the F0-Fc map at 2 a  level (Figure 4.9). Most of the model is well ordered 
except for the end-most 2-3 atoms of the side chains of residues 30, 56 and 116 which were 
modelled at zero occupancy. Methionine 105 and asparagine 124 are modelled as double 
conformations each with 0.5 occupancy. The program O (Jones et al. 1991) was used to 
rebuild the model and visualise the maps. The final model had an Rcryst of 21.4% and an 
Rfree of 26.9%. The details of data processing and refinement are in Table 4.3. All the 
following figures were made with Molscript (Kraulis 1991) and rendered with Povray 
(www.povray.org) unless otherwise stated.
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Table 4.1: Data collection statistics












Completeness (%) Rsym(final shell) 
(%)a
Native 2.71-2.62 6 9.2 (6.6) 32,286 7,272 82.3 (77.0) 7.2 (9.5)
Native 1.85-1.79 10 21.9 (3.3) 337,441 20,739 99.1 (97.9) 7.1 (46.0)
25mM NAD for lhr 2.09-2.02 10 15.8(4.1) 327,780 25,780 96.9 (96.6) 8.8(34.1)
25mM NAD for 
llhrs 2.73-2.64 10 13.1 (6.0) 123,240 7,003 99.5 (98.7) 12.6 (27.3)
50mM ADP-ribose 
for 2hrs 2.76-2.66 10 14.7 (3.6) 155,230 6,959 98.1 (92.6) 11.1 (39.8)
50mM ADP-ribose 
for 1.5 hrs 2.61-2.52 15 23.9 (9.2) 139,270 8,181 99.4 (99.1) 6.9(18.6)
50mM nicotinamide 
for 1.3hrs 2.27-2.19 12 13.8 (6.0) 194,209 20,739 91.6 (87.5) 11.5 (32.4)
Nicotinamide co­
crystals 1.74-1.68 12 20.0 (5.3) 409,845 224,78 99.4 (97.5) 8.5 (29.5)
Rsym = Sh |/(h) -  /,(h)|/ Sh Sj/(h), where //(h) and /(h) are the fth and the mean measurements of the intensity of reflection h, respectively.
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T a b le  4.3: C ry s ta llo g ra p h ic  s ta tis tic s
Native crystals NAD
Space group P2i2i2i P2i2i2i
Maximum resolution (A) 1.68 2.02




Measured reflections 409,845 327,780
Unique reflections 22,478 14,088
Completeness (%) (last shell)a 99.4 (97.5) 96.9 (96.6)
Mean I/a (last shell)a 20.0 (5.3) 15.8(4.1)
Rsym (%)" (last shell)3 8.5 (29.5) 8.8 (34.1)
Rcryst (%)° 17.0 21.4
Rfree (%)“ 23.7 27.3
Number of protein atoms 1660 1660
Number of solvent atoms 284 154
Number of ligand atoms 41
R.m.s. deviation in bond lengths (A) 0.004 0.006
R.m.s. deviation in bond angles (°) 1.3 1.3
Average B factor for protein atoms
(A2)
15.3 24.5
Average B factor for solvent 
molecules (A2)
19.0 27.3
Average B factor for ligand atoms
(A2)
31.1
a Last shell is 1.74-1.68 and 2.09-2.02 for the native and NAD complexes respectively. 
b Rsym = £h Si |7(h) -  7,{h)|/ Zh Sj/(h), where 7,{h) and 7(h) are the rth and the mean 
measurements of the intensity of reflection h, respectively.
c Rcryst= Sh |F0 - Fc |/ ZbF0i where F0 and Fc are the observed and calculated structure factor 
amplitudes of reflection h, respectively.




4.3 Results and Discussion
The Structure of C3stau2
4.3.1 Overall Topology of C3stau2
The overall structure of C3stau2 is similar to that of C3botl, i.e. a mixed oc/p fold 
with a P-sandwich core (Figure 4.8A) (Han e t a l. 2001; Menetrey e t a l. 2002). Structural 
alignment of C3stau2 with C3botl (Figure 4.8B) shows that the main differences are 
restricted to the region of helices a5 and a6 (residues 92-126) in C3stau2 which 
corresponds to the loop between pi and a5 in C3botl (residues 135-162) (Figure 3.5). 
This region in C3stau2 includes seven extra residues that contribute to two extra helices 
comprising residues 99-108 (a5) and 115-125 (a6). This extended variable region is linked
B
Figure 4.8: A: Overall structure of C3stau2 (PDB=10JQ). Schematic representation 
in which helices, strands and main chain termini are labelled. B: Superposition of 
C3stau2 (PDB=10JQ) and C3botl (PDB=1G24). C3stau2 (Evans e t a l. 2003) is 
shown in green and C3botl (Han e t a l. 2001) is shown in blue. Alignment of the two 
structures was carried out using LSQ routines within O (Jones e t a l. 1991).
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by main chain hydrogen bonding to the loop between strands P7 and p8 (residues 197-202) 
which also deviates from its counterpart in C3botl (r.m.s. deviation of C a atoms is 1.6A). 
Here, the main chain oxygens of residues Asn 199 and Lys 200 are bonded to the main 
chain nitrogen of Tyr 114 and the side-chain nitrogen of Gin 133 respectively.
NAD was added to the second model after initial refinement against the native 
C3stau2 structure showed clear difference density at 2a level. The complexed form has the 
same topology as the native form of C3stau2 with a C a r.m.s. deviation of 0.83 A.
4.3.2 The ARTT loop
The bacterial ADP-ribosylating toxins all share a conserved glutamate that is 
essential for ADP-ribosylation. In C3stau2, this residue (Glu 180) is located between 
strands p5 and p6 at the end of the second turn of what has been termed for C3botl, the 
‘ADP-ribosylating turn turn’, or ARTT, motif. The ARTT loop been shown to be essential 
for binding the NAD and positioning the C3-NAD-Rho complex for ADP-ribosyl transfer 
by mutational analysis (Menetrey et al. 2002; Wilde et al. 2002b; Tsuge et al. 2003) and 
was shown to change orientation in C3botl on NAD binding (Menetrey et al. 2002). In 
particular, three residues of the ARTT loop have been shown to be essential for C3stau2 
ADP-ribosylation. As well as the catalytic glutamate on turn two, there is a conserved 
glutamine (or glutamate) thought to be essential for positioning the ternary C3-NAD-Rho 
complex on turn two and a conserved tyrosine (or phenylalanine) on turn one necessary for 
Rho binding (Wilde et al. 2002b).
Despite the conserved role of the ARTT loop in ADP-ribosylation, the loop is 
orientated differently in C3stau2 and C3botl. In the native structure of C3stau2, the 
backbone of the first turn of the ARTT loop is shifted by up to 5.1 A compared to the 
backbone of the same turn in C3botl (Figure 4.9), although this does not affect the 
conserved position of Glu 180. The three C3-like exoenzymes from S. aureus are unusual 
amongst the C3-like and binary toxins discovered so far in that the loops immediately prior 
to their ARTT loops contain an extra two residues. These two residues appear to be 
responsible for positioning the ARTT loop in a conformation identical, not to that of the 
native C3botl structure, but to that of the C3botl-NAD complex, the ‘NAD bound’
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conformation. The loop is well ordered with B-factors (mean =10.2A2 over 8 Ca atoms) 
below average (15.3 A2) for the structure and appears optimally placed for ribosylation.
It is not surprising then, that upon binding of NAD, the ARTT loop undergoes just 
a slight conformational change (Figure 4.9). The r.m.s. deviation for the ARTT loop 
between the native and the NAD-complexed structures over 8 Ca atoms is 0.1 A. As 
expected, Glu 180 can be seen hydrogen bonding to the nicotinamide ribose nitrogen, 
N02' (Figure 4.10), an interaction for which it does not need to move. In C3stau2, the 
position of Glu 180 is not stabilised by hydrogen bonding to the PN loop as seen in 
C3botl. However, Glu 180 does interact with Ser 138, the first serine in the STX motif 
(also known as the STS motif), as seen in C3botl. The YX STX motif has been identified 
as a conserved motif across the ADP-ribosyltransferase toxins and in the case of the C3 
exoenzymes from S. a u reu s  this motif has the sequence YS STQ. This motif has generally 
been considered to help stabilise the NAD binding pocket and mutational analysis of this 










Figure 4.9: A: Superposition of the ARTT loops of C3botl (PDB=1G24) and 
C3stau2 (PDB=10JQ) (Han e t a l. 2001; Evans e t a l. 2003). C3stau2 is in green and 
C3botl in blue. Residues from C3stau2 are prefixed ‘s’ and those from C3botl ‘b \  B: 
Superposition of the ARTT loops of the C3botl-NAD complex (PDB=1GZF) and 
C3stau2 (PDB=10JQ) (Menetrey e t a l. 2002; Evans e t a l. 2003). The C3stau2 ARTT 
loop rests in the ‘NAD-bound’ conformation.
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R 150
A 0 2 ’
E l 80 iN 0 3
Figure 4.10: Movement of residues involved in binding NAD. The native C3stau2 
is shown in green and the C3stau2-NAD complex is shown in pink with the NAD in 
blue. The large domain movements involved in binding NAD have moved residues 
R85, L86, R150, N88, D90, R48 and E133 within binding distance of the NAD. 
E l80, T37 and Q140 also bind NAD. For clarity, the interactions between the main 
chain nitrogens of L86 and N88 and the N07 and A02' atoms of the NAD 
respectively are not shown.
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hydrolysis mechanism between the two types of A-B toxins (Dolan et al. 2000). Also, 
mutation of the first serine of the STX motif has shown it to be essential for NAD 
hydrolysis and ADP-ribosylation in the C. difficile Iota (binary) toxin (Nagahama et al. 
2000) and to be likely to help stabilise the transition state with the catalytic glutamate 
(Sakurai et al. 2003). However, mutation of this serine in C3botl, Ser 174 (Menetrey et al. 
2002), and C3stau2, Ser 138 (Wilde et al. 2002c), has very little effect on NAD binding or 
catalysis. Gin 140, however, the last C3stau2 residue in this motif, is positioned to 
hydrogen bond to the N 07 atom of NAD. These data may suggest that the role of this 
motif may vary between ADP-ribosyltransferases depending upon the contribution of the 
other residues in the NAD binding pocket to transition state stabilisation.
The ‘NAD bound’ conformation of the native ARTT loop also has implications for 
Gin 178. This residue, and its homologues in C3botl and the C. difficile Iota toxin, have 
been shown by mutational analysis to have a role in ADP-ribosylation, but not in isolated 
NAD or Rho binding (Menetrey et al. 2002; Wilde et al. 2002c; Sakurai et al. 2003; Tsuge 
et al. 2003). This key residue, which is thought to stabilise the C3-NAD-Rho ternary 
complex, is pointing towards the NAD binding cleft in a position identical to that of its 
equivalent residue in the C3botl-NAD complex, Gin 212 (Figure 4.9). Gin 178 does not 
move on NAD binding or hydrogen bond to the NAD confirming its non-essential role in 
NAD binding.
The other important residue at the end of turn 1 of the ARTT loop is Tyr 175. This 
tyrosine residue, and its homologue in C3botl, Phe 209, are the only residues so far 
implicated in Rho A binding. The solvent exposure of C3botl Phe 209 and its location near 
to the active site residues suggested a role in binding to a hydrophobic patch on RhoA 
(Han et al. 2001) and the necessity of C3stau2 Tyr 175 for RhoA binding has been shown 
by mutational analysis (Wilde et al. 2002c). Once again, the position of this residue in 
native C3stau2 resembles that of its counterpart in NAD-complexed C3botl and does not 
move on NAD binding.
These results lend support to one obvious conclusion: the resting position of the 
ARTT loop in different C3-like exoenzymes can resemble to varying extents the 
conformation observed in the NAD-containing complex. The loop may, of course, 
rearrange further on ternary complex formation or during catalysis.
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4.3.3 The PN binding loop
The structure of C3botl in complex with NAD identified a further loop between 
strands 03 and 04, comprising residues 141-150 in C3stau2, termed the phosphate- 
nicotinamide (PN) loop (Menetrey et al. 2002). This loop is so-called as it appears to be 
involved in binding the nicotinamide and the nicotinamide-phosphate moieties of NAD 
through provision of a hydrophobic pocket. This loop was noted to alter its shape 
dramatically on the binding of NAD to C3botl (Menetrey et al. 2002). Interestingly, in 
C3stau2, this short loop also appears in a conformation different to that found in native 
C3botl. In C3stau2, the loop appears more extended (Figure 4.11) with a r.m.s. deviation 
of 2.5 A over ten C a atoms when compared to C3botl. Although this loop contains two 
more alanines than in C3botl, making a total of three alanines and two glycines, the mean 
B-factor for this loop (16.1 A2) is not significantly higher than the mean for the whole 
molecule (15.3 A2). The loop also makes three crystal contacts with symmetry-related 
molecules which may contribute to its stability in the crystal structure. It is therefore 
possible that this loop is more flexible in solution prior to NAD binding.
Figure 4.11 shows that in contrast to the ARTT loop, the PN binding loop moves 
towards NAD on binding with a change in position corresponding to an r.m.s. deviation of
1.7 A over 10 C a atoms. C3stau2 does not have a residue equivalent to Phe 183 in C3botl 
which stacks with the adenine ring, but provides a hydrophobic pocket of alanines, 
glycines and Leu 148. The result of this conformational change is that Arg 150 is moved 
by approximately 1 A closer to the NAD, allowing binding with the N 02 atom of NAD 
(Figure 4.11).
4.3.4 C3stau2 moves to enclose the NAD
The structure of C3stau2 shows significant conformational change on binding 
NAD. The structure of C3botl in complex with NAD, when aligned along helices 2-4, 
shows a movement of a large domain comprising 02, a5, 07 and 08 towards the NAD 
binding cleft, closing the protein structure around the NAD. Figure 4.11 shows that 
C3stau2 also undergoes a similar clasping movement involving the variable domain 
(helices a5 and a6, along with strands 07 and 08) and helix a3 to enclose its substrate. 
The variable domain can be seen to rotate up to 4° about the catalytic residue, Glu 180,
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towards the binding site. As with C3botl, this change distorts the C-terminal end of strand 
pi towards the NAD, in this case, bringing Arg 85 and Leu 86 into range for NAD 
binding. Also, helices a3 and a4 on the other side of the NAD binding cleft can be seen 
rotating a similar amount in the opposite direction to close the gap further.
Figure 4.11: Superposition of native C3stau2 (PDB=10JQ) and the C3stau2-NAD 
(PDB=10JZ) (Evans et al. 2003) complex in two orientations. Native C3stau is in 
grey and the domains that have moved to bind NAD in the complex are shown in pink. 
The PN binding loop is shown in green, NAD is in blue. The first orientation (left) 
shows the change in the conformation of the PN binding loop most clearly. The second 
orientation (right) best shows the clasping of the domains to enclose the NAD in the 
binding site. The insert shows how the change in orientation of the PN binding loop 
allows R150 to bind to the NAD.
Figure 4.10 shows that these large structural changes bring the a  carbons of seven 
of the ten NAD binding residues between 0.82 A and 1.51 A closer to the NAD. This, in 
turn, allows the critical side chains to be brought within bonding distance of the NAD. 
Most notable are residues Arg 85 and Arg 48 which have been shown by mutational 
analysis to be essential for NAD binding in C3stau2 (Wilde e t a l. 2002c). A change in the
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side chain conformation and a main chain Ca shift of 0.82 A in Arg 85 on strand p 1 moves 
its NH2 atom 2.95 A, allowing interaction with the adenosine phosphate AOl atom of 
NAD. For Arg 48 on helix a3, a change in side chain conformation and a Ca shift of 1.51 
A moves its NH1 atom 2.16 A, allowing bonding with the NAD A 02 atom.
4.3.5 Analysis of the common NAD-binding site of the C3-like and binary toxins
The structures of the C3-like and binary toxins determined so far reveal similar, but 
not identical NAD binding sites. Table 4.4 shows the residues of C3stau2, C3botl 
(Menetrey et al. 2002), and the binary toxins, Iota toxin from C. perjringens (Sakurai et al. 
2003; Tsuge et al. 2003) and VTP2 from B. cereus (Han et al. 1999), that are involved in 
binding NAD/NADH. Superposition of the binding sites from all four structures shows that 
the nicotinamide portion of the NAD is in a similar orientation with the central phosphates 
and the adenine differing slightly in their positions. The NAD binding site is characterised 
not only by the ARTT and PN loops but also by two arginines conserved in the C3-like and 
binary toxins, and a third conserved in the C3-like toxins.
The most conserved feature of the binding site is the positioning of the 
nicotinamide moiety by the main chain nitrogen and oxygen atoms of the residue following 
the conserved arginine equivalent to Arg 85 in C3stau2 (Position 2, Figure 2.3, Chapter 2). 
As the identity of this residue varies from glycine in C3botl to tryptophan in VIP2, it is 
likely that any residue that can adopt the appropriate backbone conformation will support 
this interaction. Apart from this residue and the catalytic glutamate, the only other 
conserved interaction is some stabilisation/orientation of the adenine ring which is 
positioned by hydrogen bonds in C3stau2, C3botl and the Iota toxin and by hydrophobic 
packing in C3botl and VIP2.
In C3stau2, three arginines conserved amongst the C3-like toxins (labelled 1-3 in 
Figure 2.3, Chapter 2) are seen to interact with the central phosphates of the NAD (Figure 
4.11). These interactions have been proposed to be involved in increasing affinity for the 
substrate (Han et al. 1999; Sakurai et al. 2003). Mutational analyses of these residues
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Figure 4.12: Interactions of conserved arginines in C3stau2, C3botl, Iota toxin and 
VTP2 with NAD. Residues that interact with NAD from the respective crystal structures 
(Han et al. 1999; Menetrey et al. 2002; Evans et al. 2003; Tsuge et al. 2003) are shown. 
Underlined residues have been shown to be essential for NAD binding by previous 
mutational analysis (Menetrey et al. 2002; Wilde et al. 2002b; Tsuge et al. 2003) and 
potential hydrogen bonds are indicated by dashed lines. Positions 1-3 are the positions 
of arginine residues, conserved in the C3-like toxins, that interact with NAD in the 
C3stau2 structure. The arginines at positions 1 and 2 are also conserved in the binary 
toxins. Their interactions are conserved in the Iota toxin. The nature of the interaction at 
position 3 varies (VIP2 R315 engages in ti-ti interactions with the adenine ring whereas 
C3botl R91 C5 and Ns atoms make van der Waals interactions with the AN6 and AC6 
atoms of the NAD).
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AN6 Glu-133-0E1 2.9 Glu-169-OEl 2.9
AN7 — — — —
adenine — Arg-91-side chain
NAD Iota toxin (dist A) VIP2 (dist A)
nicotinamide — —
N07 Arg-296-N 2.7 Trp-350-N 2.6






N03' — — — —
NOl Arg-352-NHl 2.8 — —
N02 Arg-352-NH2 2.6 — —
AOl Arg-295-NHl 3.3 — —
A02 — — — —
A03' — — — —
A02' Gln-300-NE2 3.1 — —
AN 6 Asn-335-ODl 3.2 — —
AN7 Asn-335-ND2 3.1 — —
adenine — Arg-315-side chain
Table 4.4: Summary of the 
interactions of C3stau2, 
C3botl, Iota toxin and VIP2 
with NAD/NADH. Potential 
hydrogen bonding interactions 
for C3stau2 and VIP2 were 
calculated using HBPLUS 
(McDonald and Thornton 
1994) with a distance cut-off 
of 3.3A and D-H-A angles 
>90°.
Interactions for C3botl and the 
Iota toxin were taken from the 
crystal structure references. 
(Menetrey et al. 2002; Tsuge 
et al. 2003). The nicotinamide 
and adenine interactions are 
hydrophobic in nature.
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have been reported for C3stau2 (Wilde et al. 2002c), C3botl (Menetrey et al. 2002), as 
well as for the Iota toxin (Sakurai et al. 2003; Tsuge et al. 2003) and confirm the 
importance of these arginines in NAD binding or hydrolysis. Surprisingly, comparison of 
the structures of all four enzymes show that the interactions between these arginines and 
NAD are not always identical (Figure 4.12 and Table 4.4). The two arginines conserved in 
the C3-like and binary toxins interact with the central phosphates in all the structures 
except VIP2. VIP2 does undergo a similar conformational change to C3stau2 upon NAD 
binding, and although it retains these arginines in positions similar to those of C3stau2, 
they are not close enough to provide the same type of interactions. This difference seems to 
correlate with the difference in the orientation of the NAD in the binding pocket of VIP2 
and does not necessarily reflect the nature of transition state binding, which could be 
similar for all four enzymes. Alternatively, the need of the first serine in the STX motif for 
Iota toxin NAD hydrolysis (Nagahama et al. 2000), which is not the case in C3stau2 and 
C3botl (Menetrey et al. 2002; Wilde et al. 2002c), may indicate a difference in the mode 
of transition state stabilisation between the C3-like and binary toxins.
The arginine at position 3 is only conserved in the C3-like toxins but also occurs in 
the binary toxins VIP2 and C2 from C. botulinum and may be presumed to have a 
conserved function. This arginine has also been shown to be essential for NAD binding to 
C3stau2 (Wilde et al. 2002c) and is seen binding to the A02 atom of NAD. However, in 
C3botl, despite having the potential to bind to the central phosphate, it adopts a different 
conformation and its C8 and Ne atoms engage in van der Waals interactions with the AN6 
and AC6 atoms of the NAD. In VIP2, the guanidinium group makes %-n interactions with 
the adenine ring suggesting that this residue has several possible means of positioning the 
NAD, or that these orientations are preliminary to further change on hydrolysis. The 
variation in the orientation of this residue also coincides with the larger divergence of this 
(adenine) end of the binding pocket.
4.3.6 Implications for RhoA and RalA binding
Although structural data and mutational analysis have some way towards 
identifying residues involved in NAD cleavage and ADP-ribosylation amongst the C3-like 
toxins, only Tyr 175 in C3stau2 (Wilde et al. 2002c) and its equivalent, Phe 209 in C3botl 
(Wilde et al. 2002a), have been identified as essential for binding RhoA by
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mutational analysis. The variation of this residue between the two enzymes may have some 
part to play in protein target specificity, although C3cer, which does not ribosylate RhoE 
(Wilde e t a l. 2003) also has a tyrosine at this position in the sequence alignment (Figure 
2.3, Chapter 2). However, more detailed mutational analysis of the C. d iffic ile  Iota toxin 
suggests that helix a8 (equivalent to helix a3 in C3stau2) may also be partly responsible 
for the binding of protein substrate, which for the Iota toxin is actin (Tsuge e t al. 2003). 
Also, two residues from this helix, Tyr 246 and Asn 255, in structurally equivalent 
positions to Ser 40 and Asn 44 in C3stau2, have been identified as residues important for 
protein substrate binding (Sakurai e t a l. 2003). Asn 255 was additionally identified as 
being important for protein substrate specificity (Sakurai e t a l. 2003). Interestingly, VIP2 
and Iota toxin, which share actin as a substrate, align very well along helix 3 with an r.m.s. 
deviation of 0.3 A over 12 Ca atoms, whereas C3stau2 and C3botl, which have slightly
Figure 4.13: Surface diagrams of the NAD bound conformation of A, C3stau2 
(PDB=10JZ) (Evans et al. 2003), and B, C3botl (PDB=1GZF) (Menetrey et al. 
2002). The ARTT loop is shown in turquoise, the PN binding loop in yellow, the 
variable domain in grey and helix a3 in green. The NAD binding cleft is partially 
defined by N178/N212 (pink) and the three arginines which bind NAD (blue).
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different substrate specificities, do not align so well and have an r.m.s. deviation of 1.2 A. 
The N-terminal end of helix a3 in C3stau2 is shifted up to 4 A  away from the NAD 
binding site compared to the position of the corresponding helix in C3botl. This is partly 
attributable to the inclusion of two prolines, Pro 42 and Pro 46, in this helix in C3stau2. By 
analogy with the Iota toxin, it is possible that specific residues in this helix are involved in 
Rho binding and that the change in conformation of this helix (Figure 4.13) contributes to 
the subtle difference in substrate specificity observed between C3botl and C3stau2. 
Further mutational analysis and/or the structure of a ternary complex will be required to 
substantiate this hypothesis.
Recently it has been reported that the ras-related GTPase RalA acts as an inhibitor 
of C3botl, C31im and C3cer, but not of C3stau2 (Wilde et al. 2002a). RalA is not 
ribosylated by these C3s but appears to bind them in a manner that blocks RalA functions, 
prevents C3 ribosylation of RhoA and enhances C3 NAD glycohydrolase activity. 
Mutation of Phe 209 in the C3botl ARTT loop did not decrease RalA binding, suggesting 
that RalA binds in a different way to RhoA. The level of inhibition of RhoA ribosylation 
varied from 90% inhibition of C3botl, to none at all for C3stau2 (Wilde et al. 2002a). It is 
likely that this variation in inhibition, and therefore binding, is attributable to differences in 
structure. The structures of C3stau2 and C3botl reveal that the segment immediately 
following p i not only varies in length but also adopts a different secondary structure. The 
variability of this region as well as its role in positioning residues for NAD hydrolysis 
make it a candidate to contribute to the RalA binding site.
4.3.7 Further Thoughts
The recent discovery that EDIN A also ribosylates RhoE/Rnd3 as well as C3stau2 
(Wilde et al. 2003) suggests that this may be a common feature of the C3 exoenzymes 
from S. aureus. This reaction was not quantified and so how the differences in the 
sequence of these enzymes may effect the activity is not known. Comparison of the 
sequence of helix a3 between the S. aureus exoenzymes and the Clostridial exoenzymes 
does not reveal any residues that are substantially different between the two groups but 
conserved within them (Figure 2.3, Chapter 2). However, as discussed above, if  this region 
is involved in substrate specificity it is probably due to the orientation of the helix. This
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orientation may be in part due to the number and positions of prolines within it, but may 
also be positioned by other unidentified features in the surrounding sequence.
It is also interesting to note, that of the residues identified in RhoA as required for 
recognition of C3botl, only three out of six, the three glutamates, are conserved in 
RhoE/Rnd3 (Figure 2.6, Chapter 2). Of the remaining three residues, Val 43 is not 
conserved in RhoC either and is replaced by an isoleucine. RhoE/Rnd3 has a serine at this 
position suggesting that a hydrophobic residue rather than a polar one is required for 
C3botl recognition. More significantly, Arg 5 and Lys 6, conserved in RhoA-C are 
replaced by a lysine and a cysteine in RhoE/Rnd3. It is possible that the loss of a positive 
charge at this position prevents binding to C3botl. Figure 4.14 compares the surfaces and 
the residue positions of the Rho GTPases. Further mutational analysis would help clarify 
these points but it is likely that the precise interactions involved in the specificity of these 
reactions will be hard to unpick without a structure of a C3-Rho complex or NMR binding 
studies.
Publication
The work in this chapter is being published in the Journal of Biological Chemistry 
and is currently available as an e-publication ahead of print. Both structures have been 
submitted to the pdb and their codes have been referenced with this chapter in the figure 
legends.
Evans, H.R., Sutton, J.M., Holloway, D.E., Ayriss, J.A., Shone, C. C., Acharya, K. R. 
(2003)
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Figure 4.14: Surface comparison of the C3 binding residues in A, RhoA-GDP 
(PDB=1FTN) (Wei e t  a l. 1997), B, RhoA-GTP (PDB=1 A2B) (Ihara e t  a l. 1998), C, 
RhoE (PDB=1M7B) (Fiegen e t  a l. 2002) and Racl (PDB=1DS6) (Scheffzek e t  al. 
2000; Evans e t a l. 2003). Switch I and II are in blue, N41 from RhoA and its 
equivalents in red and the residues shown to be essential for C3botl recognition of 
RhoA (and their equivalents) in yellow. Residues are labelled for RhoA and where they 
differ from RhoA in the other structures.
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5.1 Introduction
Rho GTPases interact with many proteins including GAPs, GEFs and GDIs as well 
as their effector proteins. The specificity of these proteins for the various Rho GTPases 
varies from the highly specific effector proteins to the common rhoGDIs which bind all 
Rho GTPases. All of these proteins bind to Rho via its switch regions, and regulation of 
these interactions is mediated by the conformation of the switches depending on the 
guanine nucleotide bound. The specificity of these interactions, however, varies. For 
example, rhoGDI which binds all Rho GTPases but not Ras, relies on only two conserved 
residues, Arg66 in switch II and Hisl03 (Grizot et al. 2001). Whereas, the GAP and GEF 
interactions, involving only a handful of residues, are more specific for particular Rho 
GTPases.
Although much is known about the specificity of Rho GTPases and their regulators 
and effectors, less is known about the specificity of C3botl-RhoA interaction. It has 
always been presumed that the ribosylation of RhoA was a compulsory order mechanism 
with NAD binding first. Recent papers, however, have reported that C3botl binds RhoA in 
the absence of NAD. An assay where Rho-GST is used to ‘pull down’ C3botl in the 
absence of NAD has been used to characterise the specificity of the ribosylation (Wilde et 
al. 2000). This assay has subsequently been used to characterise the catalytic residues of 
C3stau2 (Wilde et al. 2002b; Wilde et al. 2002c) and C3cer (Wilde et al. 2003). The 
limited characterisation of the C3botl-RhoA interaction with this assay identified the Rho 
residues Arg 4, Lys 6, Glu 40, Val 43, Glu 47, and Glu 54 as important (Wilde et al. 2000). 
By contrast, the only C3botl residue proposed to be involved in the interaction is Phe 209 
(Han et al. 2001), for which the equivalent residues in C3stau2 (Y175) and C3cer (Y180) 
have been shown to be important for Rho binding by mutagenesis (Wilde et al. 2002c; 
Wilde et al. 2003).
Although the specificity of C3botl for RhoA-C and not other Rho GTPases is well 
established, it was recently shown that C3botl binds, but does not ADP-ribosylate, the ras- 
related GTPase RalA. This interaction blocks RalA functions, prevents C3 ribosylation of 
RhoA and enhances C3 NAD glycohydrolase activity (Wilde et al. 2002a). Glutathione 
pull down assays also demonstrated this interaction for C31im and C3cer and the affinity of
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RalA for C31im was shown to be 12nM by fluorescence titration (Wilde et al. 2002a). 
Interestingly, C3stau2 did not appear to bind RalA, suggesting that RalA binds C3 
exoenzymes in a manner different to RhoA, raising another interesting question of 
specificity.
This chapter describes the basic characterisation of our recombinantly produced 
C3botl and C3stau2. To investigate the specificity of C3botl for RhoA, binding 
experiments in the presence and absence of substrate analogues were performed to attempt 
to stabilise a complex between C3botl and RhoA for crystallisation. A limited 
characterisation of the C3botl-RalA was also attempted.
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5.2 Methods
Purification o f RhoA and RalA- For assaying the activity of C3botl and C3stau2 a 
supply of RhoA and RalA was needed. These were made recombinantly as GST-fusion 
proteins. E. coli cell paste containing soluble, overexpressed RhoA-GST or RalA-GST was 
obtained from Dr. J.M. Sutton at the HP A. 100ml cultures in Terrific broth with lOOpg/ml 
ampicillin and 0.5% glucose were grown overnight at 30°C. 20ml of these cultures were 
transferred to a litre culture of the same media and grown at 30°C. Protein production was 
induced at 25°C with ImM (final concentration) IPTG when the cells reached a density of 
0.8 absorbance units. Batches of 500mls cells were harvested, resuspended in lysis buffer 
(50mM Hepes pH7.3, 0.5M NaCl, 5mM MgCk, ImM DTT and ImM PMSF) and stored at 
-20°C. Thawed cells were lysed by sonication on ice (5x 40s bursts at 26microns -  
Soniprep 150) and cell debris were separated by centrifugation. The GST fusion protein 
bound a GST-trap column (Amersham) equilibrated with thrombin resuspension buffer 
(50mM Hepes pH7.3, 150mM NaCl, 5mM MgCb, 2.5mM CaC^, and ImM DTT) and was 
eluted with the same buffer plus 20mM reduced glutathione. The GST was cleaved at 4°C 
for 4-6 days with 4U thrombin/mg fusion protein. The cleaved GST re-bound the GST 
column and the non-bound protein was concentrated in a centrifugal 15KDa cut off 
concentrator (Amicon). Finally, the protein was purified in batches of 300pi on a 
Superdex-200 HR 10/30 gel filtration column run at 0.75ml/min. RhoA was purified in 
20mM Hepes pH7.3, 20mM NaCl, 5mM MgCb and ImM EDTA, concentrated to 10- 
12mg/ml, aliquoted and stored at -70°C. RalA was purified in 20mM Hepes pH7.3, 
120mM NaCl, concentrated to 4mg/ml, aliquoted and stored at -70°C.
ADP-ribosylation assay for C3botl- 50pl 0.01-2.5pg/ml C3botl was mixed with a 
reaction mix containing lOpl DTT assay buffer (50mM Hepes/NaOH pH 7.5, 5mM MgCb 
and 5mM DTT), 20pl 25pg/ml Rho A in assay buffer and 20pl 4pM NAD with 50pCi/ml 
[adenylate- P32] NAD. The reaction mix was incubated at 37°C for 2hrs and stopped with 
lOOpl 2mg/ml BSA followed by 0.5ml 24% trichloroacetic acid (TCA). The precipitated 
protein was collected by high speed microfuge centrifugation and the pellets washed with 
lml 12% TCA. The pellets were resuspended in 1ml Hepes/NaOH pH 7.5. 5mls of 
scintillation fluid was added to each sample before counting.
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ADP-ribosylation assay for C3stau2- 50pl 0.5-500pg/ml C3stau2 (in 20mM Hepes 
pH 7.4, 0.1 mg/ml BSA) was mixed with a reaction mix containing lOpl assay buffer 
(50mM Hepes/NaOH pH 7.4, 5mM MgCb), 20pl 2mg/ml RhoA in assay buffer and 20pl 
200pM NAD with 50pCi/ml [adenylate- P32] NAD. The reaction mix was incubated at 
37°C for lhr and stopped with lOOpl 2mg/ml BSA followed by 0.5ml 24% TCA. The 
precipitated protein was collected by high speed microfuge centrifugation and the pellets 
washed with 1ml 12% TCA. The pellets were resuspended in 1ml Hepes/NaOH pH 7.4. 
5mls of scintillation fluid was added to each sample before counting.
Inhibition assay- 20pl 70ng/ml C3botl was added to a reaction mix containing 
20pl DTT assay buffer (50mM Hepes/NaOH pH 7.5, 5mM MgCk and 5mM DTT), 20pl 
25pg/ml Rho A in assay buffer, 20pl ImM NAD analogue and 20pl 50pCi/ml [adenylate- 
P ] NAD. The reaction mix was incubated, stopped and counted as above. The substrate 
analogues used are shown in Table 5.1. The C3botl used for these experiments was bought 
from Sigma and the RhoA was provided by Dr. C.C. Shone at the HPA.
Assessment o f analogues as inhibitors o f substrates- As inhibition assay, but 
samples were pre-incubated for lhr at 37°C before addition of the [adenylate- P32] NAD 
either with, or without, substrate analogues 1, 5, 6 and 9 (Table 5.1). The stock 
concentrations of the substrate analogues 1,5, 6 and 9 used were 0.5mM, 0.5mM, 0.2mM 
and ImM respectively. The C3botl used for these experiments was bought from Sigma 
and the RhoA was provided by Dr. C.C. Shone at the HPA.
NAD glycohydrolase assay for C3stau2 - 50pl 500pg/ml C3stau2 in 20mM 
Hepes/NaOH pH7.4, 0.1 mg/ml BSA, was mixed with 50pl 200pM NAD including 20pM 
[nicotinamide- 14C] NAD in Hepes/NaOH pH 7.4. Samples were incubated over a 5hr time 
course and stopped by vortexing with 1ml water-saturated ethyl acetate for 3x 10 seconds. 
0.75mls of the ethyl acetate phase was added to 5mls scintillation fluid and counted.
NAD glycohydrolase assay for C3botl - 50pl 250pg/ml C3botl in 20mM Na.Hepes 
pH7.4, 0.1M NaCl, 5mM MgCb, O.lmg/ml BSA, was mixed with 50pl 200pM NAD 
including 20pM [nicotinamide- 14C] NAD in Na.Hepes pH 7.4, 0.1M NaCl, 5mM MgCl2 . 
Samples were incubated over a 5hr time course and stopped by vortexing with 1ml water-
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saturated ethyl acetate for 3x 10 seconds. 0.75mls of the ethyl acetate phase was added to 
5mls scintillation fluid and counted.
Glutathione-captured RhoA-GST binding assays- lmg C3botl and 0.5mg RhoA- 
GST in 5mls binding buffer (50mM Na.Hepes pH7.3, 2mM MgCk, ImM EDTA, ImM 
DTT), were incubated overnight at 4°C. The mixture was loaded onto a GST-Trap column 
(Amersham) in chilled binding buffer and bound material eluted with binding buffer plus 
20mM glutathione.
Gel filtration binding assays- Either 60pg C3 and 30pg RhoA, or 60pg RhoA and 
30pg C3 were incubated overnight at 4°C in 50-75pi 50mM Na.Hepes pH7.3, 0.1M NaCl, 
5mM MgCh and ImM DTT. The proteins were separated by gel filtration with a 
Superdex-200 HR 10/30 or Zorbax Bio Series GF-250 gel filtration column using the same 
buffer. Fractions were precipitated by saturated TCA and viewed by SDS-PAGE. Assays 
were also carried out in the presence of 150pM 3-acetylpyridine adenine dinucleotide. A 
similar assay was used for RalA.
Growth o f NIH 3T3 cells- The cells were cultured with the help of Dr J. Ayriss at 
the HPA. NIH 3T3 cells were grown at 37°C with 5% CO2  in Dulbecco Modified Eagle 
Medium (DMEM) with 10% Calf serum, 2mM L-Glutamine and 0.1 mg/ml 
Penicillin/Streptomycin. Cells were sub-cultured every 3-4 days.
Visualising changes in cell morphology- Cells were seeded on coverslips or 
chamber 8 well slides at a density of 2x104 or 2x105 and grown overnight at 37°C at 5% 
CO2 . For the assay, the growth media was replaced with uptake media containing DMEM, 
0.5M sucrose, 10% PEG1000, 0.1mg/ml ovalbumin and 15-150pg/ml exoenzyme, or 
uptake media for the control. The cells were incubated for 8mins at 37°C before washing 
twice with growth media. The cells were then incubated for l-3hrs in fresh growth media 
and visualised with an inverted LEICA DMIRB microscope at 5x magnification.
Visualising actin changes with Rhodamine-phalloidin- Cells were seeded on 
coverslips at a density of 2xl04 or 2xl05 and grown overnight at 37°C at 5% CO2 . The 
assay was performed as above. To fix the cells, the coverslips were washed twice in lx
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PBS, pH 7.4 and incubated with 4% paraformaldehyde in PBS for lOmins at room 
temperature. The cells were permeabilised by incubation with 0.1% Triton X-100 in PBS 
for 4mins and blocked by incubation with 1% bovine serum albumin (BSA) for 20-30mins. 
The cells were stained for 20mins with 0.4pM Rhodamine-phalloidin in PBS containing 
1% BSA and mounted on microscope slides. The cells were visualised with an inverted 
LEICA DMIRB confocal microscope with water emersion at 63x magnification.
Amine coupling o f chips for Biacore- Amine coupling was performed following the 
manufacturers instructions. The chip surface was activated by injection of 35pl 1:1 mixture 
of NHS (0.05M N-hydroxysuccinimide) and EDC (0.2M N-ethyl-N’- 
(dimethylaminopropyl)-carbodiimide). 70pl 200pg/ml C3botl or 35pl 100pg/ml RhoA- 
GST in lOmM Acetate pH 4 were injected over the activated surface of flow cell 1 with 
HBS-EP buffer (lOmM Na.Hepes pH7.4, 150mM NaCl, 3mM EDTA, 0.005% Surfactant 
P20) at lOpl/min. The remaining amide groups were deactivated by injection of 35pl 1M 
ethanolamine hydrochloride pH8.5. The coupling was repeated for flow cell two using 
buffer instead of protein to create a control. NHS, EDC, HBS-EP and ethanolamine 
hydrochloride were all supplied by Biacore. The RhoA-GST for these experiments was 
supplied by Dr. J.M. Sutton at the HPA.
Injection o f Biacore samples- All experiments were performed using the 
recommended HBS-EP running buffer (lOmM Na.Hepes pH7.4, 150mM NaCl, 3mM 
EDTA, 0.005% Surfactant P20) at speeds of 20-80pl/min. Protein samples were exchanged 
into this buffer using buffer exchange columns (PD10, Amersham). lOOpl samples were 
injected using the recommended technique. Washing of the injection loop was delayed 
600s to prevent interference with the trace. Both chips were washed using lOpl 50-200mM 
sodium carbonate pH 9.6. The coupling was repeated for flow cell two using buffer instead 
of protein to create a control. HBS-EP was supplied by Biacore. The RhoA-GST and 
RalA-GST for these experiments was supplied by Dr. J.M. Sutton at the HPA.
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5.3 Results and discussion
5.3.1 Purification of RhoA and RalA
The investigation of C3botl and C3stau2 binding to either RhoA or RalA, required 
expression and purification of both these proteins. Also, it was hoped that either a complex 
of C3botl-RhoA-substrate analogue, or C3botl-RalA could be produced in large amounts 
for crystallisation.
5.3.1a Results
RhoA is routinely expressed as a GST-fusion protein and E. co li cultures 
containing overexpressed RhoA-GST were provided by Dr. J. M. Sutton at the HPA. 
Purification of the fusion protein on a glutathione column produced a reasonably clean 
peak with a yield of 30mgs fusion protein per litre cells. Initial trials indicated that the 
cleavage reaction required 0.2U thrombin to cleave 20pg fusion protein at room 
temperature in 16hrs. However, protein purified in this way was shown to be inactive and 
was not ADP-ribosylated by C3botl in assays, whereas the un-cleaved protein could be 
ribosylated. The cleavage reaction was eventually refined to 4U thrombin/mg fusion 
protein at 4°C for 4-6 days to prevent denaturing. The RhoA was separated from the GST 
which re-bound the glutathione column (Figure 5.1). More latterly, RhoA was also purified
1 2 3 M 4 M KDa
—  <-20
Figure 5.1: 12% SDS PAGE showing 
the purification of RhoA. Lane 1, the 
soluble cell extract, 2, the protein 
which did not bind the GST-trap 
column (Amersham), 3, the peak eluted 
from the GST-trap column, 4 the 
cleaved protein after the second GST- 
trap purification and M, the low 
molecular weight marker (Amersham).
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by gel filtration to prevent any impurities confusing the gel filtration binding assay. After 
concentration, the RhoA was stored at -70°C as it was found to precipitate during 
prolonged storage at 4°C.
RalA-GST was also provided overexpressed in E. co li cultures by Dr. J. M. Sutton 
at the HPA. The expression and purification of this protein were carried out as for RhoA 
and not optimised. A significant proportion of the fusion protein was insoluble after cell 
lysis by sonication and a yield of only 15mgs fusion protein resulted from 1 litre of cells. 
RalA-GST also proved to be quite resistant to cleavage and incubation with 7U 
thrombin/mg fusion protein for four nights at 4°C did not result in total cleavage (Figure 
5.2). Further purification to remove the GST by glutathione column did not result in pure 
protein as judged by SDS-PAGE so the RalA was further purified by gel filtration. 
Unfortunately this resulted in a yield of only 0.39mg per litre cells. The pure protein was 
concentrated to 4mg/ml and stored at -70°C.
Figure 5.2: 12% SDS PA G E show ing the 
purification  o f  R alA . Lane 1, the low molecular 
weight marker (Amersham), 2, the soluble cell 
extract, 3, the insoluble extract, 4, the protein that 
did not bind the GST-trap column (Amersham), 5, 
the peak eluted from the GST-trap column and 6, 
the cleaved protein after incubation with 7U 
thrombin/mg fusion protein for four nights at 4°C.
KDa 1 2  3 4 5 6
111
Chapter 5 Characterisation of C3botl and C3stau2
5.3.1b Discussion
RhoA has previously been expressed with a GST-tag (Wei et al. 1997), a His tag 
(Shimizu et al. 2000) and a FLAG affinity tag (Longenecker et al. 1999) for crystallisation. 
However, the yield of these purifications was not commented on except for the FLAG tag. 
RhoA-FLAG, was expressed in yeast and purified as a complex with rhoGDI. Therefore, 
the resulting yield of 4-6mg from 18 litres of cells (Longenecker et al. 1999) is not 
comparable. Although expression as a GST-fusion protein gives an initial yield equivalent 
to 15mgs of RhoA, the inefficiency of the cleavage reaction make this method less 
convenient for very large scale purification. A trial to assess whether the cleavage reaction 
is more efficient when RhoA is cleaved straight from the GST-beads in a batch method, 
showed that the cleavage was still very inefficient. This method was also hindered by the 
inefficient binding of RhoA-GST to the beads. After cleavage, purification by the GST- 
trap and gel filtration columns did yield very pure protein, although care was needed to 
prevent it precipitating upon concentration. Although no accurate yield measurements were 
made, I estimate that up to 4-6mgs highly pure protein could be purified from the initial 
15mg with careful concentration, although this purification would take two weeks. The 
published method of purification for crystallisation using the GST-tag (Wei et al. 1997) 
cleaved the protein on the column which may have been more effective. Also, 10% PEG 
400 was included in the buffer which may have helped the stability of the protein, although 
this was not commented on.
The poor cleavage of the GST from the RalA suggest that another construct may be 
more appropriate for purification. RalA has recently been purified using a His tag without 
cleavage for NMR titration experiments (Mott et al. 2003) but the purification details and 
yield were not reported. Although expression of RalA as a GST fusion protein results in a 
large proportion of the protein being insoluble, the yield from the purification could 
probably be improved by using more cleavage enzyme and maybe an anion exchange step 
rather than the gel filtration. Alternatively, the expression and lysis protocols could be 
optimised to produce more soluble protein. Also, more work would need to be done to 
characterise the activity of the RalA, probably using a radioactive GTPase assay. 
Unfortunately, the lack of success with the initial RalA experiments prevented continuation 
within the time frame of this Ph. D. project.
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5.3.2 Characterisation of C3botl
The following assays were carried out in order to optimise them for the inhibitor 
studies and to assess the activity of C3botl in comparison with C3stau2.
5.4.2a ADP-ribosyltransferase activity
The ADP-ribosyltransferase activity was measured by the incorporation of labelled 
ADP-ribose into RhoA. C3botl was incubated with RhoA and [adenylate- 32P-adenylate] 
NAD for lhr at 37°C and the labelled protein precipitated with TCA. The precipitated 
protein was resuspended with buffer and the radioactivity counted. Most of these assays 
were only done in duplicate as they were just intended to be comparative. These 
comparative assays showed the activity of our recombinant C3botl to be greater than 
commercially bought C3botl (Sigma). The method described in section 5.2 details the 
experiment performed to estimate the specific activity of C3botl. Excess cold NAD was 
added to ensure the both substrates were in excess. However, plotting the number of moles 
ADP-ribosylated RhoA against C3botl concentration resulted in a curve rather than a 
straight line so the specific activity of 0.38mol ADP-ribose/mol enzyme/min could only be 
estimated from the beginning of this curve (Figure 5.3).
5.3.2b NAD glycohydrolase activity
In the absence of a protein substrate, C3 exoenzymes can catalyse the hydrolysis of 
NAD at a slower rate. This assay, based on an assay designed for diphtheria toxin (Kandel 
et al. 1974), was also adapted to include excess cold NAD. lOOpl samples containing 
5.3pM C3botl and lOOpM NAD (including 10pM [nicotinamide- 14C] NAD) were 
incubated at 37°C over a time course of 5hrs. Reactions were stopped by mixing with 1ml 
water-saturated ethyl acetate. 750pl of the ethyl acetate phase, which captures >95% of the 
nicotinamide (Kandel et al. 1974), was mixed with 5mls scintillation fluid for counting. 
Plotting of the number of moles of nicotinamide released against time shows a linear 
relationship for the first 2hrs (Figure 5.4) from which a specific activity of 0.12 mol/mol 
enzyme/min can be calculated.
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Figure 5.3: The transfer of [adenylate- 32P-adenylate] ADP-ribose to RhoA over 
2hrs at different C3botl concentrations. A, the relationship is not linear showing that 
the substrates may be not in excess for the higher concentrations of C3botl. B, the first 
part of the curve in A is linear and can be used to calculate specific activity. The 
gradient is 46.7pmol ADP-ribose/pmol C3botl from which a specific activity of 
0.38mol ADP-ribose/mol enzyme/min can be calculated. Assays were performed in 
triplicate and analysed using GraFit (Leatherbarrow 2001).
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Figure 5.4: C3botl dependant release of nicotinamide from NAD over time.
Triplicate 5.3pM C3botl samples were incubated with 200pM NAD including 20pM 
[n ico tinam ide- 14C] NAD. The relationship is linear over 2hrs with a gradient of 
0.03nmol/min, from which a specific activity of 0.12mol/mol enzyme/min can be 
calculated. Fitting performed with GraFit (Leatherbarrow 2001).
5.3.2c Cell assays
C3botl was initially characterised by its rounding effect on NIH 3T3 cells (Rubin 
e t a l. 1988) which was later attributed to the dissolution of actin filaments by inactivation 
of Rho proteins (Paterson e t a l. 1990). Therefore, the effect of our C3botl on cultures NIH 
3T3 cells was assessed by visualisation of morphological changes and rhodamine- 
phalloidin staining of the F-actin filaments. As C3botl is not easily taken up into cells, an 
osmotic shock method (Rubin e t al. 1988) was used to aid uptake, lhr after the addition of 
the lowest concentration (15pg/ml) of C3botl, reversible cell rounding (Figure 5.5) and 
actin dissolution were observed. Assays were performed in triplicate.
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Figure 5.5: NIH 3T3 cell rounding upon addition of C3botl. A and C: Controls 
without C3botl, B and D: after incubation for l-3hrs with 15pg/ml C3botl. A and B 
were visualised on a LEICA DMIRB microscope at 5x magnification. C and D were 
visualised with an inverted LEICA DMIRB confocal microscope with water emersion at 
63x magnification after staining with Rhodamine-phalloidin.
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5.3.2d Discussion
The original use of the ADP-ribosylation assays was purely comparative for 
evaluation of NAD analogues. Early observations showed that our C3botl was at least as 
active, and often more so, that commercially bought enzyme. Later, we wanted to calculate 
the specific activity of C3botl for comparison with C3stau2 and other C3 exoenzymes. 
However, the level of activity observed, as judged by the counts of the scintillation 
counter, appeared to have decreased. This may have been due to the change in scintillation 
counter or a decrease in the activity of the C3botl. However, it proved difficult to 
reproduce the previous results for more careful analysis or to re-optimise the assay to get a 
suitable figures for analysis. The current calculation of the specific activity, from the linear 
part of the graph, and taking into account the efficiency of the scintillation counter, does 
not seem to be as high as I would expect. Confusingly, comparison of the number of moles 
of RhoA ribosylated, and the original concentration of RhoA and NAD, shows that both 
substrates should still be in excess for all concentrations of C3botl by the end of the 
experiment. A non-linear relationship between enzyme concentration and product release 
under these conditions would suggest product inhibition of the reaction. The other 
alternative is that only a small percentage of the RhoA is active. However, further 
experiments would be required to characterise this reaction fully.
The consolation, on analysis of previously published activities for C3 exoenzymes 
(Table 5.1), is that there seems to be little agreement on its activity suggesting that either 
C3 exoenzymes vary considerably in activity between batches, or that the methods of 
calculation are not very accurate. Interestingly, all these activities are published from the 
same group (Aktories et a l)  and references 3 and 4 (Table 5.1) are from the same author 
and still disagree. The published assays were all monitored by phosphorimaging of SDS- 
PAGE whereas ours were monitored by scintillation counting of resuspended precipitated 
protein. It is possible that the sensitivity of the assays varies. The lack of consistency 
between the published results and the fact that they all came from the same group, jnakes it 
hard to draw any concrete conclusions about the activity of this enzyme in vitro.
The NAD glycohydrolase activity for our C3botl, 0.12mol/mol enzyme/min, is 
more comparable with published results for C3stau2 (0.61mol/mol/min) (Wilde et al. 
2002c) and C3cer (0.29mol/mol/min) (Wilde et al. 2003) suggesting that these enzymes
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have similar levels of NAD glycohydrolase activity, whatever the differences reported in 
transferase activity (Wilde et al. 2003). This would be expected from their common active 
site architecture. The effect of C3botl on NIH 3T3 cells also mirrored the published results 
(Rubin et al. 1988) with similar concentrations of the enzyme. In the light of these results, 
it seems even more confusing that there should be such discrepancy in the ADP- 
ribosyltransferase assays. Considering the stability of C3botl and the consistency of the 
other results it is likely that variations in the RhoA used for these assays maybe affecting 
the results. RhoA-GDP is a better substrate than RhoA-GTP for C3botl due to the 
conformation of the switches. Therefore it is possible that heterogeneity of the RhoA 
conformation either due to nucleotide binding or slight denaturation may affect the 
outcome of these assays. This may account for the inconsistencies in our results as the 
RhoA samples used varied in age (older for the later experiments) and some of the RhoA 
samples were provided by Dr. C.C. Shone at the HP A. An independent assay for RhoA 
activity may help validate future experiments in this area.
C3 type Reference Published rate Specific activity (mol/mol/min)
C3botl 1 6.4 nmol/mg/min 0.151
C3botl 4 n/a 60
C31im 1 3.1 nmol/mg/min 0.073
C31im 2 12nmol/mg/min 0.28
C31im 4 n/a 90
C3stau2 3 n/a 159
C3stau2 4 n/a 100
C3cer 4 n/a 22.25
Table 5.1: Reported specific activities for RhoA ADP-ribosylation by C3 exoenzymes.
References are 1, (Just et al. 1992), 2, (Bohmer et al. 1996), 3, (Wilde et al. 2002c) and 4, 
(Wilde et al. 2003). All reported activities are calculated from phosphorimaging of SDS- 
PAGE. For conversion to mol/mol/min, lmg C3 exoenzyme (-23.6 kDa) is taken to be 
approximately 42.4nmols.
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5.3.3 Characterisation of C3stau2
These experiments were carried out to characterise C3stau2.
5.3.3a ADP-ribosyltransferase activity
C3stau2 was also assayed for its ADP-ribosyltransferase activity. Initial 
experiments using the same method as C3botl showed its activity to be much reduced to 
levels not detectable by the assay. It was also noted that whilst for C3botl the K<i for NAD 
is reported as 6pM (Chavan et al. 1992) and the Km as 0.4pM (Just et al. 1992), for 
C3stau2 the IQ is reported as 20pM by fluorescence quenching assays (Wilde et al. 
2002c). Therefore, the ribosylation assay was adapted with increased enzyme 
concentrations to raise the production of labelled ADP-ribose above the radioactive 
background and with increased substrate concentrations, including cold NAD, to keep the 
substrate in excess. The ten-fold dilutions of C3stau2 from the highest concentration of
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Figure 5.7: Linear increase of nicotinamide release with time for the NAD 
glycohydrolase activity of C3stau2. 10.5pM C3stau2 was incubated with 200pM 
NAD for up to 300mins. Triplicate samples were stopped by mixing with water- 
saturated ethyl acetate and counted. Results displayed are calculated taking into 
account the radioactivity of the NAD. Linear fitting with GrafFit (Leatherbarrow 
2001) gives a gradient equal to 2.7 pmol/min giving an approximate specific activity 
of 0.005mol/mol enzyme/min.
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10.6pM, incubated at 37°C for lhr with 20pM NAD, including lOnM [adenylate- 32P] 
NAD, and 19.4pM RhoA, did not show a directly proportional increase in production of 
labelled substrate with increase in enzyme. This suggested that the substrate may be 
limiting. However, an approximate specific activity of 0.19 mol ADPR/mol enzyme/min 
was calculated from the highest concentration of C3stau2 used. This is probably 
underestimated however as the NAD concentration for the assay should ideally be lOx the 
K<i and the RhoA was only 2-fold in excess.
5.3.3b NAD glycohydrolase activity
The NAD glycohydrolase activity of C3stau2 was also measured to further 
characterise the enzyme. lOOpl samples containing 10.6pM C3stau2 and lOOpM NAD 
(including lOpM [nicotinamide- 14C] NAD) were incubated at 37°C over a time course of 
5hrs. Reactions were stopped by mixing with 1ml water-saturated ethyl acetate. 750pl of 
the ethyl acetate phase was mixed with 5mls scintillation fluid for counting. Plotting of the 
number of moles of nicotinamide released against time shows a linear relationship (Figure 
5.7) from which a specific activity of 0.005 mol/mol enzyme/min can be calculated.
5 3 3 c  Cell assays
Published characterisation of C3stau2 also reports similar cell rounding effects of 
NIH 3T3 cells upon addition of the enzyme, engineered to be taken up as a binary toxin 
(Wilde et al. 2001). It was hoped that cell rounding would therefore be observed by the 
addition of C3stau2 via the osmotic shock method used for C3botl. NIH 3T3 cells were 
incubated with concentrations of up to 400pg/ml without visible changes in cell 
morphology. Staining with Rhodamine-phalloidin also produced no quantifiable difference 
in F-actin staining between C3stau2 incubated cells and controls, although the staining did 
appear lighter in some of the C3stau2 samples (Figure 5.8) All assays were done in 
triplicate.
5.3.3d Discussion
The differences seen between the published ADP-ribosyltransferase activity of 
C3stau2 (Wilde et al. 2001; Wilde et al. 2002c) and our activity may be in part due to 
differences in the methods used as discussed previously. The inadequate measurement of
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Figure 5.8: NIH 3T3 cell rounding upon addition of C3botl and C3stau2. A and C
c evaV o*
after incubation for l-3hrs with 15pg/ml C3botl. B and D after incubation for l-3hrs 
with 400pg/ml C3stau2. C and D were visualised on a LEICA DMIRB microscope at 
5x magnification. A and B were visualised with an inverted LEICA DMIRB confocal 
microscope with water emersion at 63x magnification after staining with Rhodamine- 
phalloidin.
the ADP-ribosyltransferase activity was due to the need to increase the C3stau2 
concentration to a level which pushed the activity into the detection range. This high level 
of C3stau2 meant that it was hard to keep the substrates, particularly RhoA, in excess. 
Also, the Kd of RhoA for any C3 exoenzyme is unknown. From our observations, it would 
appear that the similarity in the specific activities of our C3botl and C3stau2 must be 
incorrect as direct comparisons suggest that C3stau2 is less active than C3botl. This
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disagrees with the published results which suggest that both activities are similar. It is 
possible that the variation in specific activity between our results and the published ones 
are due to differences in RhoA activity as mentioned previously.
The specific NAD glycohydrolase activity of C3stau2, being approximately 20 
times less active than C3botl, is more consistent with our observed comparison of the two 
enzymes. It is approximately 100 times less than the published activity (Wilde et al. 2002c) 
for reasons which are unclear. Similarly, the effect of C3stau2 on NIH 3T3 cells was much 
less than observed previously (Wilde et al. 2001). The published results were observed 
after efficient incorporation using engineered toxins rather than by osmotic shock. It is 
possible that toxin-mediated uptake optimally localises the C3stau2 near its targets in a 
way that osmotic shock does not, although this would be assumed to be the same for 
C3botl. However, the cell assay results are consistent with the NAD glycohydrolase assays 
which suggest that C3stau is approximately 100 times less active than the published NAD 
glycohydrolase activity and our observed ADP-ribosyltransferase activity for C3botl.
Ignoring the previously published results, the difference in activity between 
C3stau2 and C3botl, purified by the same method, could be due to the specificity of these 
enzymes for RhoA, although this was not quantified by the ADP-ribosylation assays. 
However, this would not explain the difference in NAD glycohydrolase activities. There 
are also no obvious clues in the structure to suggest that there is some difference between 
them. These results may just have to add to the small number of conflicting results on C3 
activity which require further investigation.
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53.4 Investigation of the C3botl-RhoA complex
Although the structures (Han et al. 2001; Menetrey et al. 2002) of C3botl and 
mutational analyses of C3botl (Menetrey et al. 2002) and RhoA (Wilde et al. 2000) gave 
some insight into RhoA binding, the structure of a C3botl-RhoA complex would answer 
many of the questions about specificity. This is not a straight forward problem as the 
interaction is enzymatic and little is known about the binding strength of the complex. 
Also, mutation of the active site residue of C3botl, which would prevent ADP- 
ribosyltransfer, also prevents NAD binding (Saito et al. 1995). These factors make it 
unclear as to whether a complex could be formed that was tight enough for crystallisation 
trials. The following experiments show the attempts to produce evidence o f complex 
formation in the presence or absence of an NAD analogue.
53.4a NAD analogue experiments
The aim of these assays was to screen potential NAD analogues/inhibitors for their 
ability to promote C3botl-RhoA binding in vitro. Non-hydrolysable NAD can be 
synthesised but is not routinely available. Therefore, it was hoped that a suitable NAD 
analogue could be found which would stabilise a C3bot 1 -analogue-RhoA complex for 
crystallisation. To assess the usefulness of various NAD analogues to aid stable complex 
formation, a group of twelve potential inhibitors, were bought or acquired and assessed for 
their ability to inhibit ADP-ribosylation (Table 5.2). The assay was based on the ADP- 
ribosylation assay and the ability of the analogue to inhibit the incorporation of labelled 
ADP-ribose into RhoA.
All assays were done in duplicate, averaged and the results calculated as a 
percentage loss of C3botl activity compared to a positive control as shown in Figure 
5.9(A). The analogues showed various degrees o f inhibition and the most promising, 1, 5, 
6 and 9 were picked for further study. These four analogues were then tested to determine 
whether they were inhibitors which blocked the active site or were alternative substrates 
for the enzyme. This was done by incorporating another step into the assay where the 
samples where pre-incubated for lhr, before addition of the NAD, either in the presence, or 
absence of the analogues. If the analogues were alternative substrates for the enzyme there 
would be a greater apparent loss of activity for the C3botl. This would be due to the extra 
time to incorporate the unlabeled analogue into RhoA, reducing the concentration of Rho 
for modification by the labelled NAD. Again, the results are measured as a percentage of a
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Table 5.2: Analogues screened for inhibition of [adenylate- 32 P] ADP-ribose 
incorporation into RhoA
1. 3-acetylpyridine adenine dinucleotide
2. 3-actelypyridine hypoxanthine dinucleotide
3. alpha-nicotinamide adenine dinucleotide
4. nicotinamide 1, N6 -etheno adenine dinucleotide
5. nicotinamide guanine dinucleotide
6. nicotinamide hypothanthine dinucleotide
7. nicotinic acid adenine dinucleotide
8. 3-pyridinealdehyde adenine dinucleotide
9. thionicotinamide adenine dinucleotide
10. adenosine monophosphate (AMP)
11. p-methylene-thiazole-4-carboxamide adenine dinucleotide (P-TAD)*
12. selenazole adenine dinucleotide (SAD)*
* A gift from Victor E. Marquez, PhD, Chief, Laboratory of Medicinal Chemistry, Centre 
for Cancer Research, NCI-Frederick.
positive control as shown in Figure 5.9(B). Unfortunately, the analogues which showed the 
greatest inhibition, also appear to be alternative substrates for the enzyme as the apparent 
activity goes down with pre-incubation of the analogue. The most promising looking 
analogue from this assay, 3-acetylpyridine adenine dinucleotide, required final 
concentration of lOOpM in the reaction indicating a lack of tight binding.
It can be concluded from these experiments that none of the analogues tried are 
suitable for stabilisation of a C3botl-RhoA complex as they are either substrates for 
C3botl, or do not bind with sufficient strength to promote complex formation.
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Figure 5.9: A, A bar chart showing the ADP-ribosyltransferase activity of 
C3botl in the presence of the 12 NAD analogues (lmM) shown in Table 5.2 as a 
percentage of a positive control. B, A bar chart showing the ADP- 
ribosyltransferase activity of C3botl in the presence of analogues 1, 5, 6 and 9,
pre-incubated for lhr at 37°C before addition of [adenyla te- 32P] NAD, either in the 
presence or absence of the analogue. Concentrations of 1, 5, 6 and 9 were 0.5mM, 
0.5mM, 0.2mM and lmM respectively.
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5.3.4b GST binding assays
The characterisation of C3botl-RhoA binding by Wilde e t al. suggested an 
alternative approach (Wilde e t a l. 2000). In this reference, a GST-pull down assay was 
used to demonstrate C3botl-RhoA binding in the absence of NAD or an NAD analogue. 
The assay used glutathione sepharose-bound RhoA-GST to pull down C3botl which was 
detected by western blot. This assay was adapted to use larger quantities of protein than 
described in the method to allow visualisation of C3botl and RhoA by chromatograph or 
SDS-PAGE. This adapted assay would also more closely mimic the concentrations of 
proteins needed for crystallisation.












Figure 5.10: Chromatograph for the C3botl RhoA-GST binding experiment.
C3botl and RhoA-GST were incubated overnight at 4°C in 50mM Na.Hepes pH7.3, 
2mM MgCh, lmM EDTA, lmM DTT. Bound protein was eluted from the column with 
glutathione. The peak during loading shows that C3botl did not bind.
lmg C3botl and 0.5mg RhoA-GST in 5mls binding buffer (50mM Na.Hepes 
pH7.3, 2mM MgCh, lmM EDTA, lmM DTT), were incubated overnight at 4°C. The
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mixture was loaded onto a glutathione sepharose column in chilled binding buffer and 
bound material eluted with binding buffer plus 20mM glutathione. A large peak was 
observed on the chromatograph during the loading of the protein onto the column (Figure 
5.10) suggesting that not all the protein was bound. SDS-PAGE confirmed that C3botl 
localised to this peak and none was observed in the glutathione-eluted RhoA-GST peak. 
This experiment suggested that any complex formed was not tight enough to withstand the 
glutathione column chromatography.
5.3.4c Gel filtration binding assays
Subsequent to the failure of the GST-capture assay, gel filtration was an obvious 
choice for purification of a complex. Initial experiments were carried out with a Superdex 
200 HR 10/30 gel filtration column using the same buffer as used for the GST-capture 
assays (50mM Na.Hepes pH7.3, 2mM MgCk, lmM EDTA, lmM DTT) with the addition 
of 0.1 M NaCl to prevent binding of the proteins to the column. Varying concentrations of 
the proteins were used to monitor any difference in complex saturation depending on 
which protein was in excess. The results of these experiments, although confused by 
impurities in the RhoA causing peaks in the chromatograph, clearly showed no evidence of 
a C3botl-RhoA complex (Figure 5.11) with excess C3botl or RhoA.
As a final attempt to purify a C3botl-RhoA complex, the gel filtration assay was 
repeated in the presence of 150pM 3-acetylpyridine adenine dinucleotide. Although this 
concentration is not as high as required for the inhibition assay, it was the highest that 
could be achieved using a minimal 50mls of running buffer. It was hoped that this 
analogue may show some ability to produce a transient complex as even transient 
complexes can be measured by the change of peak positions on the chromatograph 
(Beeckmans 1999). A Zorbax Bio Series GF-250 column was used for this assay to reduce 
the quantity of the sample and the volume of running buffer required. Although these 
results were also slightly confused by an unclear trace for C3botl, possibly due to its 
adhesion to the column at only 0.1M NaCl, it is clear that complex formation was not 
promoted by the 3-acetylpyridine adenine dinucleotide (Figure 5.12). The lack of success 
in these assays suggests that if  C3botl and RhoA can form a complex, in vitro, in the 
absence of NAD, then it is not a particularly tight complex. It is not tight enough to detect 
by glutathione pull-down in the absence of salt, or by gel filtration in the presence of 
salt at concentrations below physiological levels.
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Figure 5.11: A, Overlay of the chromatographs from the C3botl RhoA binding 
experiment. Individual samples of C3botl and RhoA as well as a mixture incubated 
overnight at 4°C in 50mM Na.Hepes pH7.3, 2mM MgCl2 , lmM EDTA, lmM DTT, were 
separated by gel filtration with a Superdex 200 HR 10/30 column (Amersham). No peaks 
were observed in the mixed sample which did not correspond to C3botl or RhoA. The 
peak on the right is a buffer effect. B, 12% SDS-PAGE gel of the C3botl RhoA 
binding experiment. M is the low molecular weight marker (Amersham), CR, a sample 
of C3botl and RhoA and the numbers relate to the fractions. RhoA is found in the first 
peak corresponding to fractions 19-22 and C3botl in the second, corresponding to 
fractions 22-23.
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Figure 5.12: Overlay of the chromatographs for the C3botl RhoA binding 
experiment. Individual samples of C3botl and RhoA, as well as a mixture incubated 
overnight at 4°C in a molar ratio of 1:2, were passed over the Zorbax Bio Series GF-250 
gel filtration column in 50mM Na.Hepes pH7.3, 0.1M NaCl, 5mM MgC^ and lmM 
DTT with 150pM 3-acetylpyridine adenine dinucleotide. The mixed sample shows no 
peaks preceding, and therefore corresponding to a molecular weight larger, than C3botl 
or RhoA, suggesting that a complex was not formed.
5.3.4d Surface plasmon resonance experiments
As chromatographic experiments had not identified a C3botl-RhoA complex, the 
nature of the binding was investigated further by surface plasmon resonance. The affinity 
of protein complexes can be measured by the direct interaction of two proteins monitored 
using surface plasmon resonance (SPR) through a Biacore machine. The surface plasmon 
resonance of a protein ‘ligand’ chip changes on the formation and dissolution of complexes 
when a liquid ‘analyte’ sample is passed over. This allows kinetic measurements of low 
affinity binding interactions and the affinity of second substrates in two substrate reactions 
to be measured. The high sensitivity of this technique makes it ideal for measuring 
transient enzymatic complexes such as C3botl-RhoA.
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Figure 5.13: A typical Biacore trace. The surface plasmon resonance response units 
increase during sample injection as the analyte binds the ligand. After injection is 
finished, the ligand equilibrates with the buffer passing over the chip and the response 
units decrease.
A C3botl chip was successfully made with amine-coupling resulting in 
approximately 6.3pg protein bound to the chip as detected by a change in the running 
baseline of 6,256 SPR units. The kinetics of binding are measured by the association and 
dissociation of the Biacore trace (Figure 5.13) but the total mass of analyte bound 
corresponds to the increase in SPR units before dissociation. Amine coupling does not 
guarantee a favourable orientation for the C3botl on the chip but the binding of a similar 
size protein (such as RhoA) would be expected to give and increase in response units of up 
to 50% of the difference seen for C3botl on chip creation. Injection of lOOpl 1 mg/ml
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RhoA over the chip at 50pl/min, however, only resulted in a response difference of 20 
units (0.3% of the C3botl response of 6000). This, along with some RalA experiments 
suggested that only a very small fraction of the C3botl on the chip was able to bind 
analytes or that the affinity for RhoA in the absence of NAD was very low. Although 
further experiments could be carried out with NAD, it would be hard to optimise binding 
of two substrates in the absence of a positive control to show the maximum binding.
These results lead to the design of a second experiment using a RhoA-GST chip in 
the hope that the amine coupling would leave more of the RhoA free to bind the C3botl. 
Unfortunately the largest response difference observed for injection of 390|ig/ml C3botl at 
50pl/min was -100 units (<1% of activated surface of 12,000) which did not seem to be 
large enough to indicate either an active chip or tight binding as injection of BSA produced 
a similar response.
Although Biacore would seem to be the ideal way to study these reactions, the time 
and expense required to get a functional assay system was beyond the scope of the size of 
this PhD project It is possible to use carefully added tags to position proteins optimally on 
the chip surface but this requires much work and often trial and error using several 
(expensive) chips. It is also necessary to have good controls to analyse the total active 
protein on the chip and to reduce noise from non-specific binding. Further experiments 
would have to consider these factors carefully.
5.3.4e Discussion
Although these experiments were performed with a variety of different RhoA 
samples, the total lack of success of any of these experiments suggests that the binding 
strength of any C3botl-RhoA interaction in the absence of NAD is likely to be low and 
would not lend itself to crystallisation. It is also unfortunate that none of the NAD 
analogues tried appeared to promote this interaction and mainly acted as substrates. The 
best option to stabilise a C3botl-RhoA complex would be with a non-hydrolysable NAD 
analogue such as carbanicotinamide adenine dinucleotide (Slama and Simmons 1988). 
However, either this experiment or further Biacore experiments would prove to be 
expensive.
131
Chapter 5 Characterisation of C3botl and C3stau2
5.3.5 Investigation of the C3botl-RalA complex
The report that the binding affinity of the C31im-RalA complex was 12nM (Wilde 
et al. 2002a), coupled with the evidence that RalA inhibited C3botl and C31im functions to 
similar levels, suggested that the C3botl-RalA complex would be suitable for 
characterisation with our techniques. The following experiments show the attempt to 
characterise the C3botl-RaLA complex for crystallisation.
5.3.5a Gel filtration binding assays
To attempt to purify a C3botl-RalA complex for crystallisation, the previously 
described gel filtration binding assays were repeated with RalA. The binding assays were 
performed with the Superdex 200 HR 10/30 column in the published binding buffer 
(50mM Na.Hepes pH7.3, 2mM MgCl2, lmM DTT, 0.5% NP40) plus 0.1M NaCl to 
prevent protein adhesion to the column. 2.6nmol RalA were incubated with either 5.1 nmol 
or 1.3nmol C3botl in a volume of lOOpl buffer overnight at 4°C before separation by gel 
filtration. Column fractions were concentrated by precipitation with TCA before separation 
by SDS-PAGE. Figure 5.14 shows the chromatograph and gel for the 1:2, C3botl:RalA 
ratio. Although it is difficult to spot the peaks above the noise on the chromatograph due to 
the small amounts of protein used, the gel makes it clear that none of the fractions contain 
C3botl and RalA indicating that a C3botl-RhoA complex was not formed. This was also 
the case for the reverse experiment.
The lack of complex formation suggests that either that the additional salt added for 
the gel filtration experiment interferes with the complex, that the affinity of RalA for 
C3botl is not as high as presumed, or that the RalA was denatured in some way. The first 
of these would seem to be the least likely, so the obvious choice was to test RalA binding 
to C3botl using Biacore.
5.3.5b Surface plasmon resonance experiments
The binding of RalA to C3botl was analysed by Biacore using the C3botl chip and 
the running buffer described previously for Biacore experiments. Unfortunately, injection 
of lOOpl 0.15mg/ml RalA-GST at 50pl/min only resulted in a response difference of 35 
units suggesting that either this chip or the RalA were only minimally active or that the 
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Figure 5.14: A, Chromatograph of the C3botl RalA binding experiment. C3botl 
and RalA were incubated overnight at 4°C in 50mM Na.Hepes pH7.3, 2mM MgCb, 
lmM DTT, 0.5% NP40. B, 12% SDS-PAGE gel of C3botl-RalA binding. M is the
low molecular weight marker (Amersham), U, a sample from another experiment, C3 
and Ral, C3botl and RalA markers and A7-B14 their respective fractions. Peaks A7 and 
A9 are noise with no protein associated with them. RalA and C3botl are found in 
fractions A13 and B14 respectively. No C3botl-RalA complex is observed.
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5.3.5c Discussion
Although the reported strength of the C3botl-RalA interaction is in the nM range, 
no complex formation was observed by gel filtration or Biacore assays. The Biacore assays 
cannot be held to be conclusive as they were not optimised and suitable controls were not 
found. The reason for the failure of the gel filtration assay is less certain unless the binding 
strength of the interaction is less than expected, or the RalA is inactive. Although the 
GTPase activity of the RalA was not tested, the purification was identical to that of RhoA, 
which was active. However, similar proteins do not always have similar activities as shown 
by the differences between C3botl and C3stau2. More time to optimise the purification 
and activity of this enzyme would be needed for further investigation of the binding 
specificity.
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neurotoxins Hc/F and Hc/A
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6.1 Introduction
Botulinum toxins are now widely used therapeutically sifter the success of BoNT/A 
in correcting strabismus (Johnson 1999) due to its the effectiveness in weakening muscle. 
BoNT/A is licensed in the United Kingdom for treating blepharospasm, hemifacial spasms, 
cervical dystonia and axillary hyperhidrosis (Misra 2002) although there are many reports 
of success with other conditions. BoNT/B is also licensed in the U.S.A for cervical 
dystonia (Klein 2003). Botulinum toxins are ideal nerve blocking agents due to their 
specificity for cholinergic neurones, the reversibility of their action and because their 
mechanism is understood (Johnson 1999). Successful injection into the required area can 
be achieved without undue side effects on surrounding neurones. However, their main 
draw back is an induction of an immune response with repeated injection. Although the 
effect of BoNT/A can last up to three months (Munchau and Bhatia 2000), other 
neurotoxins such as BoNT/B, E, F and C, which can be as effective as BoNT/A, do not 
have such long lasting effects (Eleopra et al. 1998; Houser et al. 1998; Foran et al. 2003).
The distinct domain structure of the BoNTs and the high level of specificity of both 
the heavy chain and the light chain has also lead to the possibility of using individual 
domains of the toxin as chimeric therapeutics. For example, the light chain and 
translocation domain fragment of BoNT/A, LHn/A , has been engineered with the Ethyrina 
crystagalli lectin to change its cell binding specificity to disable nociceptive neurones for 
the prevention of pain (Duggan et al. 2002). The other possibility is to use the binding 
domains to target other proteins to neuromuscular junctions. Most research in this field has 
been done with the tetanus He domain, which has been shown to be capable of retrogradely 
transporting chimeric proteins to the motor neurones (Coen et al. 1997) and coupled with 
diphtheria toxin can be effectively transported into the cytosol (Francis et al. 2000). The 
tetanus He domain has been engineered to carry various therapeutics including p-A- 
acetylhexosaminidase A for the prevention of lysosomal storage diseases (Dobrenis et al. 
1992), the neuroprotective superoxide dismutase (Figueiredo et al.) and adenoviral vectors 
(Schneider et al. 2000). Recently, it has been coupled with diphtheria toxin and a DNA- 
binding domain for translocation to the nucleus (Barati et al. 2002).
Much less work has been carried out on BoNT fragments and only one construct 
has been reported using non-recombinant, cleaved, toxin (Goodnough et al. 2002). The
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reason for this contrast in research is that, unlike tetanus toxin, it is difficult to express 
active recombinant BoNT He fragments. Of the BoNTs, only recombinant Hc/F and Hc/C 
showed any neuronal binding and that, much less than the native toxin (Sutton, J.M., 
Shone, C.C., -unpublished results). The reason for this disparity in unknown. The exact 
nature of the ganglioside binding site for the BoNTs is also not fully understood and the 
this site has mainly been studied in tetanus toxin where the He domain has been 
crystallised with various sugars and a ganglioside GTlb analogue (Emsley et al. 2000; 
Fontinou et al. 2001).
Therefore, in order to understand the difference in affinity of Hc/F domain for 
gangliosides, in the absence of the rest of the toxin, we attempted to crystallise the He 
domain of BoNT/F, and also BoNT/A for comparison. These experiments were also hoped 
to increase our understanding of the ganglioside binding site for these toxins. This chapter 
describes the unsuccessful crystallisation attempts for Hc/F and Hc/A and comments on the 
solubility of the proteins for use in further trials.
6.2 Methods
BoNT/F and BoNT/A He -  These were purified as described previously (Shone and 
Tranter 1995) and supplied in lOmM Hepes, pH 7.2, 0.2M NaCl, 2mM DTT at a 
concentration of 5mg/ml, by Dr. C.C. Shone at the HP A.
Hanging drop method- 1.5pl well solution was mixed with 1.5pl protein and 
suspended above 0.7/1 ml reservoir. The drops were incubated at 4°C, 16°C or 22°C.
Hanging drop method with oil- As above, but 500pi of 50:50 parafinrsilicone oil 
was layered over the well solution to slow the diffusion between the drop and the 
precipitant.
Crystallisation under oil- lp l precipitant was mixed with lul protein and eluted 
under oil in a microbatch plate. The drops were incubated at 16°C.
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6.3 Results
Initial screening was carried out for both BoNT/F He and BoNT/A He with the 
commercially available screens at the maximum concentration of protein (5mg/ml) and 
incubated at 16°C. These screens represent a range of a hundred conditions which have 
commonly given crystals in previous experiments. The commercial screens produced many 
drops with heavy amorphous precipitate for both proteins suggesting that either the protein 
or the precipitant concentration was too high in most cases. Table 6.1 shows the only 
precipitant from the 100 screened that did not precipitate the proteins. For Hc/F, only 10 
out of a 100 precipitants gave clear drops. For Hc/A, this number was not much better with 
only 17/100. To get a better idea of the concentration of a variety of precipitants required 
to precipitate the protein, the commercial screens were carried out at half the precipitant 
concentration. These screens proved to be at a more suitable concentration for Hc/F as just 
under half the precipitants did not precipitate the protein and the ones that did gave a range 
of precipitation levels. Although for Hc/A, only a quarter were clear drops, most drops 
only had small amounts of precipitate, some of which were more crystalline in nature. 
These screens were also set up as microbatch experiments to tiy out this method and to see 
if the lack of vapour diffusion gave crystals for these conditions. In general, these screens 
gave very similar results to the vapour diffusion experiments. Also, they were more time 
consuming to set up so this approach was abandoned. None of the conditions tried 
produced crystals of Hc/A, but a small crystal was observed in a Hc/F screen with 0.4M 
Na/K Tartrate after 3 months. Unfortunately, this crystal dissolved when extra mother 
liquor was added to the drop. Repeated experiments of this and similar conditions 
produced no crystals.
Following the lack of success with the commercial screens to produce any 
preliminary crystals, screens based on the published conditions for the crystals of BoNT/A 
and BoNT/B were tried. Screens based around the conditions of the tetanus toxin He 
crystallisation were also extensively tried. Tetanus toxin He, in 20mM Imidazole, pH 7, 
lOOmM NaCl was crystallised at 2.8-3mg/ml in 200mM ammonium sulphate with 40% 
PEG 4000 and 1% MPD (Emsley et al. 2000), 20% PEG 4000, 0.2M Imidazole, pH 7 
(Fontinou et al. 2001), or 20% PEG 8000, 0.2M Na2 KPC>4 , 0.1M Tris, pH 8.5 (Fontinou et 
al. 2001). However, at 3mg/ml, both F and A He were very strongly precipitated by these 
conditions at 16°C. Variations on these conditions did not produce crystals.
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BoNT Hc/F BoNT Hc/A
0.4M Na/K Tartrate 1M Imidazole
1 .OM Ammonium phosphate 
0.1M Na Citrate pH 5.6
20% 2-propanol, 0.1M Hepes pH 7.5 
0.2M Na Citrate
0.1M Na Acetate,0.1M Imidazole pH 6.5 30% PEG 1500
3.4M 1.6, Hexanediol
0.1M Tris pH 8.5, 0.2M Mg Chloride
30% MPD, 0.1M Na Acetate pH 4.6 
0.02M Ca Chloride
4.3M Na Chloride, 0.1M Hepes pH 7.5 2M Urea
2M Ammonium Formate 
0.1M Hepes pH 7.5
1M Ammonium dihydrogen phosphate 
O.IMNa Citrate pH 5.6
2M Na Chloride, 0.1M Mes pH 6.5 
0.2M Na/K phosphate
18% PEG 8000, 0.2M Ca Acetate 
0.1M Na Cacodylate pH 6.5
0.5M Na Chloride, 0.1M Mg Chloride 
0.01M Cetyl trimethyl Ammonium Bromide
3.4M 1,6, Hexanediol, 0.1M Tris pH 8.5 
0.2M Mg Chloride
4% polyethyleneamine 
O.IMNa Citrate pH 5.6 
0.5MNa Chloride
10% Jeffamine M-600 
0.1M Na Citrate pH 5.6 
0.01M Ferric Chloride
10% Jeffamine M-600 
0.1M Na Citrate pH 5.6 
0.01M Ferric Chloride
4% polyethyleneamine 
O.IMNa Citrate pH 5.6 
0.5M Na Chloride
30% Jeffamine M-600, 0.1M Mes pH 6.5 
0.05M Caesium Chloride
2M Na Formate, 0.1M Hepes pH 7.5
2M Mg Chloride, 0.1M Bicine pH 9
0.1M 1,6, Hexanediol, Na Acetate pH 4.6 
0.01M Co Chloride
2M Ammonium Sulphate, Tris pH 8.5
10% Ethanol, 1.5M Na Chloride
8 % PEG 4000, 0.1M Na Acetate pH 4.6
Table 6.1: Precipitants from the initial commercial screens which did not precipitate 
the proteins at 16°C with a protein concentration of 5mg/ml. Some metals are written 
using their chemical symbol e.g. Na, sodium, Mg, magnesium, K, potassium, Ca, calcium, 
Co, cobalt.
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Crystal nucleation occurs at the boundary between the unsaturated protein solution 
and the supersaturated solution which precipitates the protein (see Chapter 1). Conditions 
which only precipitate the protein slightly, are probably not far, ‘in crystallisation space’, 
from those that might crystallise the protein. Therefore, the next strategy, was to take 
conditions which only precipitated the proteins slightly, and to vary and manipulate them 
with the addition of additives. Additives included glycerol, sucrose, ethanol, ethylene 
glycol, zinc acetate and sodium orthovanadate, as well as small amounts of detergents such 
as octyl-P-D-glucopyranoside (pOG), Triton X I00 and CHAPS. These experiments 
produced many clear and precipitated drops. Detergents have been reported to be useful at 
low concentrations as additives (McPherson et al. 1986a; McPherson et al. 1986b) rather 
than the higher concentrations required for solubilising membrane proteins. In particular, 
POG has been heralded as a particular success (McPherson et al. 1986a; McPherson et al. 
1986b). Of the detergents tried, Triton X I00 was the only one which produced a light 
crystalline precipitate and not amorphous precipitate. pOG usually resulted in large 
amounts of amorphous precipitate. However, none of these trials produced crystals. For 
some of the Hc/A conditions that had the most promising crystalline precipitates, trials 
with a layer of 50:50 parafin:silicone oil was layered over the well solution in an attempt to 
slow vapour diffusion and therefore give the protein more time to crystallise. However, 
this technique only varied the amount of precipitate and did not produce crystals.
The final strategy was to find more ‘borderline’ conditions by screening precipitant 
concentrations between those that had precipitated the protein in the first set of commercial 
screens but not in the second at the lower concentration. These were mainly PEG/salt 
against pH grid screens set up either at 16°C or 22°C. Table 6.2 shows the boundary 
conditions found from these screens at 22°C. Hc/F was more widely screened that Hc/A 
due to the availability of protein. Some of these precipitants were screened with quite 
finely spaced conditions but none produced crystals.
From the various screens there are some general points to be noticed. Both proteins 
was much less soluble at pH 5.5 and this is presumed to be due to a change in 
conformation, exposing hydrophobic regions, for membrane insertion. Also, Hc/F 
particularly lacks solubility in alcohols and is also less soluble in PEG than salts at the
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concentrations usually used for crystallisations (e.g. in the commercial screens). HcA 
produced many more crystalline looking precipitates than Hc/F suggesting that it may be 
more amenable to crystallisation, although without crystals this is only speculation.
BoNT/F Hc BoNT/A Hc
-18% MPD,
0.1M Na Acetate, pH 4.6
~ 1.2M Ammonium sulphate, 
0.1M Tris, pH 8.5
-1.2M Ammonium sulphate 
0.1M Tris, pH 8.5
-3 %  PEG 8000, 
0.1M Tris, pH 8.5
-0.8M Na Acetate,
0.1M Na Cacodylate pH 6.5
12-18% PEG 400, 
0.1M Hepes, pH 7.5
0.8- 1M Li Sulphate,
0.1M Imidazole/malate, pH 7
-  2.3M Na Formate,
0.1M Imidazole/malate, pH 7
-  0.8M Na Citrate,
0.1M Imidazole/malate, pH 7
-3%  PEG 8000,
0.1M Imidazole/malate, pH 7
- 6 % PEG 8000,
0.1M Na Acetate, pH 4.5
Table 6 .2 :  Boundary conditions or ranges between no precipitation and slight 
precipitation for 4mg/ml H c /F  and H c /A  at 2 2 ° C .  Sodium and lithium are abbreviated to 
their chemical symbols Na and Li, respectively.
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6.4 Discussion
Crystallisation of proteins requires finding the right set of conditions to 
supersaturate the protein solution in the most favourable way for crystallisation. Of the 
factors that effect the solubility of the protein, and therefore its saturation level, protein 
concentration, precipitant concentration and type, pH and temperature are the easiest to 
vary in crystallisation experiments. Of these, however, the hardest to screen is temperature 
as incubators are usually available at set temperatures so screening is usually carried out at 
just one temperature. In these experiments crystallisations were mostly set up at 16°C or 
22°C. Although temperature is critical in crystallisation experiments, if  it is held constant, 
the other factors can be manipulated to supersaturate the protein at that temperature. For 
ease of screening, the protein concentration is also often held constant and the precipitants 
and pH are varied. However, varying the protein concentration slightly was tried for some 
experiments.
In designing crystallisation trials, it is often hoped that the preliminary commercial 
screens will produce some form of preliminary crystals that can be optimised by adjusting 
the aforementioned parameters. In the absence of preliminary crystals, further screens must 
be designed to sample the ‘crystallisation space’ and to find the solubility boundaries at 
which crystals may grow. Without experience in complex statistical analyses, this task is 
often hard to do effectively by one person with a pencil and paper. Another way to explore 
the crystallisation space more effectively is to set up more screens. The use of robots for 
setting up large trials, and the improvements in computerised crystal identification 
techniques to observe these trials can also improve the chances of finding suitable 
conditions. In the absence of a robot, experiments must be designed as well as possible to 
sample the crystallisation space whilst conserving protein and time required to set up the 
experiments. The strategies used in these experiments became more effective throughout 
the trials as experience was gained designing trials and scoring drops for their precipitate 
quality. However, there is still a large proportion of the crystallisation space left 
unexplored. The lack of obvious leads meant that time was spent studying small parts of 
the space without the guarantee of crystals as an end product. Although these experiments 
produced no crystals, they have gone some way towards describing the solubility of these 
proteins for future screens.
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C3 exoenzyme Research
The published structures of C3botl (Han et al 2001; Menetrey et al. 2002) and 
C3stau2 (Evans et al. 2003) have identified key residues in NAD and RhoA binding and 
helped to classify the C3 and binary toxins as mechanistically distinct from the DT and 
CT-like toxins. However, there is still some confusion about the enzymatic mechanism of 
these proteins. Comparisons of active site features has been a useful tool in analysing the 
ADP-ribosylating toxins and it has often been assumed that they share a common 
mechanism for catalysis. The most detailed work to date on the transition state complex of 
an ADPRT is the characterisation of the Pertussis toxin active site using kinetic isotope 
effects. This research suggested an SN2-like mechanism involving a direct attack on the 
NCI carbon atom (Figure 2.1, Chapter 2) concurrent with cleavage of the glycosidic bond 
(Scheuring and Schramm 1997b; Scheuring and Schramm 1997a; Scheuring et al. 1998). 
The structures of VTP2 (Han et al. 1999) and C3botl (Han et al. 2001) were therefore 
analysed with the assumption of a similar mechanism. The authors o f the crystal structure 
of Iota toxin, however, are convinced that their structural and mutational analysis is more 
consistent with an SnI mechanism (Sakurai et al. 2003; Tsuge et al. 2003). In this theory, 
the positioning of the NAD in a folded conformation allows the phosphate NOl atom to 
temporarily hydrogen bond to the nicotinamide NN7 atom resulting in spontaneous 
cleavage of the glycosidic bond. The resulting oxocarbenium cation is then stabilised by 
the catalytic glutamate and the first serine from the STS motif until transfer to the protein 
substrate. So far there has been no direct evidence for either of these theories for either the 
binary toxins or the C3-like exoenzymes.
It is possible that the mechanism of NAD hydrolysis varies between the two groups 
as the first serine of the STS motif has been shown to be essential for hydrolysis in the 
binary toxins (Barth et al. 1998; Nagahama et al. 2000) but not in the C3-exoenzymes 
(Menetrey et al. 2002; Wilde et al. 2002b). This is particularly worth considering as it has 
been shown that equivalent residues in DT and CT are not interchangeable suggesting 
different mechanisms of NAD hydrolysis between these two groups (Dolan et al. 2000). 
Similar detailed study of these enzymes, such as using kinetic isotope exchange may be 
needed to resolve these questions. Alternatively, the structure and kinetic analysis of a C3
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exoenzyme or binary toxin with a transition state analogue or other substrate analogues 
may help illustrate some of these points.
The reason for the difference in catalytic rates of these enzymes is unclear. Even 
putting aside experimental differences, there are reported comparative differences between 
the C3 exoenzymes (Wilde et al. 2002b) as well as our own observed differences. More 
detailed kinetic analysis may help answer some of these questions. As far as our C3stau2 is 
concerned, an ADP-ribosylation assay with a longer incubation time which could use less 
enzyme would probably be the best way to get an accurate measurement of the activity. 
Alternatively, a time course, such as that used for the NAD glycohydrolase activity may be 
helpful. Additionally, an independent assessment of RhoA activity with the assay may be 
useful. The difference in C3 affinity in vitro for RhoB reported (Wilde et al. 2002b) is also 
unexplained. The valine to isoleucine swap at position 43 has been shown to be the reason 
for the decrease in ribosylation of RhoC. RhoB only differs from RhoA in the first 80 
residues at position 10 where it has a valine for isoleucine swap and position 29 where is 
has a glutamate rather than a glutamine. The role of these residues in the reaction could be 
tested by mutational analysis.
The specificity of C3 exoenzymes for Rho GTPases is still not understood. A 
crystallographic C3-RhoA complex would prove hard to achieve without a tight binding 
non-hydrolysable NAD analogue. An alternative might be to make an ADP-ribosylated 
RhoA-C3 complex at pH5 in the absence of nicotinamide. Some thought would need to be 
put into purifying 100% ribosylated RhoA, however. In the absence of these, modelling 
studies of the NAD-bound form of C3botl or C3stau2 with the GDP bound form of RhoA 
may give some clues. However, as both these molecules have proven to be flexible it is 
possible that either one, or both, of them may change conformation again on binding. If C3 
cleaves the NAD before RhoA binding as suggested by the SnI mechanism, this complex 
is likely to be in a conformation different again to that seen in the crystal structures for 
docking to Rho. The structure of C3stau2 has given valuable insight into the difference in 
specificity with C3botl. However, further mutational analysis based on this structure may 
help identify further residues in Rho recognition. As EDIN A has now been shown to share 
the same specificity as C3stau2 (Wilde et al. 2003), a comparison of these sequences, 
combined with the structure of C3stau2 may also help discriminate residues which are 
likely to be responsible for these differences.
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Biacore experiments may also useful for determining the affinity of the C3s for 
RhoA or RhoE if  suitable chips could be made. Direct comparisons would probably be 
more difficult, however, as a RhoA chip could not be used in conjunction with NAD. It is 
possible that a uniformly ribosylated RhoA chip investigated at pH5 may give some 
insight. Additionally, the role of C3-Rho binding in the absence of NAD is not only 
unclear but also not well characterised. Questions remain as to how far this interaction 
resembles the complex with NAD and involves the likely conformational changes. This 
phenomenon needs to be more widely studied to assess its usefulness in understanding the 
ribosylation reaction. Biacore and NMR experiments would be ideal for studying this 
interaction.
There is plenty of scope for further investigation of C3-RalA interactions. This 
interaction should be easier to study due to the reported higher affinity of this complex 
(Wilde et al. 2002a). A crystal structure of a C3botl-RalA complex could also be used to 
investigate the specificity of this reaction with by subsequent modelling of C3stau2 with 
RalA. Biacore studies of both these complexes would give valuable information about 
these interactions if  a suitable chip could be made. However, further research into a role 
for inhibition of RalA in cell disruption is essential. At present, there is a lack of evidence 
for such a role and the tight nature of the interaction would suggest that it is more likely to 
act as an inhibitor of C3, mopping it up in the cell.
Finally, the role for C3 exoenzymes in pathogenesis still needs elucidating. So far, 
the only suggestions for possible cell entry mechanisms are for the EDIN (C3stau) 
subfamily and none have these have been tested. The role of Rho in regulating immune 
functions have lead to the proposal that C3-like exoenzymes may have a possible role in 
targeting the immune system (Wilde and Aktories 2001) but this hypothesis has yet to be 
addressed directly.
Binding affinity and interactions of H c /F  and H c /A  and chimeric proteins
The lack of success of this project means that answers to questions of recombinant 
and chimeric binding domain affinities remain unanswered. Since the start of this project,
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the affinity of recombinant BoNT/C He for gangliosides has been shown to be much closer 
to the wild type than the other recombinant Hcs. However, there is still plenty of scope for 
further research into BoNT He specificity and binding affinity as most of the work in these 
areas has been done for tetanus toxin.
For the crystallisation of the He fragments, these experiments did not produce 
many leads as to where to go next. As the precipitants tried have not produced crystals, a 
more broad screening of other precipitants, using suitable concentrations based on the 
known solubility, may be the best next step to find more leads. Subsequently, streak 
seeding of the more crystalline precipitates into slightly lower precipitant concentrations 
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HKL Package (Otwinowski and Minor 1997)
This package comprises three programs: XdisplayF, for visualisation of the 
diffraction images, Denzo, for indexing the data and assigning intensities to hkl reflections 
and Scalepack, for scaling the images to a uniform background and calculating statistics 
for data quality. These programs have now been combined in the gui controlled HKL2000 
which is available at the SRS, Daresbuiy.
CCP4 (CCP4 1994)
The collaborative computational project 4 (CCP4) makes freely available publicly 
funded programs for all areas of macromolecular crystallography. The most well 
developed of these are also now available through the CCP4 gui (Potterton et al. 2003) 
which is designed for easy tracking of structure determination steps and data harvesting. 
The following list represents the programs I used, not a comprehensive’list of the programs 
available.
Scalepack2mtz converts the scaled output of the HKL suite (sea file) into mtz format 
required for CCP4 programs.
Truncate calculates structure factor amplitudes from the observed intensities.
Mtz2various converts the mtz format reflection data to other formats such as fob for CNS.
Matthews calculates the Matthews coefficient (Matthews 1968) from the size of the unit 
cell, the unit cell symmetry and the molecular weight of the molecule. From this it 
estimates the solvent content of the crystal and the number of molecules per asymmetric 
unit.
AMoRE (Navaza 1994) is designed as a fast molecular replacement program. The 
program combines six sub-programs. Sorting, reformats the mtz reflection file for 
compatibility with the program, Tabling, uses an efficient algorithm for fast computation 
of the structure factors of the model, Roting, is the fast rotation function, Traing, the fast 
translation function, Fitting, a fast rigid body refinement of the rotation and translation
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outputs and pdbset, orients the model using the calculated parameters. These programs are 
also available as autoAMoRE on the CCP4 gui.
Molrep (Vagin and Teplyakov 1997) Molrep, which can be accessed via the CCP4i gui, 
also performs rotation and translation functions. Additionally, it has a packing function 
which allows it to eliminate solutions with symmetry clashes.
Refmac (Murshudov et al. 1997) performs rigid body, restrained, unrestrained and tls 
refinement of either a least squares or maximum likelihood function. Addition of water 
molecules is achieved by an implementation of ARP/wARP (Lamzin and Wilson 1993), an 
Automated Refinement Procedure for tracing protein chains in high resolution 
experimental maps.
FFT is used to calculate the maps from Refmac refinement using the mtz and pdb output. 
Map type, size and format can be specified as appropriate.
Procheck (Laskowski et al, 1993) and SFcheck calculates a number of plots and statistics 
for data analysis and structural validation. SFcheck analyses the structure factors for 
twinning and anisotropic distribution. Procheck performs stereochemical analysis 
including Ramachandran plots (Ramachandran et al. 1963)
CNS, the Crystallography and NMR suite (Brunger et al. 1998) contains many 
programs for data manipulation, phase determination, density modification, map 
calculation and refinement. Refinement includes rigid body refinement, minimisation via 
conjugate gradient optimisation of a maximum likelihood target and simulated annealing 
(Brunger and Rice 1997). It also contains a program for producing suitable coordinate files 
for pdb submission.
SHELXL (Sheldrick and Schneider 1997) is a refinement program which does full 
matrix minimisation of a least squares target. It works best with high resolution data (>2 A).




M apman (Kleywegt and Jones 1996) normalises and converts formats of maps from 
various refinement programs.
O (Jones et al. 1991) is a graphical model building program where maps can be displayed 
and models built and manipulated. LSQ superpositioning can also be performed within the 
program.
HBPLUS (McDonald and Thornton 1994) calculates potential hydrogen bonds for 
structures and lists the distances and bond angles for further analysis.
Molscript (Kraulis 1991) creates pictures of macromolecules. The input file created 
describes the type of representation, colour and orientation of the molecules in the pdb file. 
This file, which can also specify labels and rendering, is used to create an image file.
Grasp is a graphics program which can display molecular surfaces and calculate 
parameters for them such as surface potential. These surfaces can be output for conversion 
into image files.
Povrav (www.povray.org) is a freely distributed 3D graphics drawing and rendering 
program. It can be used, via POVScript+ (Fenn et al. 2003) to render image files from 
Molscript and Grasp.
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